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Global Abstract 
 
GENES AND SYMPTOMS IN SCHIZOPHRENIA: 
MODIFIERS, NETWORKS, AND INTERACTIONS IN COMPLEX DISEASE 
 
 
by: 
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A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2009 
 
Director: 
Kenneth S. Kendler, M.D. 
Distinguished Professor, Departments of Psychiatry and Human and Molecular Genetics 
 
 
 
Understanding the genetic foundations of schizophrenia and the resultant symptom 
manifestations is an important step as we work toward development of new prevention 
and treatment strategies.  This work has sought better understanding of this disease 
through use of three subject cohorts and two studies using simulated data exploring 
features of complex disease.  
 
First, we probed the symptoms of schizophrenia in subjects of African and European 
ancestry drawn from the Genetic Association Information Network (GAIN) 
schizophrenia study and found significant differences between groups, particularly in 
affective symptoms.   
 
The genetic basis of symptom variation was then explored in a selection of candidate 
genes in two Irish samples, the Irish Study of High Density Schizophrenia Families 
(ISHDSF) and Irish Case-Control Study of Schizophrenia (ICCSS).  We found a 
significant association of PAH with delusions, GABRB3 with hallucinations, and 
SNAP25 with both of these symptom factors.  AKT1 alleles conferred greater 
Schneiderian symptoms, but dysbindin, MAOB, and SLC6A4 were not related to any 
symptom dimensions.   
 
Simulated data was used to probe the parameters necessary to detect susceptibility genes 
as modifiers in a scenario in which two disease groups with incompletely overlapping 
symptom profiles are examined together.  The heterogeneous genetic underpinnings and 
variable symptom manifestation of schizophrenia make the findings from this study 
particularly relevant to this disease.   
 
Convergent lines of evidence implicating myelin and synaptic dysfunction in 
schizophrenia prompted us to test related gene networks for association with this disease 
in two populations, African-ancestry and European-ancestry, from the GAIN study.  
 x
Some evidence supporting myelin-related genes in the etiology of schizophrenia was 
presented but only in the African-ancestry group. 
 
Epistatic (gene-gene) interactions may confer much greater disease risk than single-gene 
results would indicate, but their detection is often difficult.  The final study included here 
explored two approaches to family-based epistasis detection under a range of epistatic 
models.  The haplotype relative risk (HRR) approach yields greater power for detection 
under conditions of dominance, but the Cordell approach is more powerful under most 
other models. 
 
Together, these studies provide a modest advancement in our understanding of 
schizophrenia and the methodological avenues available for future studies of this disease.   
 
 
 xi
 
 
 
 
 
 
 
 
 
Chapter 1:  General Introduction 
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Schizophrenia Symptoms and Demographics: 
 
Schizophrenia is a severe and debilitating mental disorder characterized by distorted 
perceptions of reality.  Approximately .4% of the world population has schizophrenia 
(Bhugra, 2005), but the full impact of this disease on individuals, their families, and 
society is difficult to assess.  A diagnosis of schizophrenia can be given at almost any 
stage of life from childhood to old age, but it most commonly appears in the late teenage 
or early adult years.  Women generally have a later age of onset than men, but lifetime 
prevalence rates of schizophrenia are similar between the sexes.  A somewhat lower life 
expectancy is related to this diagnosis owing to an elevated suicide risk and health 
complications often concomitant with antipsychotic-related weight gain.       
 
Symptoms of schizophrenia generally include positive symptoms, which are experiences 
additional to the usual human experience.  Auditory hallucinations (i.e. hearing voices) 
are among the most common positive symptoms, but any sensory experience for which 
there is not a physical cause constitutes a hallucination.  Schizophrenics may experience 
hallucinations related to any of the five senses.  Delusions are also frequently experienced 
positive symptoms, and these include any aberrant beliefs about the world not grounded 
in reality and not experienced by most other members of their culture.  Schizophrenia 
also almost always involves negative symptoms as well.  These represent diminished 
experiences compared to the normal population.  Negative symptoms include: flattened 
affect (reduced emotional expression), alogia (reduced speech), or avolition (reduced 
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motivation).  A third category of symptoms is usually mentioned, too, but it is more 
variable.  Cognitive symptoms such as difficulty planning and working memory 
disturbances sometimes represent this third category.  Mood symptoms including features 
of depression or mania are also sometimes highlighted.   
 
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (American 
Psychiatric Association, 1994) criteria for diagnosing schizophrenia are as follows: 
 
1) Characteristic symptoms: Two or more of the following, each present for much of the 
time during a one-month period (or less, if symptoms remitted with treatment).  
 Delusions  
 Hallucinations  
 Disorganized speech (a manifestation of formal thought disorder) severe enough 
to impair communication 
 Grossly disorganized behavior (e.g. dressing inappropriately, crying frequently) 
or catatonic behavior  
 Negative symptoms—affective flattening, alogia, or avolition  
If the delusions are considered bizarre, or auditory hallucinations involve a running 
commentary of the patient's actions or hearing two or more voices conversing with 
each other, only that symptom is required above.  
 3
2) Social/occupational dysfunction: For a significant portion of the time since the onset of 
the disturbance, one or more major areas of functioning such as work, interpersonal 
relations, or self-care, are markedly below the level achieved prior to the onset.  
3) Duration: Continuous signs of the disturbance persist for at least six months. This six-
month period must include at least one month of symptoms (or less, if symptoms remitted 
with treatment). 
These symptoms cannot be due to a mood disorder, pervasive developmental 
disorder, or the use of drugs.   
 
Five clinical subtypes of schizophrenia are recognized by the DSM-IV-TR:  Paranoid, 
Disorganized, Catatonic, Undifferentiated, and Residual.  These clinically derived 
subtypes are not generally validated through statistical methods of symptom analysis as 
later chapters attest. 
 
 
Etiology of Schizophrenia:  
 
 
Schizophrenia is a complex genetic disease, and, as such, many genes confer some risk 
for illness, but no single genetic markers confer a certain diagnosis of schizophrenia.  
Genetic hererogeneity has complicated gene finding efforts, and although many genes 
have been proposed as candidate genes for schizophrenia, none have been unequivocally 
linked to the disease.   
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All complex genetic diseases also have environmental components, and several non-
genetic causal factors have been implicated in schizophrenia.  Pre- and perinatal factors 
such as gestational viral exposure (Brown, 2006) and obstetric complications have been 
linked to later schizophrenia diagnosis (Mittal et al, 2008).  Cannabis use may also be a 
factor in subsequent psychosis (Moore et al, 2007).  Migration or the experience of being 
a minority could also play a role in developing schizophrenia (Cantor-Graae et al, 2005; 
Fearon et al, 2006; Chakraborty and McKenzie, 2002).  Environmental factors probably 
represent the best targets for prevention of some cases of schizophrenia, since genes are 
immutable and gene expression is usually difficult to modify.    
 
The heritability of schizophrenia has been estimated at 81% by meta-analysis (Sullivan et 
al, 2003) which indicates a very strong genetic influence for this disease compared to 
most other mental illnesses.  For many years, genetic studies of schizophrenia centered 
around linkage and candidate-gene association methods.  The genes yielded from these 
studies have rarely been substantiated through replication without numerous contrasting 
reports of non-association.  The advent of GWAS studies offered much promise with 
coverage of the entire genome instead of requiring pre-selection of genetic loci.  
Unfortunately, even using large samples of subjects, GWAS studies have added few 
uncontested candidate genes to the field of schizophrenia.  A recent spate of copy number 
variation (CNV) studies has generated a few loci with replicated associations with 
schizophrenia, but these account for only a small proportion of cases.   
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Additional ways of analyzing SNP chip data have recently been gaining in popularity.  
Pathway or network analyses show promise for determining biological processes 
implicated in schizophrenia and identifying causal alleles.  Epistatic interactions may also 
be responsible for some of the lack of success in unveiling single-locus genetic 
associations.  New and more powerful methods for detecting gene-gene interactions 
would be useful in assessing this possibility.  The recent and rapid advances in 
developing methods uncovering genetic variation predisposing to schizophrenia and other 
complex diseases give hope to a field that has long been plagued by slow progress and 
inconsistent associations.    
 
 
 
Cohorts:  ICCSS, ISHDSF, GAIN: 
 
 
The studies presented here which used real data (as apposed to simulations) drew subjects 
from three cohorts: the Irish Study of High Density Schizophrenia Families (ISHDSF), 
the Irish Case-Control Study of Schizophrenia (ICCSS), and the Genetic Association 
Information Network (GAIN) schizophrenia study.  Details of their ascertainment, 
assessment, and genotyping are included here to avoid redundant descriptions throughout 
this document.   
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Irish Study of High Density Schizophrenia Families (ISHDSF) 
 
The ISHDSF is a collaborative effort between Queen’s University, Belfast, the Health 
Research Board, Dublin, and Virginia Commonwealth University, Richmond, VA.  
Subject recruitment was conducted in Northern Ireland, the United Kingdom and the 
Republic of Ireland.  
 
 
Ascertainment criteria, subject characteristics, and phenotypic assessments: 
 
The full sample consisted of 1,425 individuals from 270 families ascertained on the basis 
of two or more members with DSM-III-R schizophrenia or poor outcome schizoaffective 
disorder.  Families were ascertained through public psychiatric services in Ireland and 
Northern Ireland that together provided over 90% of all in-patient psychiatric care in the 
island of Ireland. Interviews were conducted between April 1987 and November 1992 by 
Irish psychiatrists and social scientists following informed consent. 
 
 Diagnoses were generated using modified sections of the Structured Clinical Interview 
for DSM-III-R (SCID) for selected Axis I disorders (Spitzer et al., 1979). All relevant 
diagnostic information for each individual relative was reviewed, blind to pedigree 
assignment and marker genotypes, independently by Kenneth S. Kendler, MD and 
Dermot Walsh, MB, FRCPI.  Each diagnostician made up to three best estimate DSM-III-
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R diagnoses. Four definitions of affection were used, as follows:  narrow, including only 
schizophrenia and poor-outcome schizoaffective disorder; intermediate, adding also 
schizophreniform disorder, delusional disorder, atypical psychosis, good-outcome 
schizoaffective disorder, and schizotypal personality disorder; broad, further adding 
psychotic affective illness, and paranoid, avoidant, and schizoid personality disorders; 
very broad, adding to the broad definition all other psychiatric diagnoses (e.g., psychotic 
and non-psychotic affective disorders, anxiety disorders, alcoholism, and other non-
schizophrenia spectrum personality disorders) (Fanous et al, 2004). 
 
In the ISHDSF, the operational criteria checklist for psychotic illness (OPCRIT) 
(McGuffin et al, 1991) was used for phenotypic assessment.  Sixty of the 75 items in the 
OPCRIT were selected for inclusion in a factor analysis based on their assessment of 
signs and symptoms rather than course or historical features of illness.  This yielded five 
symptom factors: hallucinations, delusions, and negative, manic, and depressive 
symptoms.  Subjects were assigned scores for these factors by summing items clustering 
within each factor (Fanous et al, 2005). 
 
Genotyping: 
 
In the initial phase of the ISHDSF genome scan, the sample was randomly divided into 
three family sets.  Of the 684 markers used, 488 were unique to individual subsets.  
Markers used in the preliminary analyses presented here were all unique to one subset of 
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subjects and represent a 30 centimorgan scan.  The majority of markers genotyped were 
tri- and tetra-nucleotide repeat microsatellites generated by the Cooperative Human 
Linkage Center (CHLC), and many are included in the Weber screening set, version 8.0.  
Methods used in genotyping have been previously described (Straub et al, 1993, 1999). 
 
 
Irish Case-Control Study of Schizophrenia (ICCSS): 
The Irish Case-Control Study of Schizophrenia (ICCSS) sample was collected in the 
same geographic regions as that of the ISHDSF sample, but does not include any of the 
same subjects.  
 
Ascertainment criteria, subject characteristics, and phenotypic assessments: 
 
The 1021 affected subjects were selected from in-patient and outpatient psychiatric 
facilities in the Republic of Ireland and Northern Ireland. Subjects were eligible for 
inclusion if they had a diagnosis of schizophrenia or poor-outcome schizoaffective 
disorder by DSM-III-R criteria, which were confirmed by a blind expert diagnostic 
review.  Controls were recruited in Northern Ireland predominantly from volunteers 
donating at the Northern Ireland Blood Transfusion Service and also from the Republic 
from the Garda Siochana (the national police force) and the Forsa Cosanta Aituil (the 
army reserve).  Both cases and controls were included only if they reported all four 
grandparents as being born in Ireland or the United Kingdom (Chen et al, 2007).   
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 Subjects were rated for each symptom using case records and interviews independently. 
All subjects were assessed using a modified version of the Structured Clinical Interview 
for DSM-III-R (Spitzer et al. 1987), and family history was assessed using a modified 
version of the Family History Research Diagnostic Criteria.  In addition, case notes were 
thoroughly reviewed and rated using our Casenote Rating Scale (Fanous et al, in 
preparation).  These assessments were averaged and entered into a factor analysis using 
the statistical program MPLUS (Muthen and Muthen, 2001).  This yielded three symptom 
factors: Positive, Negative, and Schneiderian.  Sum scores were generated for each factor 
with eleven items used to generate Positive and Schneiderian symptom scores and eight 
for Negative symptoms.  These were then standardized to have values ranging from one 
to two (Fanous et al, in preparation).   
 
Genotyping: 
Individual genes or small groups of genes were genotyped using a range of assays.  Some 
were genotyped using the GenomeLab SNPstream platform from Beckman Coulter 
which is used for multiplex reactions of 12-plex or 48-plex levels.  Single SNPs were 
genotyped using the TAQMAN system from ABI (Foster City, CA).  Fluorescence 
polarization detection with template-directed dye-terminator incorporation (FP-TDI) 
(Chen and Kwok, 1997) was also used for some genotyping experiments in this sample. 
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Genetic Association Information Network (GAIN): 
 
The GAIN schizophrenia study is one of six diseases under investigation by this 
consortium.  The other diseases are: bipolar disorder, major depression, attention deficit 
hyperactivity disorder, neuropathy in type I diabetes, and psoriasis.   
 
Ascertainment criteria, subject characteristics, and phenotypic assessments: 
 
Participants were recruited from 11 sites: Chicago, IL; Irvine, CA; Denver, CO; Houston, 
TX; Iowa City, IA; St. Louis, MO; New York, NY; Philadelphia, PA; New Orleans, LA; 
Atlanta, GA; Brisbane, Australia.  Subjects were all of European or African ancestry.  To 
meet ascertainment criteria for this GAIN study, probands must have a consensus best-
estimate DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) diagnosis of 
schizophrenia or of schizoaffective disorder with at least six months' duration of the "A" 
criteria for schizophrenia.  Furthermore, subjects must be at least 18 years of age and give 
informed consent for participation.  Currently, the full sample includes 4591 participants 
(1217 EA cases, 1442 EA controls, 953 AA cases, 979 AA controls) (NCBI, Genome-
Wide Association Study of Schizophrenia, August, 2009).     
 
Subjects were interviewed by trained clinicians using the Lifetime Dimensions of 
Psychosis Scale (LDPS) (Levinson et al, 2002).  Using the LDPS, interviewer’s narrative 
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report, and all available psychiatric records, two experienced clinicians determined all 
relevant diagnoses.   
 
Genotyping: 
 
For the GAIN study, the Broad Institute Center for Genotyping and Analysis used the 
Affymetrix Human Mapping Array 6.0 gene chip.  In addition to detecting 906,600 
SNPs, this chip also contains more than 946,000 probes for the detection of copy number 
variation.  Quality control procedures performed prior to data release include:  removal of 
SNPs not in Hardy-Weinberg equilibrium (p>.000001), and dropping SNPs with a call 
rate <95%.  Duplicate samples should have concordance rates of >99.5% (Foundation for 
the National Institutes of Health GAIN Program, 2007).   
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Chapter 2:  Schizophrenia Symptom Characteristics in 
Subjects of African and European Ancestry 
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Abstract: 
The heterogeneous presentation of schizophrenia makes symptom-level analyses 
particularly important in designing studies exploring the etiology and pathophysiology of 
this disorder.  In this study, symptoms were assessed using the Lifetime Dimensions of 
Psychosis Scale (LDPS) in 996 subjects of African ancestry (AA) and 999 of European 
ancestry (EA) drawn from the Genetic Association Information Network (GAIN) 
schizophrenia study.  Factor analysis in MPlus yielded three symptom factors in both the 
separate and combined AA and EA cohorts:  positive symptoms, negative symptoms, and 
affective symptoms.  However, the factor loadings and thresholds significantly differed 
between groups, and allowing these to vary resulted in different factor structures.  
Differences were also observed between demographic variables such as age of onset, 
duration of illness, and sex and the factors in the AA and EA samples.  Earlier age of 
onset predicted higher scores for all factors in both groups.  This did not appear to be a 
function of duration of illness as this variable only predicted higher affective scores in the 
AA sample and greater negative scores in the EA sample.  Females demonstrated higher 
affective scores in the EA group, but no other sex differences were observed.  The extent 
to which AA and EA populations differ in symptom expression may be a function of 
differential environmental exposures or genetic predispositions between groups.  
Subsequent analyses incorporating genome wide genotypic data will aid in distinguishing 
these possibilities.   
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Introduction:  
 
From its original naming in 1911 by Eugen Bleuler as the “group of schizophrenias”, this 
illness has been recognized as encompassing a wide variety of clinical symptoms.  
However, affected individuals almost never exhibit all of these behaviors.  The 
heritability, or genetic contribution to the variation, of a schizophrenia diagnosis has been 
estimated at 81% by meta-analysis (Sullivan et al, 2003) signifying that the expression of 
the disease itself is predominantly mediated by genes.  A growing number of genes have 
been identified as modifiers of schizophrenia symptoms, indicating that at least some of 
the variability within this illness is genetically mediated.     
 
Investigations of the variability in schizophrenia symptoms have most often taken place 
within the same, generally Caucasian, population, but some studies exploring differences 
in rates of symptoms between ethnic groups have been conducted previously.  One early 
study found higher ratings in African-Americans than European-Americans for nearly 
every symptom they examined (Adebimpe et al, 1982).  First-rank symptoms such as 
hearing conversing voices, thought insertion or thought broadcasting are reportedly 
higher in African-Americans than European-Americans (Strakowski et al, 1996).  This 
was replicated in a later study in which raters blinded to ethnicity detected higher levels 
of first-rank and psychotic symptoms in African-American men compared to European-
American men.  However, no differences were detected for symptoms in women or for a 
diagnosis of schizophrenia between ethnic groups (Arnold et al, 2004).   
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 Factor analysis is one tool often employed to assess unobserved variables tapped by 
measured items that tend to be endorsed together.  Factor analyses of schizophrenia 
symptoms in Caucasian samples have usually found two to five factors with most 
converging on a three factor solution: positive symptoms, negative symptoms, and a 
disorganization or cognitive symptoms factor (Andreasen et al, 1995).  Some studies have 
also found affective factors incorporating anxiety, depression and/or manic symptoms.  
One factor analytic study incorporating subjects of both European (mostly British) and 
African (African-Caribbean) descent favored a six factor solution (Hutchinson et al, 
1999).  Only one factor, composed of manic items (distractability, flight of ideas, and 
pressure of speech) and catatonic symptoms (mannerisms and posturing, and stereotypies 
and tics) differed between groups with the African-Caribbean subjects having elevated 
factor scores.   
 
This is the first study of schizophrenia symptoms to use a large sample from two 
populations that were ascertained and analyzed together.  In the studies undertaken here, 
we compare the expression of schizophrenia symptoms in subjects with African and 
European ancestry.   
 
Methods: 
Subjects and Demographics:  
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Subjects were drawn from the GAIN schizophrenia study detailed in chapter 1.  The 
Lifetime Dimensions of Psychosis Scale (LDPS) (Levinson et al, 2002) was used to 
assess the duration and severity of symptoms based on a diagnostic interview and review 
of medical records.  Examination of the item endorsements across the 11 ascertainment 
cities revealed many significant differences.  Since the origin of these differences could 
be legitimate variation by city or unintentional differences in application of the rating 
criteria, we chose to restrict subsequent analyses to a subset of sites with similar 
proportions of AA and EA subjects, thereby limiting the potential for interpretation of 
site differences as ancestry group differences.  Six sites met our criteria for having 
relatively balanced proportions of AA and EA subjects (i.e. no more than 70% of subjects 
from either ancestry group).  Subsequent analyses pooled subjects by ancestry groups 
across these six sites: Atlanta, GA; St. Louis, MO; New York, NY; Philadelphia, PA; 
Chicago, IL and New Orleans, LA.   
 
Table 2.1.  Demographic information for subjects from the six included sites. 
sd = standard deviation 
 
  Subject N  Males  Females  Age at Onset (sd)  Duration (sd) 
AA  996  628  368  22.4 (7.3)  20.2 (10.8) 
EA  999  662  337  22.2 (7.2)  23.0 (11.2) 
Total  1995  1290  705     
 
Age at onset was similar for subjects in both groups (t = .37, p = .714), but EA subjects 
tended to have a longer duration of illness at the time they were interviewed (t = -5.50, p 
<.0001) (Table 2.1).  Female subjects were diagnosed with schizophrenia later than male 
subjects (23.7 yrs, sd = 7.9 versus 21.9 yrs, sd = 6.8) in keeping with prior findings (t = -
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3.40, p = .0007).  T-tests were conducted for each of the LDPS items between groups 
using SAS software (SAS Institute, 2005).   
 
Factor Analyses:  
 
Fourteen items from the LDPS were selected for inclusion in the factor analyses, and 
scores for duration and severity were summed for each item to yield one ordinal score per 
item per subject.  Exploratory factor analyses (EFAs) were implemented using a 
VARIMAX (orthogonal) rotation in MPlus (Muthen and Muthen, 2001).  A scree plot of 
the eigenvalues suggested a three factor solution fit best for the combined and individual 
samples.  The EFAs indicated distinct factor structures for AA and EA groups compared 
to the combined sample.  Confirmatory factor analyses (CFAs) followed using a 
WLSMV estimator.  To test for invariance of the factor structure across ancestry groups, 
a robust chi-square difference test for ordinal data available in MPlus was utilized to 
determine whether factor loadings and symptom thresholds could be constrained to be 
equal across groups.  This is a restrictive test of whether the factors are equivalent in the 
two groups.     
 
Relationships between the sum scores derived from the factor structures within each 
group and the demographic variables of sex, age of onset, and duration of illness were 
examined using PROC REG in SAS (SAS Institute, 2005).  
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Results: 
 
EA subjects had higher ratings for all four affective items relating to depression or mania 
as well as blunted affect (Table 2.2).  AA subjects demonstrated higher levels of 
hallucinations and conversing/commenting/continuous hallucinations.  Positive and 
negative symptom items were generally endorsed at higher rates than affective symptom 
items for both groups.  All significant item-level results maintain significance following a 
Bonferroni correction (p = .0035).   
 
 
Table 2.2.  Item level comparisons by group.  Number of subjects ranged from 995-999 
for each group and item comparison. 
 
Item 
AA 
Mean 
EA 
Mean  difference  t  p 
paranoia  7.01  7.05  ‐0.04  ‐0.45  0.65
delusions  7.38  7.48  ‐0.10  ‐1.71  0.09
hallucinations  7.12  6.81  0.30  3.64  0.0003
control delusions  3.22  3.08  0.13  0.84  0.40
conversing/commenting/cont hall  5.49  4.89  0.60  3.90  <.0001
abnormal perception of thought  2.88  2.67  0.22  1.42  0.16
blunted affect  5.08  5.46  ‐0.38  ‐3.07  0.002
poverty of speech  3.56  3.80  ‐0.24  ‐1.59  0.11
formal thought disorder  4.76  4.98  ‐0.22  ‐1.58  0.11
bizarre behavior  4.65  4.79  ‐0.14  ‐1.00  0.32
depression  2.99  3.80  ‐0.81  ‐5.78  <.0001
depression with psychotic features  0.96  1.44  ‐0.48  ‐4.22  <.0001
mania  1.04  1.74  ‐0.70  ‐6.46  <.0001
mania with psychotic features  0.62  1.07  ‐0.45  ‐4.78  <.0001
 
 
Exploratory factor analysis indicated a three factor solution for the combined sample 
which took the form of positive symptoms (paranoia, delusions, hallucinations, control 
delusions, conversing/commenting/continuous hallucinations, and abnormal perception of 
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thought), negative symptoms (blunted affect, poverty of speech, formal thought disorder, 
and bizarre behavior), and affective symptoms (depression, depression with psychotic 
features, mania, and mania with psychotics features) (Appendix A).  Although the factor 
structure was fairly definitive, some items identify factors more strongly than others.  
Namely, the items “control delusions” and “abnormal perception of thought” have lower 
loadings than the other positive factor items.  The difference in factor loadings is most 
striking for the affective symptom factor in which the depression item loadings are only 
about half that of the mania item loadings.   
 
A robust chi-square difference test of full invariance of the factor loadings and symptom 
thresholds for the three factors across the ancestry groups was significant (chi-square = 
83.4, df = 25, p-value <.0001).  This finding suggests that some of the factors may not be 
equivalent (i.e., measuring the same latent constructs) across the AA and EA groups.  The 
same factor structure was maintained for the EA group when analyzed separately, but in 
the AA subjects, the depression and depression with psychotic features items loaded most 
highly (and in the negative direction) with the negative symptom factor.  Factor loadings 
for the affective items were similar in the EA and combined samples.  The positive factor 
items had similar patterns between groups and compared to the combined sample with 
“control delusions” and “abnormal perception of thought” having somewhat lower 
loadings than the other items.  “Delusions” and “paranoia” had more equivocal loadings 
in the EA group with high loadings on the negative factors.  Negative factor items 
demonstrated factor loadings fairly similar to each other and across groups.  The fit 
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indices for the confirmatory factor analyses (CFAs) varied slightly between the combined 
sample and the two groups separately (Table 2.3).   
 
Table 2.3.  Fit indices for the separate and combined group CFAs. 
 
  combined     AA     EA 
CFI  0.893    0.903    0.889 
TLI  0.893    0.900    0.889 
RMSEA  0.131    0.139    0.127 
 
 
Slightly more variation was observed in the factor correlations with the AA group 
showing a lower positive correlation between the positive and affective factors and 
greater negative correlation between the negative and affective factors (Table 2.4).   
 
Table 2.4.  Factor correlations for AA, EA and combined samples.   
 
    combined    AA     EA 
positive w/negative  0.385    0.374    0.397 
positive w/affective  0.179    0.125    0.221 
negative w/affective  ‐0.051    ‐0.157    ‐0.009 
 
 
Sex and duration of illness were not strong predictors of the sum scores, demonstrating a 
significant relationship with only one or two factors each.  Age of onset, however, bore a 
strong negative relationship with all factors - younger ages of onset predicted higher 
symptom levels (Table 2.5).   
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 Table 2.5.  Regression results for each factor and group with sex, age of onset, and 
duration. 
 
African Ancestry             European Ancestry 
factors  covariate  t  p‐value 
mean 
(M) 
mean 
(F)    factors  covariate  t  p‐value 
mean 
(M) 
mean 
(F) 
positive  sex  ‐1.42  0.1568  33.4  32.5    positive  sex  0.98  0.3287  31.8  32.4 
negative    ‐0.15  0.8791  22.0  21.9    negative    0.43  0.6707  19.0  19.2 
affective     0.97  0.3302  1.6  1.8    affective     4.75  <.0001*  7.2  9.6 
positive  age at   ‐2.34  0.0197*        positive  age at   ‐4.18  <.0001*     
negative  onset  ‐3.44  0.0006*        negative  onset  ‐3.38  0.0007*     
affective     ‐3.97  <.0001*        affective     ‐2.36  0.0186*     
positive  duration  1.29  0.1966        positive  duration  1.41  0.1591     
negative    ‐0.32  0.7469        negative    5.62  <.0001*     
affective    2.95  0.0033*        affective    1.88  0.0601     
 
 
 
 
 
Discussion: 
 
Examination of schizophrenia symptoms in a large sample of subjects from African and 
European ancestral populations revealed much similarity, but several noteworthy 
differences.  A three factor solution fit best for the combined sample and separate groups, 
but the factor structures significantly differed between AA and EA groups with two 
affective items, depression and depression with psychotic features, inversely loading with 
the negative symptom factor in AA subjects.  Other items, such as delusions and 
paranoia, still loaded most strongly with the same factor as in the combined sample, but 
clearly show differences between groups based on the factor loadings.  Formal tests of 
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between group differences for the factor loadings and thresholds separately will provide 
additional information in this regard.   
 
Item level analyses also indicated a substantive difference in the way affective symptoms 
relate to schizophrenia between groups.  The four LDPS items indexing affective 
symptoms, depression and mania alone and with psychotic features, were more 
commonly endorsed in the EA subjects as well as blunted affect.  AA subjects, on the 
other hand, demonstrated more hallucinations as measured by the two LDPS items 
assessing these symptoms.  With the exception of the conversing/commenting/continuous 
auditory hallucinations item, we did not detect greater first-rank symptoms in the AA 
subjects as has been previously reported (Strakowski et al, 1996; Arnold et al, 2004).   
 
There are reasonable grounds for considering a genetic origin for the observed symptom 
differences.  Linkage analyses of schizophrenia in African-American and European-
American samples identified different loci between groups (Kaufmann et al, 1998; 
Takahashi et al, 2003; Faraone et al, 2005; Suarez et al, 2006), and Ioannidis et al (2004) 
showed that disease associated alleles for several complex diseases vary in frequency 
across “racial” boundaries.  It seems plausible that symptom differences might arise from 
distinct genetic etiologies as well.  The set of genes impacting symptom variation almost 
certainly overlaps with the risk alleles for schizophrenia. 
 
 23
Numerous aspects of the environment have also been suggested to explain differences in 
rates of schizophrenia between groups, and these factors may also impact symptom 
expression.  Discrimination is one variable proposed to lead susceptible individuals 
toward psychosis or other mental illnesses in minority groups and migrants (Chakraborty 
and McKenzie, 2002).  Urbanicity has also been suggested as a predisposing factor 
(Pedersen and Mortensen, 2001; Krabbendam and van Os, 2005).  Migrant status has 
been repeatedly raised as a potential risk factor, but is often confounded by the 
aforementioned possibilities (Cantor-Graae et al, 2005; Fearon et al, 2006). These and 
other environmental variables merit further study. 
 
The extent to which symptoms or subtypes cluster in families has been examined with 
some studies supporting the idea of familial aggregation (Onstad et al, 1991; Loftus et al, 
2000; Wickham et al, 2001; McGrath et al; 2009) while others have not (DeLisi et al, 
1987; Kendler et al, 1988).  Even when similar forms of schizophrenia are manifest in 
relatives, causal ambiguity between genetic and familial environmental influences 
remains.   
 
Interpretation of the results presented here should be considered in the context of several 
possible limitations.  First, we relied on self report for ancestry information and group 
assignment, but incorporation of ancestry informative genotypic markers would be useful 
in assigning finer scale distinctions to these highly admixed populations.  In addition to 
the numerous African and European populations that have migrated to America, several 
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generations of intermixing within and across these broadly defined groups have 
contributed to the genetic complexity present in our sample.  One study of African-
American admixture investigated individuals in nine American cities and detected 
marked variability in the range of “European DNA” from 12.2% Charleston, South 
Carolina to 22.8% in New Orleans, Louisiana (Parra et al, 1998).  The cross-site 
differences detected in our study may partially result from different genetic influences or 
other valid sources of variance such as more severely ill patients collected at some sites.  
Unfortunately, these legitimate differences cannot easily be disentangled from 
confounding sources of difference such as variation in applying the LDPS rating 
guidelines across sites.   Our restriction of analyses to subjects from sites with less than 
70% from either ancestry group serves to enhance confidence in the results.   
 
The difference in duration of illness between groups is of potential concern, but the 
relationship between this variable and the factors was rather weak compared with the 
influence of age of onset.  Our findings indicate that early onset of schizophrenia 
predisposes individuals to a more severe form of the illness compared with those who 
become ill later.    
 
Systematic clinician bias in schizophrenia diagnosis cannot be ruled out.  If African-
Americans are more likely than European-Americans to be diagnosed with schizophrenia 
when presenting with the same symptoms, artificial differences in symptom profiles 
could conceivably arise.  This scenario would result in increased observed severity in the 
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EA population for which there is only scant evidence.  Of the seven LDPS items 
significantly different between groups, five showed increased severity/duration in the EA 
group.  That said, the relative increase in affective symptoms we observed in the EA 
group may partially underlie the findings that this population is more often given a 
diagnosis of bipolar disorder compared to AA individuals (Mukherjee et al, 1983; 
Minsky et al, 2003).   
 
The extent to which ancestry group differences reflect clinician bias in diagnosis and 
assessment, sociocultural differences, or biological factors has thus far been inextricable.  
With this large, well-characterized sample, we finally have the opportunity to examine 
whether genetic factors underlie symptom differences between schizophrenic subjects of 
African and European ancestry.  Regardless of their sources, clinician awareness of group 
differences in illness rates and presentation would aid in the proper diagnosis and 
treatment of affected individuals.   
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Chapter 3:  Candidate Gene Investigations of 
Schizophrenia Symptom Modification 
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Chapter Abstract: 
 
 
Although nearly all efforts in the field of schizophrenia genetics have centered around 
detection of susceptibility genes, a growing literature aims to find genetic causes of 
symptom variation in schizophrenia.  This chapter details four studies of a total of seven 
genes examined for schizophrenia symptom modifier effects in two Irish samples, the 
ICCSS and ISHDSF.  The first set of genes was investigated in the ISHDSF using 
UNPHASED and QTDT.  We found tentative associations of PAH with delusions and 
GABRB3 with hallucinations, but no symptom factors were associated with SLC6A4 or 
MAOB.  We probed the remaining genes in the ICCSS cohort.  AKT1 was associated 
with Schneiderian symptoms using UNPHASED.  Using the sequential addition method 
implemented in UNPHASED, dysbindin was not associated with any symptom factor, 
but SNAP25 demonstrated association with both hallucinations and delusions.  In the 
absence of a cure for this illness, treatments aimed at ameliorating symptoms may be the 
best approach.  Additional studies identifying modifier and susceptibility-modifier genes 
will give us a better understanding of the genes (and biological pathways) giving rise to 
these symptoms and will aid in the generation of more targeted treatment options.   
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Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and                          
Modification of Psychotic Disorder Features 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from:  
Bergen SE, Fanous AH, Walsh D, O’Neill FA, Kendler KS.  (2009) Polymorphisms in 
SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features. 
Schizophrenia Research 109: 94-97.  
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Abstract 
 
We tested four genes [phenylalanine hydroxylase (PAH), the serotonin transporter 
(SLC6A4), monoamine oxidase B (MAOB), and the gamma-aminobutyric acid A 
receptor β-3 subunit (GABRB3)] for their impact on five schizophrenia symptom factors:  
delusions, hallucinations, mania, depression, and negative symptoms.  In a 90 family 
subset of the Irish Study of High Density Schizophrenia Families, the PAH 232 bp 
microsatellite allele demonstrated significant association with the delusions factor using 
both QTDT (F=8.0, p=.031) and QPDTPHASE (chi-square=12.54, p=.028).  Also, a 
significant association between the GABRB3 191 bp allele and the hallucinations factor 
was detected using QPDTPHASE (chi-square=15.51, p=.030), but not QTDT (chi-
square=2.07, p=.560).   
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Introduction 
Schizophrenia is a complex genetic disorder with numerous reported susceptibility genes 
(Harrison & Owen, 2003; Tsuang et al, 1999).  The substantial clinical variability noted 
from its earliest descriptions by Kraepelin (1921) and Bleuler (1950) through present-day 
DSM subtypes (McGlashan & Fenton, 1991) and the results of factor analysis (Peralta & 
Cuesta, 2001; Fanous et al, 2005) may arise from genetic heterogeneity.  Specific patterns 
of symptoms resulting from differing genetic etiologies may underlie variation within the 
disease or ultimately result in partitioning “the schizophrenias” into distinct diagnoses.   
 
Genes that underlie a predisposition to schizophrenia may additionally influence the 
manifestation of the disorder (termed susceptibility-modifier genes).  However, genes 
unrelated to susceptibility for the illness can affect expression of symptoms following 
onset (termed modifier genes) (Fanous & Kendler, 2005).  Several reports of associations 
between genetic polymorphisms and clinical symptoms of schizophrenia have now been 
published (Malhotra et al, 1998; Cardno et al, 1999; Kaiser et al, 2000; Zhang et al, 2000; 
Serretti et al, 2001; Fanous et al, 2004; Reynolds et al, 2005; Fanous et al, 2005; McClay 
et al, 2006, DeRosse et al, 2007).  
 
In this study, we tested for the presence of association between five clinical features of 
schizophrenia (delusions, hallucinations, mania, depression, and negative symptoms) and 
polymorphisms in four genes:  phenylalanine hydroxylase (PAH), the serotonin 
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transporter (SLC6A4), monoamine oxidase B (MAOB), and the gamma-aminobutyric 
acid A receptor β-3 subunit (GABRB3).   
 
PAH is located at 12q22-q24.2 and is most recognized for its involvement in the 
recessive metabolic disorder, phenylketonuria.  However, allelic variation that stops short 
of functional inactivation may have a markedly different clinical impact.  There was one 
report of increased incidence of schizophrenia in parents of phenylketonuric children 
(Vogel, 1985), but other studies exploring the relationship between PAH and 
schizophrenia have yielded less positive results (Sobell et al, 1993; Chao & Richardson, 
2002; Richardson et al, 2003).  Tentative reports of PAH polymorphisms impacting 
paranoid hallucinations (Uebelhack et al, 1987) and negative symptoms (Wilcox et al, 
2002) have been published.  The biological plausibility of the PAH mechanism of action 
in the pathophysiology of schizophrenia largely rests on its ties to the dopaminergic 
system, since PAH converts phenylalanine to tyrosine, a dopamine precursor.  PAH is 
also involved in serotonin synthesis, and its impairment results in lowered serotonin 
levels (Alcaniz & Silva, 1997).   
   
Multiple lines of evidence have previously also implicated alterations of the serotonin 
system in schizophrenia (Breier, 1995), and particular symptom dimensions may be more 
affected than others.  SLC6A4 (aka SERT), located at 17q11.1-q12, has demonstrated 
equivocal schizophrenia association, but a recent meta-analysis of 12 studies including 
the 17 bp VNTR polymorphism genotyped here found strong evidence for association 
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(OR 1.24, p=.00014) (Fan & Sklar, 2005).  Additionally, SLC6A4 has been linked to 
depressive symptoms in schizophrenia (Golimbet et al, 2004), the Psychopathic deviance, 
Paranoia, and Schizophrenia subscales of the MMPI in patients with affective disorders 
(Golimbet et al, 2003), and hallucinations in patients with schizophrenia or 
schizoaffective disorder (Malhotra et al, 1998).  
 
The MAOB gene, located on the X-chromosome at Xp11.23, functions in the catabolism 
of catecholamines such as dopamine, epinephrine, norepinepherine, and 
phenylethylamine (a phenylalanine metabolite).  A study of MAOB polymorphisms and 
aggression in subjects with schizophrenia failed to find a relationship between the two 
(Zammit et al, 2004), but there has been tentative support for MAOB in liability to 
schizophrenia (Dann et al, 1997; Wei & Hemmings, 1999; Carrera et al, 2008) and 
bipolar disorder (Lin et al, 2000).   
 
Examinations of GABAergic system pharmacology and neuroanatomy in subjects with 
schizophrenia have revealed numerous changes (Wassef et al, 2003).  The only study 
exploring polymorphisms in the β3 subunit gene showed no linkage with schizophrenia 
(Byerley et al, 1995).  However, GABRB3, located at 15q11.2-q12, has been implicated 
in autism susceptibility (Cook et al, 1998; Craddock et al, 1999).  Autism and 
schizophrenia share a few common features, and some evidence exists relating the 
catatonic symptoms of both to the GABAergic system (Dhossche, 2004).   
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Although these genes have not often been investigated with regard to schizophrenia, 
ample evidence exists for the involvement of neurotransmitter systems linked to these 
genes in this disorder to merit their examination as potential modifier genes.     
 
Methods 
Subjects and Assessment 
Subjects were drawn from the Irish Study of High Density Schizophrenia Families 
(ISHDSF) more fully described in chapter 1.  The full sample consisted of 1,425 
individuals from 270 families ascertained on the basis of two or more members with 
DSM-III-R schizophrenia or poor outcome schizoaffective disorder, but results presented 
here were derived from a 90 family subset with available genotypes.   
 
Diagnoses were generated using modified sections of the Structured Interview for DSM-
III-R (SCID) for selected Axis I disorders (Spitzer et al., 1979).  Four definitions of 
affection were used, as follows:  narrow, including only schizophrenia and poor-outcome 
schizoaffective disorder; intermediate, adding also schizophreniform disorder, delusional 
disorder, atypical psychosis, good-outcome schizoaffective disorder, and schizotypal 
personality disorder; broad, further adding psychotic affective illness, and paranoid, 
avoidant, and schizoid personality disorders; very broad, adding to the broad definition 
all other psychiatric diagnoses (e.g., psychotic and non-psychotic affective disorders, 
anxiety disorders, alcoholism, and other non-schizophrenia spectrum personality 
disorders). 
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 Factor analysis of the operational criteria checklist for psychotic illness (OPCRIT) 
(McGuffin et al, 1991) yielded five symptom factors: hallucinations, delusions, and 
negative, manic, and depressive symptoms (Fanous et al, 2005).  Subjects were assigned 
scores for these factors by summing items clustering within each factor. 
 
Genotyping 
In the initial phase of the ISHDSF genome scan, the sample was randomly divided into 
three sets of 90 families each.  Of the 684 markers used, 488 were unique to individual 
subsets.  Markers used in the analyses presented here were all unique to one subset of 
subjects.  The primer sequences used to amplify the 6 MAOB microsatellite alleles, 9 
PAH microsatellite alleles and 14 GABRB3 microsatellite alleles were reported by 
Grimsby et al (1992), Goltsov et al (1993) and Beckmann et al (1993), respectively.  The 
SLC6A4 marker genotyped here was a 17 bp VNTR with three alleles flanked by primers 
reported by Ogilvie et al (1996).  Methods used in genotyping have been previously 
described (Straub et al, 1993, 1999).    
 
Statistical Analyses 
Tests of association between all genes and the diagnostic categories were performed 
using PDTPHASE, which is part of the UNPHASED package (Dudbridge, 2003).  Rare 
microsatellite alleles, defined as comprising less than 3% of the sample, were dropped 
from analyses. 
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 Association tests between the gene polymorphisms and each of the five symptom factors 
were performed using QTDT (Abecasis et al, 2000) and QPDTPHASE, another facet of 
UNPHASED (Dudbridge, 2003), for all genes except MAOB.  Instead, this gene was 
only analyzed using QPDTPHASE, since QTDT is not designed to analyze X-
chromosome markers.  For each QTDT marker by factor test, a Bonferroni correction 
was calculated to account for the number of alleles tested and the most significant marker 
is reported.  UNPHASED results are global tests of significance.   
 
Results and Discussion 
Significant associations of MAOB with intermediate (chi-square=10.43, p=.034) and 
broad (chi-square=9.94, p=.041) diagnostic categories, driven by the 201 bp allele, were 
the only gene-diagnosis relationships observed (Table 3.1).  However, two genes showed 
a significant relationship with symptom factors (Table 3.2).  The PAH 232 bp allele 
demonstrated a significant association with the delusions factor using both QTDT (F=8.0, 
p=.031) and QPDTPHASE (chi-square=12.54, p=.028).  Also, a significant association 
between the GABRB3 191 bp allele and the hallucinations factor was detected using 
QPDTPHASE (chi-square=15.51, p=.030), but not QTDT (chi-square=2.07, p=.560).   
 
Our results support the tentative implication of MAOB in the etiology of psychotic 
disorders but not specifically schizophrenia, since the narrow diagnostic category did not 
demonstrate association.  These data also provide some evidence for the  
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impact of PAH and GABRB3 on the respective factors of delusions and hallucinations.  
However, these results should be interpreted with caution since no corrections for 
multiple testing across genes and factors were implemented due to the correlated nature 
of the tests.  Nevertheless, neurobiological links between the GABAergic system and 
psychosis have been drawn (Keverne, 1999).  Furthermore, dopaminergic modulation of 
delusions has also been demonstrated (Krieckhaus et al, 1992), lending credence to a 
potential PAH-delusions association.  Additional scrutiny of the relationships between 
these genes and factors in an independent sample is warranted.  
 
 
Table 3.1  PDTPHASE association test results for four genes and four diagnostic 
categories 
 
 
Table 3.2a  QTDT results for markers from three genes and five clinical factors 
 
 
 
Table 3.2b  QPDTPHASE results for markers from four genes and five clinical factors 
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Association of AKT1 with Schneiderian Symptoms in the 
Irish Case-Control Study of Schizophrenia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
DL Thiselton, SE Bergen, Wormley B, McMichael O, O’Neill FA, Walsh D, Vladimirov 
V, Fanous AH, Kendler KS, Riley BP.  AKT1 is associated with schizophrenia in the 
Irish case-control study of schizophrenia (ICCSS): Follow-up analysis of specific 
phenotypic factors.  (in preparation)  
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Abstract: 
 
Several lines of evidence, including a number of association studies, suggest a role for 
AKT1 in the pathophysiology of schizophrenia.  This research group previously 
demonstrated an AKT1 association with schizophrenia in an Irish family sample and also 
association of the risk haplotype with hallucination symptoms in that sample (Thiselton et 
al, 2008).  Prior tests of association between AKT1 and schizophrenia in the Irish Case–
Control Study of Schizophrenia (ICCSS) sample revealed a positive result for one of the 
seven SNPs tested, rs10149779 (chi-sq=7.041, empirical p=0.045).  A two-marker 
haplotype, rs10149779-rs10138227, demonstrated even stronger association with 
schizophrenia (chi-sq=21.79, p=3.04E-06) (Thiselton et al, in preparation).  In this study, 
we explored whether the risk haplotype in the ICCSS also predisposes subjects to 
particular symptom dimensions.  Interviews and medical records provided phenotypic 
information which was entered into a factor analysis and revealed three symptom factors: 
Positive, Negative, and Schneiderian (Fanous et al, in preparation).  In analyses using 
individual SNPs, the same SNP demonstrating positive association with schizophrenia, 
rs10149779, was also positively associated with the Schneiderian symptom factor (chi-
square=5.3, p=.021).  Mirroring the schizophrenia association results, the risk haplotype 
demonstrated an even stronger association with this factor (chi-square=8.1, p=.004).  Our 
finding of AKT1 association with Schneiderian symptoms in combination with prior 
work showing association with hallucinations indicates some variants of this gene may 
predispose individuals to a particular form of schizophrenia with high levels of positive 
symptoms.   
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Introduction: 
 
The AKT1 gene, also known as v-akt murine thymoma viral oncogene homolog 1, is 
located at 14q32.32 and encodes a serine/threonine protein kinase involved in 
intracellular signaling pathways that impact cell survival, synaptic transmission and 
neuronal plasticity (Grimes and Jope, 2001).  Multiple lines of evidence have implicated 
AKT1 in schizophrenia pathophysiology.  AKT1 is a vital part of the normal 
dopaminergic transmission pathway and acts downstream of the DRD2 receptor, a target 
of many antipsychotic drugs (Beaulieu et al, 2004).  AKT1 protein levels showed a 68% 
decrease in the brains of individuals with schizophrenia by one report (Emamian et al, 
2004).  Decreased expression of AKT1 mRNA has been reported in the dorsolateral 
prefrontal cortex of individuals with schizophrenia, a brain region frequently implicated 
in schizophrenia neuropathology (Thiselton et al, 2008).  Additionally, it has been 
suggested that dysbindin promotes neuronal viability through AKT signaling, providing a 
link between AKT and another putative susceptibility gene (Numakawa et al, 2004).    
 
Since altered mRNA and protein levels could result from primary genetic changes or be 
downstream effects of other altered processes, genetic association tests are informative.  
Seven reports of positive association of AKT1 and schizophrenia have been published 
(Emamian et al, 2004; Ikeda et al, 2004; Schwab et al, 2005; Bajestan et al, 2006; Norton 
et al, 2007; Xu et al, 2007) including one from this research group using the Irish High 
Density Study of Schizophrenia Families (ISHDSF) (Thiselton et al, 2008).  However, 
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six negative findings of association have also surfaced (Ohtsuki et al, 2004; Ide et al, 
2006; Liu et al, 2006; Turunen et al, 2007; Sanders et al, 2008; Liu et al, 2008).  With 
about half of the published association tests of this gene with schizophrenia reporting 
positive results, tentative support for a primary role of AKT1 in schizophrenia etiology 
has been presented.   
 
In the previous study of AKT1 from this group, relationships between this gene and 
symptom factors of schizophrenia were explored, and the hallucinations factor showed 
the strongest association (Thiselton et al, 2008).  One other exploration of AKT1 and 
symptoms of schizophrenia was conducted, but no significant relationships with positive, 
negative, or general psychopathology were found (Liu et al, 2008).    
 
In the present study, association analysis of single SNPs in the whole sample revealed a 
significant association with schizophrenia for rs10149779 (chi-sq = 7.041, p = 0.008) and 
trends towards significance for rs3730358 (chi-sq = 3.197, p = 0.074) and rs12878684 
(chi-sq = 3.567, p = 0.059).  In each case the major allele was over-represented in cases 
relative to controls.  Only the association with rs10149779 survived a 100,000 
permutation test (chi-sq = 7.041, empirical p = 0.045) (Thiselton et al, in preparation).   
 
Given the linkage disequilibrium relationships between the markers tested, a haplotypic 
association test between the rs10149779-rs10138227 block and schizophrenia was 
conducted. A stronger association was observed between this haplotypic combination and 
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disease compared to the individual SNPs (G-C; chi-sq = 21.79, p = 3.04E-06).  There was 
an under-representation in cases of the rare-common haplotype (Thiselton et al, in 
preparation). 
 
Based on the aforementioned results, we embarked on this study exploring whether 
genetic variation in AKT1 was related to schizophrenia symptom dimensions in the 
ICCSS sample.     
 
 
Methods: 
 
The subjects examined in this study were drawn from the Irish Case–Control Study of 
Schizophrenia (ICCSS) for which an in depth exposition can be found in chapter 1.  The 
full sample includes 1021 affected individuals, and seven AKT1 SNPs were genotyped 
using validated Taqman SNP genotyping assays from ABI 
(www.appliedbiosystems.com).  They were:  rs3803300, rs12878684, rs1130214, 
rs10138227, rs10149779, rs3730358 and rs2498799.     
 
Subjects were rated for each symptom using case records and interviews independently.  
These assessments were averaged and entered into a factor analysis using the statistical 
program MPLUS (Muthen and Muthen, 2001).  This yielded three symptom factors: 
Positive, Negative, and Schneiderian (Fanous et al, in preparation).  Sum scores were 
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generated for each factor with eleven items contributing to the Positive and Schneiderian 
symptom scores and eight for Negative symptoms.  These sum scores were merged with 
the AKT1 genotypes for each subject using SAS 9.1 (SAS Institute, 2005) and analyzed 
using Unphased (Dudbridge, 2003).  All three symptom factors were tested separately 
against each marker as well as the high risk haplotype consisting of rs10138227 and 
rs10149779.    
 
Results: 
 
Significant associations were observed between the same SNP showing schizophrenia 
association, rs10149779, and the Schneiderian symptom factor (chi-square=5.3, p=.021) 
(Table 3.4).  The risk haplotype also demonstrated significant association with the 
Schneiderian factor (chi-square=8.1, p=.004).   
 
Table 3.4.  Association results for AKT1 and schizophrenia and three symptom factors.   
 
  Schizophrenia  Negative   Positive   Schneiderian 
Marker   
chi-
square 
p-
value  
chi-
square 
p-
value  
chi-
square 
p-
value   
chi-
square
p-
value 
SNP1 rs3803300 0.436 0.509  2.152 0.142  1.616 0.204  0.530 0.467 
SNP2 rs12878684 3.701 0.054  0.908 0.341  1.780 0.182  1.035 0.309 
SNP3 rs1130214 0.512 0.474  0.139 0.710  0.084 0.772  0.444 0.505 
SNP4 rs10138227 2.088 0.148  1.034 0.309  1.009 0.315  0.007 0.932 
SNP5 rs10149779 7.296 0.007*  3.665 0.056  2.277 0.131  5.345 0.021*
SNP6 rs3730358 3.044 0.081  3.691 0.055  0.218 0.641  0.724 0.395 
SNP7 rs2498799 0.815 0.367  1.113 0.291  0.011 0.918   0.284 0.594 
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Discussion: 
 
Our investigations of AKT1 and symptom factors of schizophrenia revealed that the same 
risk SNP and haplotype predisposing individuals to the illness itself are also related to 
increased Schneiderian symptoms.  Although the prior study of AKT1 and schizophrenia 
symptoms in an Irish family sample found association with hallucinations, several 
possibilities may explain this difference.  One reason for the apparent discrepancy 
between the findings in the ICCSS and ISHDSF could be the risk allele differences 
between groups.  The different AKT1 risk alleles may predispose to slightly different 
symptoms.  Also, Schneiderian symptoms and hallucinations are not mutually exclusive.  
Schneiderian symptoms were initially thought to be specific to schizophrenia but may 
appear in related disorders, and they include several types of hallucinations such as 
audible thoughts, voices conversing, or a voice commenting on one’s actions.  Some 
delusions are also Schneiderian symptoms, and these include: external control of 
thoughts, thought broadcasting or insertion, or delusional perceptions.  All hallucinations 
and Schneiderian symptoms are positive symptoms which may have similar underlying 
biological mechanisms including alterations of the AKT1 gene.   
 
We would also like to mention that caution is warranted in interpreting these results given 
the number of statistical tests implemented and the absence of multiple testing 
corrections.  Nevertheless, sufficient evidence exists to merit further research to 
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understand the relationship between AKT1 and positive symptoms of schizophrenia and 
the mechanisms by which this may occur.   
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and Delusions Symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
Fanous AH, van den Oord ECG, Thiselton DL, Bergen SE, Wormley BT, Amdur RL, 
O’Neill FA, Walsh D, Kendler KS, Riley BP.  Association study of SNAP25 and 
schizophrenia in Irish family and case-control samples. Neuropsychiatric Genetics 
(accepted) 
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 Abstract: 
 
Alterations at the synaptic level have been found in numerous studies of schizophrenia 
using a variety of methods.  SNAP25, one of the vesicular docking proteins, has 
specifically been implicated in protein and functional studies as well as some association 
studies.  Support for the involvement of this gene in schizophrenia was deemed sufficient 
to warrant additional genetic studies, and we tested for association of SNAP25 with this 
illness in the Irish Study of High Density Schizophrenia Families (ISHDSF).  Eighteen 
SNPs (five haplotype blocks) were genotyped and tested using FBAT and PDTphase.  
The block five haplotype, consisting of two SNPs, rs362988 and rs6039820, was 
significantly associated with schizophrenia for all four concentric diagnostic categories 
and both statistical software packages.  Consequently, this haplotype was selected for 
association tests with the symptom factors.  The sequential addition method, 
implemented using UNPHASED, found this haplotoype of SNAP25 to be preferentially 
overtransmitted to subjects in the upper ~60% of the hallucinations (empirical P=.006) 
and delusions factors (empirical P=.01).  These results suggest SNAP25 is a 
schizophrenia susceptibility gene which predisposes individuals to a form of illness with 
high rates of positive symptoms.   
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 Introduction: 
 
Synaptosomal-Associated Protein of 25 kDa (SNAP25) is a component of the soluble N-
ethylmaleimide-sensitive factor attachment receptor (SNARE) complex which mediates 
the exocytosis of neurotransmitters from the presynaptic neuronal membrane.  Alterations 
of presynaptic proteins have been implicated in schizophrenia through a variety of studies 
(thoroughly detailed in chapter 5).  SNAP25 specifically has been the focus of several 
studies of schizophrenia.  An association between SNAP25 and decreased pre-pulse 
inhibition, a schizophrenia-related sensory gating defect, was found in mice (Jeans et al., 
2007).  Reductions in the SNAP25 protein have been reported in the hippocampus 
(Fatemi et al., 2001; Thompson et al., 2003a; Young et al., 1998; Thompson et al., 1998), 
prefrontal cortex (Karson et al., 1999; Thompson et al., 1998), temporal cortex  
(Thompson et al., 1998), and cingulate cortex (Gabriel et al., 1997), as well as increased 
levels of CSF SNAP25 (Thompson et al., 2003b; Thompson et al., 1998; Thompson et 
al., 1999) in schizophrenia. 
 
The initial association study of SNAP25 in schizophrenia using a single-marker was 
negative (Tachikawa et al., 2001) as were two later studies (Wong et al, 2003; Musil et al, 
2008).  However, the two largest and most recent studies yielded more promising results.  
Kawashima et al (2008) found support for SNAP25 association in the first stage of a two-
stage association design but not in the second stage, and Caroll et al (2009) reported a 
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positive association of this gene with schizophrenia.  In the Irish Study of High Density 
Schizophrenia Families (ISHDSF), significant associations were observed for 9 of the 18 
SNPs examined in at least one of the four diagnostic categories using one or both of the 
software packages, FBAT and PDTphase.  Only one haplotype block, block 5 (rs362988 
and rs6039820), was used for subsequent phenotypic analyses as it was the only one that 
was significant across all four concentric diagnostic groups and in both analysis 
packages. 
 
Evidence that SNAP25 is altered in schizophrenia has arisen from multiple 
methodologies and prompted additional interest at the genetic level.  Association of 
SNAP25 with this disease in the ISHDSF led us to examine this gene with respect to 
symptom dimensions of schizophrenia in this sample.   
 
 
Methods: 
 
Subjects and genotyping: 
 
Subjects were drawn from the Irish Study of High Density Schizophrenia Families 
(ISHDSF) detailed in Chapter 1.  Phenotypic measures were obtained for the 755 subjects 
used in these analyses using the operational criteria checklist for psychotic illness 
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(OPCRIT) (McGuffin et al, 1991).  Factor analysis of items from the OPCRIT yielded 
five factors:  hallucinations, delusions, and negative, manic, and depressive symptoms.   
 
Eighteen single nucleotide polymorphisms (SNPs) tagging haplotypes in the SNAP25 
gene were genotyped.  Some were genotyped by template-directed dye-terminator 
incorporation with fluorescence polarization detection (FP-TDI) using the relevant 
AcycloPrime FP SNP detection kit (PerkinElmer Life Sciences, Boston, MA) according 
to the manufacturer’s instructions, and an automated allele scoring platform (Van Den 
Oord et al., 2003).  Multiplex genotyping of additional SNPs was conducted on the 
GenomeLab SNPstream (Beckman Coulter, Fullerton, CA).   
 
Statistical analyses:   
 
We tested the associated haplotoype, rs362988 and rs6039820, for effects on the clinical 
phenotype using UNPHASED.  To determine whether a subset of the subjects was 
driving the observed association between SNAP25 and schizophrenia, all cases were rank 
ordered according to each of five symptom factors previously extracted from the 
OPCRIT in this sample: negative symptoms, depressive symptoms, manic symptoms, 
delusions, and hallucinations (Fanous et al., 2005).  The sequential addition method 
(Macgregor et al. 2006) was used as follows:  first, a chi-square test was performed for all 
cases and controls.  Next, for each factor, cases with the highest scale scores were 
compared with all control subjects using a chi-square test.  Cases with incrementally 
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lower scores were progressively included until the chi-square value met or exceeded that 
of the full case sample.  To assess the probability of a factor-haplotype association under 
the null hypothesis, permutations were carried out in which the same proportion of cases 
achieving a significant association was randomly sampled from the total case population 
using SAS 9.1.3 (SAS Institute, 2005) and compared to all controls using UNPHASED  
(Dudbridge, 2003) software suite v.2.404.  Empirical p-values were determined from 
these permutations by the formula P=d+1/n+1, where d is the number of chi-square 
statistics observed in n=5000 permutations that exceeded the chi-square observed in the 
full sample.   
 
 
Results: 
 
Analysis of clinical covariates using sequential addition yielded non-significant results 
for the negative, manic and depressive factors of the OPCRIT.  However, for the 
delusions factor, inclusion of 58% of the cases with the highest symptom levels resulted 
in a chi-square value exceeding that of the full sample (7.40 compared to 5.46, empirical 
P=.01).  Including 59% of the cases with the highest hallucination scores resulted in a 
chi-square value of 8.21 (compared to 5.46 in the full sample, empirical P=.006).   
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Discussion: 
 
We found that the most significantly associated haplotoype of SNAP25 was 
preferentially overtransmitted to subjects in the upper ~60% of the hallucinations and 
delusions factors.  These factors are correlated in this sample, as would be expected due 
to their frequent co-occurrence as “positive symptoms”.  If the marker-disease 
associations observed in this sample are true, this would suggest that SNAP25 is what we 
have termed a Susceptibility-Modifier gene.  This class of genes is one that predisposes 
to more or less specific clinical subtypes of illness, and may affect the distribution of 
clinical features in a population (Fanous and Kendler, 2005; Fanous and Kendler, 2008). 
 
SNAP25 has been linked to schizophrenia through a variety of research methods, and this 
is the first report of association of this gene with the positive symptoms of hallucinations 
and delusions.  Additional studies to clarify the mechanisms by which this gene could 
facilitate a diagnosis of schizophrenia or impact the manifestation of symptoms would be 
useful in elucidating the role of SNAP25 in this disease.    
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Adapted from:  
Bergen SE, Fanous AH, Riley BP, Kuo PH, Wormley BK, O’Neill FA, Walsh D, 
Kendler KS.  No association of dysbindin with symptom factors of schizophrenia in an 
Irish case-control sample. Neuropsychiatric Genetics (accepted) 
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Abstract 
 
Robust associations between the dysbindin gene (DTNBP1) and schizophrenia have been 
demonstrated in many but not all samples, and evidence that this gene particularly 
predisposes to negative symptoms in this illness has been presented.  The current study 
sought to replicate the previously reported negative symptom associations in an Irish 
case-control sample.  Association between dysbindin and schizophrenia has been 
established in this cohort, and a factor analysis of the assessed symptoms yielded three 
factors, Positive, Negative and Schneiderian.  The sequential addition method was 
applied using UNPHASED to assess the relationship between these symptom factors and 
the high risk haplotype.  No associations were detected for any of the symptom factors 
indicating that the dysbindin risk haplotype does not predispose to a particular group of 
symptoms in this sample.  Several possibilities, such as differing risk haplotypes, may 
explain this finding.   
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 Introduction 
 
Schizophrenia is a severe neuropsychiatric disorder affecting approximately 1% of the 
global population.  Despite decades of research, conclusive facts regarding the etiology of 
schizophrenia have remained elusive.  However, a substantial genetic underpinning is 
indicated by a meta-analysis-derived heritability estimate of 81% (Sullivan et al, 2003), 
and evidence is mounting for some susceptibility genes.  Dysbindin (dystrobrevin binding 
protein 1; DTNBP1) in particular is one of the most promising candidate genes for 
schizophrenia to date (Sun et al, 2008) with numerous positive associations reported 
(Straub et al, 2002; Van Den Oord, 2003a; Schwab et al, 2003; Kirov et al, 2004; Funke 
et al, 2004; Williams et al, 2004; Fallin et al, 2005; Li et al, 2005; Tochigi et al, 2006; 
Tosato et al, 2007; Vilella et al, 2007; Duan et al, 2007) but several negative reports, as 
well (Morris et al, 2003; Hall et al, 2004; Li et al, 2005; Holliday et al, 2006; Joo et al, 
2006; Pedrosa et al, 2007; Wood et al, 2007; Bakker et al, 2007; Datta et al, 2007; Liu et 
al, 2007; Zinkstok et al, 2007; Turunen et al, 2007).  
 
Of the many studies reporting associations between schizophrenia and dysbindin, most 
have genotyped somewhat different markers, and considerable heterogeneity in risk 
haplotypes has been reported.  Variability in study design has hampered attempts at 
cross-study interpretation.  One meta-analysis failed to find allelic heterogeneity 
(Mutsuddi et al, 2006), while another more recent meta-analysis did uncover substantial 
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allelic heterogeneity for the DTNBP1-schizophrenia association (Maher et al, in press 
Human Heredity).   Marker rs2619538 (aka SNP A) did attain overall significance in this 
report (Maher et al, in press Human Heredity), and another meta-analysis of associations 
reported in the SzGene database found SNP rs1011313 to be significantly associated in 
Caucasian populations (Allen et al, 2008). 
 
Some aspects of the dysbindin protein functions have been elucidated including its role in 
the biogenesis of organelles such as lysosomes, melanosomes, and platelet dense granules 
(Dell’Angelica, 2004).  The mouse homologue of dysbindin binds to alpha and beta-
dystrobrevins in muscle tissues (Benson et al, 2001), and dysbindin has also been 
localized to glutamatergic presynaptic terminals in humans (Talbot et al, 2004).  The 
mechanism by which dysbindin polymorphisms impact the liability to schizophrenia is 
unknown, but affected subjects have shown reduced protein and mRNA expression in 
brain regions implicated in this disorder such as the hippocampus (Talbot et al, 2004; 
Weickert et al, 2008), the prefrontal cortex, and a non-significant reduction in the 
midbrain (Weickert et al, 2004).  A study examining prefrontal and hippocampal 
dysbindin expression levels in mice treated with common antipsychotic medications 
revealed unchanged mRNA levels compared to an untreated group suggesting that the 
changes observed in human populations are unlikely to be due to the effects of 
medication (Chiba et al, 2006).  
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Prior reports have linked dysbindin with negative symptoms in schizophrenia.  Fanous et 
al (2005) examined the relationship of dysbindin with clinical features of schizophrenia 
in a sample of 270 multiply affected Irish families, containing no overlapping individuals 
with the present cohort.  Dysbindin’s role as a susceptibility gene in this sample had been 
previously established (Straub et al, 2002), and further examination revealed that subjects 
in the upper 40th percentile for negative symptoms were significantly more likely to have 
the high-risk haplotype.  This was in contrast to the other four symptom factors, 
hallucinations, delusions, manic, and depressive symptoms, which showed no association 
with the haplotype of interest.   
 
DeRosse et al (2006) also reported association of a dysbindin risk haplotype (Table 1) 
and negative symptoms in 181 Caucasian men and women with schizophrenia, covarying 
for neurocognitive functioning.  This cohort (and healthy volunteers) had also shown 
association between this haplotype and neurocognitive dysfunction (Burdick et al, 2006).  
Although decreased intellectual functioning often accompanies negative symptoms, these 
studies suggest there may be at least partially separable effects.  Another relevant study 
of 262 Irish patients with schizophrenia found lower scores on a “hostility/excitability” 
factor and a trend for higher negative symptom scores in subjects with a “CAT” 
dysbindin risk haplotype (Table 3.5; Corvin et al, 2008).     
 
In the Irish Case-Control Study of Schizophrenia (ICCSS), an association between the 
dysbindin haplotype GCACTT (Table 3.5; Fanous et al, 2005) and schizophrenia has 
 57
been found (case frequency: .454, control frequency: .388, Χ2 =  13.561, p = .0002) 
(Riley et al, submitted to Schizophrenia Research).  The current study explores the 
relationship between this haplotype and the clinical symptoms of schizophrenia in the 
same subjects. 
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Table 1.  D
ysbindin risk haplotypes w
ith phenotypic associations by study.  
rs2619538
rs909706
rs1474605
rs1018381
rs2619522
rs760761
rs2005976
rs2619528
rs1011313
rs3213207
rs2619539
present study
T
T
C
A
C
G
Fanous et al, 2005
G
C
G
T
A
A
G
G
D
eRosse et al, 2006
G
T
G
T
A
G
Corvin et al, 2008
T
A
C
Tosato et al, 2007
A
A
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Methods 
 
Cases from the ICCSS were collected from in-patient and out-patient psychiatric facilities 
in the Republic of Ireland and Northern Ireland. Subjects were eligible for inclusion if 
they had a diagnosis of schizophrenia or poor-outcome schizoaffective disorder by DSM-
III-R criteria.   Subjects were eligible for inclusion if they had a diagnosis of 
schizophrenia or poor-outcome schizoaffective disorder by DSM-III-R criteria, which 
was confirmed by a blind expert diagnostic review.  Control subjects, selected from 
several sources, including blood donation centers, were included if they denied a lifetime 
history of schizophrenia.  Both cases and controls were included only if they reported all 
four grandparents as being born in Ireland or the United Kingdom (Chen et al, 2007).  In 
this study, 625 control subjects were used in conjunction with 730, 868, and 675 affected 
subjects for the Positive, Negative, and Schneiderian symptom factor analyses 
respectively.   
 
Subjects were rated for each symptom using interviews, derived from the expanded 
psychosis section of the Structured Clinical Interview for DSM-III-R (SCID) (Spitzer and 
Williams, 1985), and case records independently.  These two assessments were averaged 
and entered into a factor analysis using the statistical program MPlus (Muthen and 
Muthen, 2001).  This yielded three symptom factors: Positive, Negative, and 
Schneiderian.  Sum scores were generated for each factor with eleven items used to 
generate Positive and Schneiderian symptom scores and eight for Negative symptoms 
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(Fanous, in preparation).  The items were scaled using different numbers of levels (eg 1-4 
or 1-5) then combined and standardized to have values ranging from one to two.  
Example items loading on the Positive symptom factor included Visual and Somatic 
Hallucinations and Grandiose Delusions.  The Schneiderian symptom factor incorporated 
Thought Withdrawal and Broadcasting and Voices Discussing items, and the Negative 
symptom factor included items such as Alogia, Avolition, and Affective Flattening.   
 
We genotyped a total of 12 single nucleotide polymorphisms (SNPs) in DTNBP1 which 
is transcribed in opposite orientation to the human genome sequence.  Markers were 
selected from those included in previous reports from our group and others, and were 
chosen to allow reconstruction of the specific haplotypes widely observed in this locus 
(Van den Oord et al, 2003a).   
 
All markers were genotyped using fluorescence polarization detection of template-
directed dye-terminator incorporation (FP-TDI).  We used the AcycloPrime SNP 
detection kits appropriate for the specific polymorphism (PerkinElmer Life Sciences, 
Boston, MA) and manufacturer’s instructions.  Genotypes were called using an 
automated allele scoring platform (Van den Oord et al, 2003b).  PCR and single-base 
extension primers were designed manually and are available on request.  The average 
genotyping completion rate was 94.7% (range 89.3-98.7%). 
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We used a sequential addition approach well suited to data such as these in which a 
quantitative trait is measured in cases but not controls (Macgregor et al, 2006).  Briefly, 
this method consists of an initial chi-square test between all cases and controls evaluating 
risk allele or haplotype proportions between groups.  Next, the cases with the highest 
level of the quantitative trait are analyzed against all controls and the resulting chi-square 
value is compared to that for the full sample.  Subjects with progressively lower levels of 
the quantitative trait are incorporated into the case group until the chi-square statistic 
meets or exceeds that of the full sample.  For these analyses, we used the sum scores for 
the three symptom factors, Positive, Negative, and Schneiderian, as the quantitative traits 
and the previously determined risk haplotype, GCACTT, defined by the minor allele of 
rs2619538 and the major alleles of rs1474605, rs1018381, rs2619522, rs760761, and 
rs2005976 (Riley et al, submitted to Schizophrenia Research).  All analyses were 
implemented using SAS (SAS Institute Inc, 2005) and UNPHASED (Dudbridge, 2003).  
 
Linear regression analyses were also utilized to assess potential relationships between 
symptom factors and the high-risk dysbindin haplotype.  Using only data from the 
affected subjects, scores for each factor were separately regressed against the high-risk 
haplotype.  Additionally, t-tests of sum scores for each factor by risk haplotype carrier 
status were performed using SAS (SAS Institute Inc, 2005).   
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Results 
 
We found no association of the high-risk dysbindin haplotype with any of the symptom 
factors using sequential addition.  While the Negative symptom factor sequential addition 
analyses did ultimately yield a chi-square value exceeding the full sample chi-square 
value, 84% of the cases were incorporated into the analyses before this was 
accomplished.  There is no established cutoff for the percentage of included case subjects 
necessary to demonstrate association; however, with such a high percentage of cases 
used, a strong association with negative symptoms no longer seems plausible.  
Additionally, no relationships between the risk haplotype and symptom factors were 
found using linear regression (Negative p=.53, Positive p=.51, Schneiderian p=.96) or t-
tests (Negative p=.52, Positive p=.54, Schneiderian p=.78) (Table 3.6).  
 
 
Table 3.6.  Sum score statistics for all factors by risk haplotype carrier status. 
             SD = standard deviation      
       
Factor Carrier Status Subjects Mean SD t p-value 
Negative Symptoms non-carriers 181 1.507 0.37 -0.65 0.5156 
 carriers 435 1.528 0.35   
       
Positive Symptoms non-carriers 163 1.516 0.34 0.61 0.5439 
 carriers 375 1.498 0.33   
       
Schneiderian Symptoms non-carriers 137 1.502 0.35 -0.27 0.7846 
 carriers 330 1.512 0.34   
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Discussion 
 
None of the symptom factors analyzed demonstrated an association with the dysbindin 
risk haplotype in this cohort.  This was unexpected considering two prior studies 
examining negative symptoms and dysbindin did find an association (Fanous et al, 2005; 
DeRosse et al, 2006), but several possible reasons may account for this discrepancy.   
 
First, the symptom factor structure differed between the Irish family sample and the 
present Irish case-control sample.  For the three symptom factors used here, negative 
symptoms were possibly more broadly defined than for the Irish family sample which 
had five symptom factors, and the items in each differed as a result of the instruments 
used.  Three items were similar across samples: inappropriate affect, affective flattening, 
and thought disorder.  Negative symptoms in this sample included four additional items 
and in the Irish family sample, eight more items.  DeRosse et al (2006) used only three 
items, affective flattening, alogia, and avolition, all of which were incorporated into the 
negative symptom factor in the present study.   
 
Additionally, the high-risk haplotypes defined in the Irish samples are highly cladistically 
divergent from each other.  It is conceivable that one haplotype only confers risk to 
schizophrenia while the other predisposes to schizophrenia as well as a high degree of 
negative symptoms.  Another possibility is that the dysbindin haplotype association with 
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negative symptoms is actually driven by linkage disequilibrium with an evolutionarily 
recent, causal polymorphism.  
 
Manifestations of schizophrenia involving a high degree of negative symptoms are often 
considered the most severe.  Negative symptoms are among the most persistent and 
refractory to treatment, making these symptoms imperative to examine (Stahl and 
Buckley, 2006).  Since prior reports of modification by dysbindin have included negative 
symptoms (Fanous et al, 2005; DeRosse et al, 2006), cognitive function (Donohoe et al, 
2007; Burdick et al, 2007), low hostility/excitability (Corvin et al, 2008) and poor clinical 
outcome (Tosato et al, 2007), this suggests two distinct possibilities.  First, all of these 
interrelated disease dimensions may be tapping a common physiological process partially 
underlying each of them.  Alternatively, of the various dysbindin haplotypes that have 
been associated with schizophrenia, they may have distinct symptom modifying 
properties or none at all.  Dysbindin variation has also been associated with cognitive 
function in normal individuals (Luciano et al, 2009; Burdick et al, 2007). 
 
Continuing efforts to explore the genetic underpinnings of clinical variation in 
schizophrenia are vital to understanding and treating this disorder.  Advances in 
identifying susceptibility genes have been hindered by genetic and clinical heterogeneity, 
but understanding the nature and extent of the relationship between them may bring us 
closer to a useful comprehension of schizophrenia.    
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Chapter 4:  Detection of Susceptibility Genes as Modifiers 
Due to Subgroup Differences in Complex Disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
Bergen SE, Maher B, Fanous AH, Kendler KS.  Detection of susceptibility genes as 
modifiers due to subgroup differences in complex disease.  (in revision at European 
Journal of Human Genetics) 
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 Abstract: 
 
Complex diseases invariably involve multiple genes and often exhibit variable symptom 
profiles.  The extent to which disease symptoms, course, and severity differ between 
affected individuals may result from underlying genetic heterogeneity.  Genes with 
modifier effects may or may not also influence disease susceptibility.  In this study, we 
have simulated data in which a subset of cases differ by some effect size on a quantitative 
trait and are also enriched for a risk allele.  Power to detect this “pseudo-modifier” gene 
in case-only and case-control designs was explored blind to case substructure.  
Simulations involved 1000 iterations and calculations for 80% power at p<.01 while 
varying the risk allele frequency (RAF), sample size (SS), effect size (ES), odds ratio 
(OR), and proportions of the case subgroups.  With realistic values for the RAF (.20), SS 
(3000) and ES (1), an OR of 1.7 is necessary to detect a pseudo-modifier gene.  Unequal 
numbers of subjects in the case groups result in little decrement in power until the group 
enriched for the risk allele is less than 30% or greater than 70% of the total case 
population.  In practice, greater numbers of subjects and selection of a quantitative trait 
with a large range will provide researchers with greater power to detect a pseudo-
modifier gene.  However, even under ideal conditions, studies involving alleles with low 
frequencies or low ORs are usually underpowered for detection of a modifier or 
susceptibility gene.  This may explain some of the inconsistent association results for 
many candidate gene studies of complex diseases.  
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Introduction:   
 
 
As the risk genes for complex diseases are rapidly being identified (Wellcome Trust Case 
Control Consortium, 2007; Barrett et al, 2008; Jakobsdottir et al, 2005), there has been 
increasing attention to the factors influencing variability within these disorders.  For 
complex genetic disorders in which multiple genes act in concert to produce the disease, 
variability in phenotypic expression seems likely to result, at least in part, from 
underlying genetic heterogeneity. Genes impacting age of onset, severity, and differences 
in symptom clusters, but not susceptibility to illness have been termed modifier genes 
(Fanous & Kendler, 2005).  Several such genes have now been identified for diseases 
such as sickle cell anemia (Steinberg, 2005), cystic fibrosis (Salvatore et al, 2002), 
nonsyndromic cleft lip (Zucchero et al, 2004), and spinocerebellar ataxia type II (Hayes 
et al, 2000, Pulst et al, 2005).      
 
While susceptibility genes – those which influence disease liability - and modifier genes 
– those which impact on clinical variation within the illness - can be distinct, it is also 
possible for one gene to predispose individuals to a disease as well as specific symptom 
dimensions within the illness (Fanous & Kendler, 2005).  In fact, for schizophrenia, a 
number of genes are reported to have both susceptibility and modifier influences 
including dysbindin (Straub et al, 2002; Fanous et al, 2005; DeRosse et al, 2006), COMT 
(de Chaldee et al, 1999; McClay et al, 2006; DeRosse et al, 2006), and DISC1 (Thomson 
et al, 2005; DeRosse et al., 2007).  These have been termed susceptibility-modifier genes.   
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 Difficulty in replicating findings for association studies of complex diseases has led to 
the stratification of subjects based on variation in disease characteristics as one plausible 
way to enhance the signal to noise ratio by reducing heterogeneity.  Consequently, there 
have been attempts to identify biological features specific to particular forms of illness. 
However, classifying clinical subtypes of complex diseases has proven exceedingly 
difficult.  Age of onset, severity, and familial or sporadic inheritance patterns have 
sometimes been used to subdivide case populations.  Other strategies for grouping 
patients have focused on symptomatology, either through use of a priori criteria or by the 
more statistically rigorous methods of cluster or latent class analysis.  Subjects can then 
be categorized as high or low scorers for a given factor.  There are also methods which 
allow for the maximization of evidence for association by covariate-based subdividing 
without a priori cutpoints or data processing (Perdry et al, 2007; Macgregor et al, 2006).  
Each of these categorization approaches has some appeal, but the best approach for each 
complex disease has yet to be determined.   
 
Since genes that confer susceptibility to a form of illness with a distinct symptom profile 
would manifest as susceptibility-modifier genes, the results of modifier gene association 
studies may yield information regarding variation in the genetic architecture of complex 
disease liability in addition to variability in symptom expression.   
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We suggest there are two particularly plausible mechanisms whereby a gene variant is 
associated with a symptom in a complex disease. First, the disorder is etiologically 
homogeneous and this gene “truly” impacts on that symptom – a true modifier. Second, 
the disorder is etiologically heterogeneous. This “pseudo-modifier” gene is really a risk 
gene but only for one subtype AND the subtypes differ on the levels of this particular 
symptom. We term this type of gene a “pseudo-modifier” because its effects on the 
symptoms in question actually arise from it conferring liability to a particular disease 
subtype. In this paper, we study this second mechanism to see under what circumstances 
it might be detected.  
 
To do so, we simulated two case groups, for one of which the gene variant influencing 
symptom variability also confers disease susceptibility.  The other case group arrives at 
the disease state through another, unspecified mechanism.  A control group was 
simulated as well, but since power for case-control (susceptibility) analyses has been 
thoroughly investigated elsewhere, these results are included here for comparison 
purposes only.  Case-only designs (for modifier effects) were considered, blind to case 
substructure, as risk allele frequency, sample size, odds ratio, effect size, and proportion 
of cases with the pseudo-modifier allele were varied.   
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Methods: 
Two case groups and a control group were simulated according to a range of specified 
parameters, then tested for power to detect the pseudo-modifier gene of interest.  
Simulations were carried out using the software program SAS 9.1 or 9.1.3 (SAS Institute, 
2005).  All sets of simulations involved 1000 iterations and calculations of power given 
the risk allele frequency (RAF), odds ratio (OR), sample size (SS), and effect size (ES).  
We did not directly simulate an effect of the variant on the quantitative trait.  Instead, we 
simulated a variant with population allele frequency in controls and type I cases and 
RAF*OR in type II cases.  Importantly, this results only in an increased RAF among the 
type II cases.  In case-control comparisons where the number of cases and controls is 
equal, the effective OR is then 1 + ((OR-1)/2).  For example, a risk allele with a 
frequency of .1 at an OR of 1.4 would yield frequencies of .1, .1, and .14 in controls, type 
I cases and type II cases respectively in a sufficiently large sample.  In case-control 
comparisons, grouping the heterogeneous case sets, the allele frequencies would be .1 in 
controls and .12 in cases.  
 
For use in case only analyses, a quantitative phenotype was simulated sampling from a 
normal distribution with a mean of 0 and standard deviation of 1 in type I cases and a 
mean equal to the effect size (ES), the standardized mean difference of a trait between the 
two groups of cases, in type II cases, thus indirectly creating an association between the 
SNP and the quantitative trait.  That is, the case group enriched for the risk allele also has 
a mean difference from the other case group.   
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 For each set of parameter specifications, power to detect the influence of the impact of 
genotype on variation in the combined case groups (case-only) was calculated as well as 
power to detect the allele as conferring disease susceptibility (case-control).  Although 
the case-control power calculations are not novel, they provide a useful comparison for 
the case-only investigations.  We chose to use a one stage design since studies exploring 
modifier gene influences are not contingent on susceptibility gene association results.   
 
Main analyses 
 
We created two case subgroups differentiated on mean group differences for an 
unspecified, normally distributed, quantitative trait.  The type II cases were enriched for 
the pseudo-modifier allele of interest, while the type I cases were not.  Figure 4.1 
illustrates the two case population distributions and their combined distribution when 
subgroup membership is unknown.  All analyses were performed blind to case type.  
Unless otherwise specified, simulations included 3000 total subjects in which 750 were 
type I cases, 750 were type II cases and 1500 were controls. RAFs were varied from .10 
to .50, and ORs of 1.1 to 2.0 by increments of .10 were modeled, initially holding the ES 
at 1.  We defined sufficient power for detection as .8 or greater with a p-value ≤ .01.   
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Additional analyses 
 
The RAF was fixed at .20 and ES at 1 for analyses in which other parameters varied.  To 
explore the effects of sample size, the total number of subjects was increased 
incrementally by 1000 from 2000 to 6000 while maintaining the same proportion of 
subjects in each group.  Additionally, since it is implausible that two subpopulations of 
affected individuals would naturally divide the subject pool neatly in half, we also varied 
the percent of Type II subjects, possessing an enriched proportion of the risk-conferring 
allele.  Total case and control numbers were held even.  Furthermore, the effect sizes that 
might be observed could vary considerably and depend entirely on the phenotypic trait 
assessed.  We consequently modeled a broad range of effect sizes from .5 to 3.0 with 
increments of .5 representing mean differences of half a standard deviation to three full 
standard deviations.    
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 Figure 4.1.  Case population distributions in relation to a clinical trait scale.  Type I cases 
are depicted as scoring lower on the scale.  Type II cases, enriched for the pseudo-
modifier allele of interest, score higher by an effect size (ES) difference of one standard 
deviation in most simulations.  The combined case population is also shown since 
investigators (and our analyses) are blind to case substructure. 
 
 
Results: 
 
To detect modifier associations that result from underlying genetic heterogeneity, in 
which the allele impacts on disease risk in only one subgroup, with our core set of 
parameter specifications (sample size of 3000, effect size of 1, and RAF of .20) we had 
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sufficient power to detect a pseudo-modifier association with an OR of 1.7 or greater 
(Figure 4.2).  For comparison, a susceptibility allele with an OR of 1.2 is detectable under 
the same conditions.     
 
Allele Frequency 
RAFs of .10 or less are not sufficient to detect pseudo-modifier genes with a one standard 
deviation mean trait difference.  However, susceptibility gene detection is possible with 
an OR of 1.3 or greater.  Power curves grow progressively steeper as the RAF increases, 
culminating with detection of OR 1.15 and 1.3 for the susceptibility and pseudo-modifier 
gene analyses respectively.     
 
Sample Size 
With 2000 total subjects, only ORs of 1.8 and greater are sufficient for detection of 
pseudo-modifier effects.  However, each additional 1000 subjects lowers the detectable 
OR by ~.10 until a sample size of 6000 is used.  With this large sample size, power to 
detect an OR of 1.4 is just under .80 but falls sharply to ~.50 for OR detection of 1.3.  
Case-control simulations for susceptibility gene effects exhibit much steeper curves with 
a smaller range, allowing for detection of a RAF of .20 or greater and OR of 1.15-1.25 
across all sample sizes examined.       
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Effect Size 
When the mean phenotypic differences between subgroups is less than half a standard 
deviation, detecting pseudo-modifier effects is unlikely with odds ratios under two.  
Standard deviation differences of 1 and 1.5 are distinguishable at odds ratios of 1.7 and 
1.5 respectively.  From standard deviations of 2 to 3, however, the increased phenotypic 
disparity does not confer markedly enhanced detectability for pseudo-modifier genes.    
 
Unbalanced Case Groups 
Little decrement in power for the detection of pseudo-modifier effects was observed 
across a broad range of the percent of subjects with the subtype containing an enriched 
proportion of the risk-conferring allele.  At any OR for which there is sufficient power for 
detection, 30-70% of the Type II cases are sufficient, and for high ORs, an even broader 
range may suffice (Figure 4.3).   
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Figure 4.2.  Power by odds ratio (OR) curves.  When fixed, the risk allele frequency 
(RAF) = .2, effect size (ES) = 1 and sample size (SS) = 3000.  Lines with these parameter 
specifications are represented on each plot and emphasized for frame of reference.  A) 
Power to detect pseudo-modifier genes for RAF of .1-.5.  B) Power to detect a 
susceptibility gene in case-control analyses varying the RAF from .1-.5 and OR from 
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1.05-1.50.  C)  Power for pseudo-modifier gene detection for SS = 2000-6000.  D) Power 
for susceptibility gene detection with SS = 2000-6000.  E) ES .5-3.0 impact on power to 
detect pseudo-modifier effects.   
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Figure 4.3.  Effects of varying the proportion of Type II cases, enriched for the risk allele, 
on power across odds ratios (OR) 1.2-2.0.  A) Case-only results for pseudo-modifier 
discrimination.  B) Power for risk allele detection in case-control analyses.   
 
 
Discussion: 
 
From these results, it is clear that the discovery of modifier gene effects that arise from 
genetic heterogeneity in complex diseases is critically dependent on most of the 
parameter estimates examined here.  However, it is interesting to note that the proportion 
of cases with the risk-conferring allele can vary between 30-70% with little observed 
deviation in power.  Since subtypes are unlikely to evenly divide an affected population, 
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this is a reassuring finding.  On the other hand, RAF is a vital factor in detecting pseudo-
modifier genes.  With 3000 subjects, a RAF of .10 (or less) is insufficient for detection of 
a pseudo-modifier gene for any OR under 2.0, and even under ideal circumstances with a 
RAF of .50, the OR must be 1.3 or greater.   
 
Effect size is another important determinant of pseudo-modifier gene detection, although 
the phenotypic differences between case groups have no impact on susceptibility gene 
detection.  This is an important consideration when selecting a trait on which to explore 
modifier effects since the groups should minimally differ by one standard deviation and 
preferably two or more on the trait of interest.  As group membership is generally 
unknown, high trait variance is the best selection criterion usually available.   
 
In practice, sample size is the most manipulable of the parameters explored here.  It is 
intuitively obvious that greater numbers of subjects confer greater power, but beyond 
5000, the additional effort of subject recruitment and assessment may not yield 
sufficiently enhanced power to be worthwhile.  Even with very high numbers of subjects, 
detection of genes with low RAFs or low ORs is extremely difficult.  For many complex 
diseases this may explain conflicting results from association studies.    
 
For the parameters tested, attempts were made to examine realistic values.  For example, 
the Affymetrix Mapping 500K Array and GenomeWide Human Mapping 5.0 Array both 
report average minor allele frequencies of .22 (www.affymetrix.com, 2008). and the 
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Illumina HumanHap550 and 650Y detect SNPs with average minor allele frequencies of 
.20-.23 depending on the population sampled (www.illumina.com, 2008).  Consequently, 
simulations in which risk allele frequencies were held constant were given values of .20.  
Also, the odds ratio range we used is comparable to ORs commonly reported for complex 
genetic diseases (eg ~1.1-2.0; Wellcome Trust Case Control Consortium, 2007; Allen et 
al, 2008; Barrett et al, 2008; Zeggini et al, 2008).   
 
The added power conferred by greater subject numbers has led to recent increases in 
multi-center collaborations generating cohorts consisting of thousands of individuals. 
Accordingly, the number of subjects used for most simulations in this study 
approximated that of some of these cooperative efforts.  These include several of the 
Genetic Association Information Network (GAIN) studies such as that for ADHD 
(involving 2877 participants), major depression (3720), bipolar disorder (3316), 
schizophrenia (5189), and psoriasis (2902) (The GAIN Collaborative Research Group, 
2007).  The Wellcome Trust Consortium is another large collaborative effort which 
examined 2000 cases for each of 7 major complex diseases and a shared set of 3000 
controls (Wellcome Trust Case Control Consortium, 2007).    
 
Despite our attempts at modeling realistic values, some limitations were imposed out of 
necessity.  The simulations presented here only assess the impact of a single gene on the 
predisposition to a certain form of a complex disease.  In fact, a more likely scenario 
involves overlapping constellations of susceptibility genes as well as environmental 
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insults which are also not included in these models.  In addition, we have presumed that 
the minor allele is the risk-conferring allele.  However, common alleles with small main 
effects may act in concert with alleles in other genes to additively or epistatically 
influence liability to complex diseases, and we have not modeled these possibilities.  
Furthermore, the simulations presented here were restricted to two subtypes, when in 
reality, many more subtypes may exist for some diseases.    
 
We have additionally presumed that the modifier effects of the allele in question are 
restricted to (or only assessed in) the case population.  Detection of more subtle 
expression in unaffected individuals, when possible, might allow for greater power to 
detect the allele (Fanous and Kendler, 2005).  Gene detection then hinges not only on 
disease expression but degrees of symptom expression as well, drawing on increased 
information to yield enhanced power.   
 
The results presented here are applicable to nearly every complex genetic disease for 
which subtypes may exist.  Several diseases may manifest with convergent symptom 
profiles but arise through different etiological mechanisms.  The extent to which 
subpopulations differ in their symptoms can yield clues to underlying biological 
differences.  For example, diabetes has two main subtypes (I and II) both of which 
present with high blood glucose levels and similar symptoms such as extreme thirst, 
fatigue, and blurred vision.  However, in type I diabetes, the symptoms are due to the 
destruction of insulin-producing cells, while type II diabetes occurs when the tissues 
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become resistant to insulin or produce too little.  Later age of onset and higher body 
weight are linked to, but not diagnostic of, type II diabetes 
(http://diabetes.niddk.nih.gov/dm/pubs/overview/index.htm, 7-12-08).  These subtle 
phenotypic differences indicative of very distinct pathophysiological origins are precisely 
the type of clues sought to unlock the etiology of complex diseases.   
 
Association studies examining modifier effects may actually uncover subtype-specific 
susceptibility genes.  Whether variable symptom profiles for numerous diseases are due 
to modifier genes and environmental influences, differing underlying genetic 
architecture, or some combination of these possibilities will likely remain under 
investigation for many years to come.  The simulation results presented here indicate 
there is reasonable power to detect pseudo-modifier genes under favorable conditions 
such as a high effect size, OR, and RAF, but they may well be missed under less ideal 
circumstances.  These results can be used to inform researchers as to the relative power 
for studies of complex disease under a range of conditions when symptom variation is 
due to different genetic subtypes.   
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Chapter 5:  Myelin and Synaptic Gene Networks                
in Schizophrenia 
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Abstract: 
 
Evidence implicating myelin and synaptic alterations in schizophrenia has been 
accumulating over the past several years from imaging, neuroanatomical, gene expression 
and association studies.  Network analyses of SNP data may add to this literature by 
offering a potentially powerful method of identifying risk genes in biological processes 
theorized to be involved in a disease.  We examined genes pertaining to myelin and 
synapses using networks generated through literature searches and then included 
additional genes to link them together using Ingenuity Pathway Analysis (IPA).  This 
yielded four networks – core and expanded networks for both myelin and synaptic genes.  
In a sample of 2093 total cases and 2332 control subjects we tested for association 
between each network and two populations, African-ancestry (AA, case N = 921, control 
N = 954) and European-ancestry (EA, case N = 1172, control N = 1378).  Significance 
was assessed through permutation and calculation of empirical-p values.  Only the core 
myelin network association with the AA group demonstrated significance (empirical 
p=.02), further substantiating the involvement of myelin-related genes previously 
implicated in schizophrenia.  This tentative finding, uncorrected for the multiple 
networks tested, also adds provisional corroboration with the growing literature 
supporting distinct genetic risk factors between AA and EA populations for this disorder.     
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Introduction: 
 
Convergent lines of evidence, to be reviewed below, have implicated alterations in 
myelin and synaptic dysfunction in schizophrenia.  Onset of schizophrenia is often 
coincident with the developmental timeframe during which maturation of the prefrontal 
cortex occurs.  This involves the refinement of synaptic connections known as synaptic 
pruning and enhancement of myelination to facilitate neuronal signaling.  These 
processes may be aberrant in and of themselves, or they may unmask preexisting 
neurodevelopmental problems in this brain region (Woo and Crowell, 2005).   
 
Functional disconnectivity occurs when there is a breakdown in signal transmission 
between brain regions.  This has been found in many studies of the p50 and p300 
electrophysiological responses (Bramon et al, 2004) and pre-pulse inhibition (Braff et al, 
2001).  These findings as well as fronto-temporal disconnectivity related to auditory 
hallucinations (Lawrie et al, 2002; Norman et al, 1997; Ford et al, 2002) could result 
from myelin deficits, synaptic dysfunction or a combination of both.  Oligodendrocyte 
involvement with axons confers enhanced viability of the axon (Wilkins et al, 2003).  
Conversely, if fewer axons are available to myelinate, fewer oligodendrocytes are likely 
to be viable as well (Burne et al, 1996).  These distinct but interrelated physiological 
processes have been increasingly examined in recent years and are frequently found to be 
altered in schizophrenia, but the reciprocal nature of this relationship makes it difficult to 
distinguish the primary pathological insult. 
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Myelin and schizophrenia 
 
Myelin is the axon-insulating substance exclusively formed by oligodendrocytes in the 
central nervous system.  Axons are mitogenic for oligodendrocytes, and myelination is 
initiated following contact of oligodendrocyte processes with axons of at least 1µm 
diameter.  These processes extend around the axon wrapping inward multiple times.  
Next, compaction occurs in which the cytoplasm is extruded from all middle layers, 
excluding the inner- and outer-most (Compston et al, 1997).  Oligodendrocytes myelinate 
about 20-30 sites on numerous adjacent axons (Butt & Ransom, 1989).  The insulation 
provided by myelination facilitates much faster propagation of an action potential by 
allowing the signal to jump from node to node (termed saltatory conduction).  
Myelination increases in a region and age-dependent progression, culminating in 
maximal white matter volumes at approximately age 43 (Sowell et al, 2003).   
 
Evidence from imaging studies 
 
A relatively new imaging modality, diffusion tensor imaging (DTI), has been employed 
in the examination of white matter integrity in schizophrenia.  This technique assesses the 
anisotropic (directional) diffusion of water molecules in the brain which corresponds to 
tissue properties such as the diameter and density of axon fibers and the thickness of 
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myelin sheaths (Kubicki et al, 2007).  A review of 18 published studies using DTI in 
schizophrenia found 15 studies revealing anisotropic alterations throughout the brain 
(Kubicki et al, 2007).  White matter tracts throughout the brain critically depend on intact 
myelin to convey signals (or water by proxy) from one region to another.  Reduced 
anisotropy strongly suggests that inter-regional connections in the schizophrenic brain are 
structurally impaired, and this is due, at least in part, to myelin deficits. 
 
Neuroanatomical findings 
 
Many histopathological studies have focused on the prefrontal cortex and have 
demonstrated reduced numbers or density of glia in schizophrenia (Stark et al, 2004; 
Vostrikov et al, 2004, 2007; Hof et al, 2003; Uranova et al, 2004, 2007).  Examination of 
glial cell density in Heschl’s gyrus revealed no differences between schizophrenia and 
control groups (Cotter et al, 2004), but a reduced oligodendrocyte to neuron ratio was 
observed in schizophrenia in the anterior principle thalamic nucleus (Byne et al, 2006).  
These findings suggest a relative sparing of primary sensory cortical regions, but 
processing centers and association cortices may be preferentially affected in terms of glial 
deficits.  Additional studies of other brain regions would be informative for this 
hypothesis.   
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Gene expression 
 
Results from gene expression studies confirm on a cellular level the broad changes 
observed in functional, imaging, and anatomical studies.  Hakak et al (2001) conducted a 
genome wide expression study of dorsolateral prefrontal cortex tissue that revealed 
reduced expression of six myelination genes in contrast to increased expression for most 
other changed genes.  Tkachev et al (2003) focused on genes expressed by 
oligodendrocytes in the prefrontal cortex and also found reduced expression for several 
genes in the schizophrenia group using qPCR and microarray assays: OLIG1, OLIG2, 
SOX10, MBP, MAG, PLP1, MPZL1, CLDN11, MOG, ERBB3, and TF.  Haroutunian et 
al (2007) carried out a thorough microarray study using brain tissue from many regions.  
Myelin-related genes were the most affected in regions with the greatest number of 
changed genes, the cingulate and hippocampus.  Dracheva et al (2006) validated these 
findings in the cingulate gyrus using qPCR. This technique was also used to examine 
MAG, CNP, and MBP in individual thalamic nuclei, but no differences were found 
between the schizophrenia and control groups (Byne et al, 2007).  Mitkus et al (2008) 
focused on expression of four genes in the dorsolateral prefrontal cortex.  No decreases in 
expression levels were found by diagnosis, but carriers of risk alleles in CNP and OLIG2 
did show reduced expression.  Expression by genotype analyses were not performed for 
the other two genes, MOBP and MAG.   
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Prior association studies  
 
Many myelin-related genes have been associated with schizophrenia hinting at a potential 
primary role in the pathology of schizophrenia.  Three transcription factors expressed by 
oligodendrocytes are involved in differentiation and associated with schizophrenia: QKI 
(Aberg et al, 2006), OLIG2 (Georgieva et al, 2006; Huang et al, 2007), and SOX10 
(Maeno et al, 2007).  Several other genes encode proteins localized to myelin or involved 
in the process of myelination and have been associated with schizophrenia including: 
CNP (Peirce et al, 2006; Voineskos et al, 2008), MOG (Liu et al, 2005), PLP1 (Qin et al, 
2005), and TF (Qu et al, 2007).  Additionally, NRG1 is one of the most replicated genes 
associated with schizophrenia (Stefansson et al, 2002; Bakker et al, 2004; Corvin et al, 
2004; Li et al, 2004, Tang et al, 2004; Kim et al, 2006; Lachman et al, 2006; Petryshen et 
al, 2005; Thomson et al, 2006; Benzel et al, 2007; Hanninen et al, 2007; Ikeda et al, 
2008; So et al, 2009) along with one of its receptors found in oligodendrocytes, ERBB4 
(Norton et al, 2006; Nicodemus et al, 2006; Silberberg et al, 2006; Benzel et al, 2007) but 
not the other, ERBB3 (Kanazawa et al, 2007; Benzel et al, 2007).  Another receptor-
ligand group has been associated with schizophrenia – the Nogo receptor (Novak et al, 
2002; Tan et al, 2005; Budel et al, 2008) and ligand MAG (Yang et al, 2005; Wan et al, 
2005), which function in neurite outgrowth inhibition.  Although all of the 
aforementioned genes have been associated with schizophrenia by at least one study, 
nearly all also have negative reports of association as well.  
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Synaptic proteins and schizophrenia 
 
Synaptic proteins common to the majority of neurotransmitter systems are predominantly 
involved in exocytosis and termed SNAREs.  The soluble N-ethylmaleimide-sensitive 
factor attachment receptor (SNARE) proteins include synaptotagmin, synaptobrevin, 
syntaxin, and SNAP-25, but many different forms of these proteins exist making the total 
number of SNARE proteins much higher.  Some SNARE proteins have also been 
localized to oligodendrocytes and are theorized to serve in membrane trafficking (Kramer 
et al, 2001; Madison et al, 1999). Since nearly every major neurotransmitter system has 
been implicated in schizophrenia, only synaptic proteins 
common to most synapses were included in these analyses.   
 
Figure 5.1. SNARE proteins. (Washington University, 
Neuromuscular website, 2007) 
 
Gene expression and neuroanatomical findings 
 
Synaptic loss has been demonstrated in schizophrenia repeatedly and in numerous brain 
regions, but neuronal loss does not seem to be a consistent feature of this illness 
(Pakkenberg, 1992; 1993).  This has given rise to the reduced neuropil hypothesis of 
schizophrenia (Selemon & Goldman-Rakic, 1999).  Reductions in cortical thickness of 3-
13% (Brown et al, 1986; Pakkenberg, 1987, 1993; Zipursky et al, 1992; Andreasen et al, 
 90
1994; Ward et al 1996; Sullivan et al, 1996; Lim et al, 1996), increased density of 
neurons (Pakkenberg, 1993; Selemon et al, 1995, 1998), and reductions in synaptic 
terminal density (Sweet et al, 2007; Kung et al, 1998; Lewis et al, 2001; Pierri et al, 
1999) all support this hypothesis.  A review of 11 studies assessing mRNA and protein 
levels for GAP43, SNAP25, VAMP, and synaptophysin in the PFC in schizophrenia 
reported mixed results but more decreased levels than increased (Halim et al, 2003).  One 
recent study of over 30,000 mRNA transcripts from the prefrontal cortex of 44 
schizophrenics and 50 controls found changes in gene sets pertaining to neurotransmitter 
release, vesicle recycling, and cytoskeletal dynamics (Maycox et al, 2009). 
 
The paucity of neuropil in schizophrenia may result from generation of fewer synapses in 
early development, or over-pruning of synapses in later development. Sub-lethal 
apoptosis has also been proposed as a mechanism by which this could occur (Glantz et al, 
2006), but none of these hypotheses preclude the involvement of genetic alterations as the 
origin of this pathology. 
 
Prior association studies 
 
Despite numerous studies documenting alterations of synaptic proteins and mRNA 
expression in schizophrenia, few association studies have been conducted for these genes.  
The SNAP29 promoter region (Wonodi et al, 2005) and syntaxin 1A (Wong et al, 2004) 
did yield positive associations with schizophrenia, and two negative reports were linked 
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to SNAP25 polymorphisms (Tachikawa et al, 2001; Wong et al, 2003; Kawashima et al, 
2008).  Kawashima et al (2008) also reported no association of syntaxin 1A and VAMP2 
in a Japanese population.  Aside from these few examples, associations between genes 
encoding ubiquitous synaptic proteins and schizophrenia have remained largely 
uninvestigated compared with the synaptic proteins specifically related to particular 
neurotransmitter systems.  
 
Heterogeneity in the genetic underpinnings of schizophrenia is a likely cause of 
inconsistent replication frequently observed in association studies of this disorder.  It has 
been suggested that multiple rare variants with high penetrance could be responsible for 
schizophrenia (McClellan et al, 2007).  Evidence supporting this hypothesis has arisen 
implicating the 22q11 deletion long held to be responsible for some cases of 
schizophrenia, as well as two more recently associated regions, 1q21.1 and 15q13 
(International Schizophrenia Consortium, 2008; Stefansson et al, 2008; Kirov et al, 
2008).  Additionally, de novo copy number mutations have been observed at higher rates 
in sporadic versus familial schizophrenia cases (Xu et al, 2008).     
 
Ample support also exists for schizophrenia arising through convergence of numerous 
allelic influences.  The lack of consensus for the involvement of any single gene in 
schizophrenia liability is compelling evidence in and of itself.  In addition, a recent paper 
from the International Schizophrenia Consortium presented data indicating several 
thousand loci may play a role in the development of schizophrenia (Purcell et al, 2009).  
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The approach suggested here is predicated on the common disease-common variant 
model in which multiple causal alleles contribute incrementally to schizophrenia liability.  
By grouping genes involved in neurological processes consistently shown to be altered in 
schizophrenia, locus heterogeneity can be examined within the context of gene clusters.  
Since mutations within a metabolic pathway can yield similar disease phenotypes (Held, 
2006), it seems reasonable that similar effects may manifest in complex disorders.   
 
Network analyses are association analyses with multiple interacting or similar genes 
considered together.  They are based on the concept of locus heterogeneity which states 
that a disease or other phenotype may arise from genetic variants at different 
chromosomal loci.  While a susceptibility allele at one locus might be too rare or have too 
low penetrance to be detectable, susceptibility alleles distributed throughout a network of 
related genes are more likely to be detected in aggregate.   
 
The analyses presented here involved four networks: the core myelin network consisting 
of genes identified in the literature, the core synaptic network composed of SNARE 
proteins, and the extended myelin and synaptic networks generated by incorporating 
additional genes to link as many of the initial genes as possible through gene-gene 
interactions.  We hypothesize that grouping genes into functional networks for 
association analyses will facilitate determination of our supposition that genes encoding 
myelin and synaptic proteins contribute to schizophrenia liability. 
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 Methods: 
 
Subjects and Genotyping 
Subjects were drawn from the GAIN schizophrenia study described in detail in chapter 1.  
For these analyses 2093 total cases and 2332 control subjects were used (AA = 1875, EA 
= 2550, 2242 males, 2063 females).  All subjects were genotyped using the Affymetrix 
GenomeWide Human SNP Array 6.0.  The 906,600 SNPs assayed were subjected to 
quality control steps specifying that the minor allele frequency be greater than or equal to 
.01, the call rate be greater than or equal to 95%, and the Hardy Weinberg Equilibrium p-
value be greater than .000001.  This resulted in 845,817 SNPs remaining in the AA group 
and 729,454 SNPs in the EA group.   
 
Network generation 
For the myelin gene network, genes were initially drawn from previously published 
association and microarray expression studies.  The synaptic genes were selected based 
on their presence at virtually all synapses since all major neurotransmitter systems have 
been implicated in schizophrenia.  This resulted in a list comprised of synaptic docking 
protein genes which function in the docking of synaptic vesicles at the presynaptic 
membrane and subsequent release of neurotransmitters.   
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Using Ingenuity Pathway Analysis (Ingenuity Systems, Inc, 2009), initial lists of myelin 
and synaptic genes were connected (separately) according to published reports and 
interaction database information. 
 
Statistical analyses 
All genotyped SNPs within 10kb of the genes of interest were included.  Association 
analyses were implemented in PLINK (Purcell et al, 2007) for each network and ancestry 
group.  Significance was assessed using the R Q-value package involving generation of 
empirical p-values resulting from 1000 association tests using all SNPs from equal 
numbers of randomly selected genes for each network.  The proportion of tests significant 
at p<.05 was calculated for each permutation and compared to network results.   
 
 
Results: 
 
The core synaptic network was not significantly associated with schizophrenia for the AA 
or EA groups (p=.72, .13 respectively).  The extended synaptic network was similarly 
nonsignificant (p=.88, .27 respectively).  However, the core myelin network did 
demonstrate significance for the AA group (p=.02), but not the EA group (p=.88).  The 
addition of related myelin genes in the extended myelin network diluted the effect to the 
point of non-significance (p=.18) for the AA group and the EA group remained 
nonsignificant (p=.56).     
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Discussion: 
 
Myelin-related genes previously implicated in schizophrenia do appear to be etiologically 
relevant, but this relationship was only observed in subjects of African ancestry.  This 
finding adds to mounting evidence supporting distinct risk genes in African and European 
ancestry groups.  Linkage and association studies examining both groups have detected 
different genetic regions impacting liability to schizophrenia (Takahashi et al, 2003; 
Faraone et al, 2005; Suarez et al, 2006; Holliday et al, 2008).  A recent paper by the 
International Schizophrenia Consortium showed that there is greater risk gene 
commonality between schizophrenia and bipolar disorder for people of European 
ancestry than between schizophrenics of European and African ancestry (2009).   
 
In terms of the biological processes examined here, the core myelin network, comprised 
solely of genes already linked to schizophrenia, had the greatest a priori likelihood of 
significant association in this study.  In a similar study, Jungerius et al (2008) constructed 
a pathway of 138 myelin genes for association analyses in a Dutch cohort of 310 cases 
and 880 controls.  The strongest result was for the PIK4CA gene, with five additional 
genes more weakly identified.  Using a different approach to pathway analysis, Reitkerk 
et al (2009) examined a gene expression dataset and discovered that two myelin-relevant 
pathways, sphingolipid metabolism and the PI signaling pathway, were most strongly 
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overrepresented in schizophrenics.  Taken together, these reports help strengthen the idea 
that myelin-related processes may be primary contributors to the schizophrenia 
phenotype.  
 
Methods for conducting network analyses of SNP data are still under development, and 
our study contains some limitations we would like to address.  For instance, in 
conducting the permutation tests to assess significance of the network results, the number 
of genes selected was fixed, but the gene sizes and numbers of SNPs per gene were not 
taken into account.  If these measures differed between the specified networks and the 
average randomly generated gene set, it could influence the results.  Also, no multiple 
testing correction was implemented for the multiple networks tested in both ancestry 
groups.  Since the core networks were a subset of the expanded networks, they were non-
independent, and it was therefore difficult to determine an appropriate correction method.  
However, some caution is warranted in interpreting our one positive result out of four 
networks tested.     
 
There are numerous ways of generating gene networks, and alternate strategies to those 
tried here may prove more fruitful in defining a more precise cluster of genes conveying 
liability to schizophrenia through these biological processes.  Furthermore, by using 
multiple concentric gene networks for each biological process of interest, the optimal size 
network could be determined for maximal association.  This may differ across processes 
and/or across ancestry groups.   
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 The results of this project prompt additional questions which remain to be answered.  
First, which genes are driving the AA-myelin association?  It is unlikely that all genes in 
the core myelin network contribute equally to the significant association in the AA group.  
Deciphering which genes are more strongly associated would strengthen their position as 
candidate genes and could lead to possible intervention or therapeutic targets.    
Additionally, when taking admixture into account, do AA subjects with more European 
DNA demonstrate less myelin association?  The African-American population is highly 
admixed with European-American populations (Parra et al, 1998), so if the myelin gene 
association is truly specific to the AA group, this association should grow weaker with 
increasing admixture.  Use of ancestry-informative markers to gauge individual 
proportions of AA and EA DNA could be used to resolve this question.  Furthermore, the 
differences observed across ancestry groups highlight the importance of broadening the 
populations included in these types of analyses to give us a better understanding of the 
mechanisms leading to schizophrenia (and other diseases) throughout the world.   
 
The extensive genetic heterogeneity of schizophrenia has led to limited success with 
commonly used gene finding methods.  Investigating related genes together may enhance 
the power to detect risk genes of very small effect.  Ultimately, network analyses could 
become vital tools in the determination of aberrant biological processes and the risk 
genes impacting them in schizophrenia and other complex diseases.   
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Chapter 6:  Power Differences for Family-Based Epistasis 
Detection Methods 
 99
 
Abstract: 
 
The impact of genetic variation on common diseases is complex, involving many loci and 
their interactions. In population-based association samples, modeling gene-gene 
interaction, or epistasis, the conditional impact of one genetic polymorphism on another, 
is a relatively straightforward exercise. In these samples, genotypes at multiple loci, with 
their interaction term(s), can be included in a regression model as predictors. Detection of 
gene-gene interactions in family-based association samples is more complicated, but 
several methods have been proposed. In these approaches pseudocontrols are created 
based on the alleles or genotypes that were not transmitted to an affected offspring from 
genotyped parents. Two main approaches to generating pseudocontrols involve using 
nontransmitted two-locus genotypes (Cordell approach) and nontransmitted alleles (two-
locus haplotype relative risk approach; HRR).  In the former, 15 pseudocontrols would be 
generated, while the latter yields only one.  These cases and pseudocontrols are then 
analyzed using logistic regression conditional on the parental genotypes. The core 
distinction between these approaches is the inclusion of transmitted alleles in the creation 
of pseudocontrol genotypes in the Cordell approach.  We have explored the power for 
both of these methods under a variety of models of epistasis in 1000 simulated samples of 
500 parent-child trios.  Under “classic” epistasis models and particularly for dominance 
models, the HRR approach yields greater power, but under most other models (additive, 
heterogeneity, and crossover) the Cordell approach demonstrates increased power for 
detecting epistasis. These results suggest different approaches to family-based epistasis 
testing are indicated depending on the expected model of epistasis in effect.    
 100
Introduction: 
 
Genes never act in isolation.  By only investigating independent main effects of genetic 
variants, the ways in which alleles influence each other goes undetected, and information 
contributing to disease predisposition is lost.  Finding the best ways to explore gene 
interactions and capture this variation is highly relevant to studies of complex disease.      
 
Epistasis is the general term for interactions between genes, but it has been defined 
somewhat differently between studies.  Departures from additivity or multiplicativity on 
the penetrance scale have been termed epistasis.  Biological epistasis, the physical 
interaction of proteins or other molecules leading to a different phenotype than when 
expressed alone, is currently difficult to study given our limited knowledge of protein-
protein interactions at this time.  Statistical epistasis, in which the penetrance of a two-
locus genotype differs from additivity on a multiplicative scale, combined with a 
plausible biological foundation is probably a more reasonable goal, and this is the 
definition to be used here.  
 
There are numerous ways in which the genotype at one locus can influence the effect of 
the genotype at another locus.  In a typical conception of epistasis, the risk conferred by 
one locus is variable depending on the alleles present at another locus.  A scenario in 
which one locus changes the direction of the effect at another locus is called a crossover 
effect.  In a heterogeneity model, a two-locus recessive disease model is used in which 
 101
two recessive alleles at either (or both) loci confer disease risk.  The penetrance need not 
be the same for both loci (Cordell, 2002).  For an additive model, the allelic loading at 
each locus influences penetrance in an additive fashion.  The dominance model involves 
one locus masking the effects of an allele at another locus.   
 
Epistatic interactions are one possible reason for the inconsistent replication in 
schizophrenia association studies.  If a particular configuration of allelic variants 
predisposes individuals to this illness to a greater extent than these variants in isolation, 
individual alleles may be difficult to detect.  In studies of schizophrenia genetics, 
epistasis is of increasing interest with several recent articles giving evidence for the 
involvement of epistatic processes in this disorder (Ott et al, 2005; Corvin et al, 2007; 
Nicodemus et al, 2007; Morris et al, 2007; Edwards et al, 2008; Burdick et al, 2008; Prata 
et al, 2009).   
 
Epistasis detection 
 
Although epistasis detection is a more straightforward process in case-control datasets, it 
can also be accomplished using family data with the added benefit of being relatively 
robust to population stratification.  Two main family-based approaches have been 
proposed.  In one, the multifactor dimensionality reduction-pedigree disequilibrium test 
(MDR-PDT), discordant sib pairs or trios can be used in the detection of joint effects of 
multiple loci in the absence of detectable main effects with significance assessed through 
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permutation (Martin et al, 2006).  In the other, pseudocontrols are created based on the 
alleles or genotypes that were not transmitted to an affected offspring from genotyped 
parents.  There are two published approaches to generating pseudocontrols which involve 
using nontransmitted two-locus genotypes (Cordell approach) to create 15 pseudocontrols 
(Cordell et al, 2004) or using nontransmitted alleles (two-locus haplotype relative risk 
approach; HRR) which yields only three (Falk and Rubenstein, 1987) (Figure 6.1).  
Through the simulated scenarios explored here, we sought to determine which approach 
yielded greater power to detect epistatic interactions.   
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Figure 6.1.  Depiction of Cordell and HRR approaches to pseudocontrol generation. 
A = affected, P = pseudocontrol.  The hypothetical cross was between double-
heterozygote parents and the genotype selected to be affected was arbitrary.   
 
Cordell 
 AA Aa aA aa 
BB P P P P 
Bb P P P P 
bB P P P P 
bb P P P A 
 
 
Haplotype Relative Risk 
 AA Aa aA aa 
BB P    
Bb     
bB     
bb    A 
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Methods: 
 
All simulations and analyses were conducted using SAS (SAS Institute, 2005) 
Each test was comprised of 1000 simulated samples of 500 parent-child trios.  
Pseudocontrols were generated in accordance with the two family-based epistasis 
detection methods under examination.  For the Cordell approach, 15 pseudocontrols were 
generated from the nontransmitted two-locus genotypes.  The HRR approach yields one 
pseudocontrol arising from the nontransmitted alleles.   
 
For the simulation, the prevalence, K, was fixed at .005 and modeled using the following 
equation in which π = the baseline risk, GRR = genotype relative risk, p and q are the 
major and minor allele frequencies for locus 1, respectively, and r and s are the respective 
major and minor allele frequencies for locus 2: 
 
K = p2r2π + 2pqr2π x GRR2 + r2q2π x GRR3 + p2rsπ x GRR4 + pqrsπ x GRR5 + q2rsπ x 
GRR6 + p2r2π x GRR7 + pqs2π x GRR8 + q2s2π x GRR9 
    
The minor (risk) allele frequencies were fixed at .1 for both loci.  Logistic regression was 
used to test for epistatic effects.  Models of additive, heterogeneity, crossover, and 
dominance epistatic effects were examined with different magnitudes of effects.  (See 
Appendix B:  Penetrance matrices used in epistasis simulations)  Several models were 
adapted from Howson et al (2005).  
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Results: 
 
The power differences between approaches varied substantially according to the models 
used and the magnitude of the epistasis effects established by the penetrance matrices 
(Appendix C).  Under dominance models, the HRR approach has greater power for 
epistasis detection (Figure 6.2).  Over a broad range of dominance models, those with 
very low and high marginal effects exhibited floor and ceiling effects attenuating the 
differences between approaches.  Although differences were most dramatic for 
intermediate penetrance values, the HRR approach showed superior power for detection 
for all dominance models tested.  However, the Cordell approach yields greater power for 
most other epistasis models.  Models termed “epistatic effects” yielded quite similar 
results between detection approaches, while additive and heterogeneity models were far 
more easily detected by the Cordell approach.  Crossover models exhibited intermediate 
results.   
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Table 6.1  Comparative power for Cordell and HRR approaches under different models 
of epistasis.  Numbers in parentheses denote the models adapted from Howson et al 
(2008).  
 
         Power 
model type Cordell HRR 
epistatic (4) 31.5 32.7
epistatic (5) 19.6 23.1
additive (7) 99.9 47.6
additive  82.2 5.3
heterogeneity (11) 49.6 4.4
heterogeneity (12) 11.1 12.0
crossover (14)  87.4 62.6
crossover (15) 100 76.7
   
dominance 2.8 9.0
dominance 3.7 22.1
dominance 5.3 36.3
dominance 13.4 55.1
dominance 21.5 70.2
dominance 50.2 91.2
dominance 67.8 98.1
dominance 82.8 99.8
dominance 90.9 99.9
dominance 98.2 100
dominance 99.3 100
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Figure 6.2.  Comparative power for Cordell and HRR approaches under dominance 
models.   
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Discussion: 
 
From these results, we conclude that different approaches to family-based epistasis 
testing are indicated depending on the expected model of epistasis in effect.  Under 
conditions of dominance, it is advantageous to generate pseudocontrols without the 
susceptibility alleles to enhance contrast with the affected individual.  For this reason, the 
HRR approach with only one pseudocontrol, lacking the alleles present in the affected 
individual, would be advisable.  Other epistatic interactions are more easily detected 
through inclusion of more pseudocontrols even if they do harbor the risk alleles.  In real 
data, it is unlikely that the model of epistasis would be known a priori, but the Cordell 
approach may be a wise choice given its higher power under most models.   
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 Once evidence for a statistical epistatic interaction has been revealed, determining the 
biological meaning it confers is challenging (Moore and Williams, 2005).  It is possible 
that the statistical result is a false positive, and consequently, corrections for multiple 
testing should be implemented to reduce this possibility.  Also, it could be the case that 
the alleles demonstrating epistasis are in linkage disequilibrium with the true causative 
alleles.  Additional genotyping or in vitro experiments may be useful in resolving that 
question.  Biological investigations of the purported interactions will certainly lend 
credence to any report of statistical epistasis.  For example, protein-protein interactions 
can be assayed by yeast two hybrid experiments, and knockout mice have also been used 
to assess downstream effects of removing one protein.     
 
Only two-locus interactions have been investigated here, but higher-order interactions are 
entirely plausible.  The computational feasibility of detecting these interactions, however, 
is low given the number of possible permutations.  Power for detection of two-locus 
interactions diminishes rapidly with lower allele frequencies and is even further 
compromised by addition of a third locus.   
 
Most investigations of epistasis in schizophrenia have been limited to genes that are 
known or theorized to biologically interact. Thus far, little evidence for epistasis in 
GWAS has been presented (Wellcome Trust Case Control Consortium, 2007), however, 
the development of new ways of analyzing large datasets will hopefully allow us to tap 
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the multitudes of interactions waiting to be discovered.  Determining the most powerful 
methods of epistasis detection in conjunction with appropriate multiple testing 
corrections will provide an important tool to extend our understanding of complex 
disease etiology.   
 
 
 
 110
 
 
 
 
 
 
 
 
 
 
Chapter 7:  General Discussion 
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The studies presented here have either directly or indirectly been aimed at developing a 
better understanding of schizophrenia and its various manifestations.  Since it is 
increasingly apparent that multiple genetic pathways to schizophrenia are possible and 
likely, it follows logically that some genetic influences may vary by population.  Support 
for this has been given through linkage studies in groups of African and European 
ancestry (Takahashi et al, 2003; Faraone et al, 2005; Suarez et al, 2006; Holliday et al, 
2008) as well as a recent paper showing greater risk gene concordance between 
schizophrenia and bipolar disorder in European-Americans than between schizophrenics 
of European and African descent (Purcell et al, 2009).   
 
Two of the studies detailed here tentatively corroborate differences in symptom profiles 
and genetic foundations of schizophrenia between subjects of African and European 
ancestry.  In phenotypic assessments, these two groups demonstrated distinct factor 
structures.  The greatest differences were observed in affective symptoms with 
individuals of European ancestry having higher levels of manic and depressive 
symptoms.  Explorations of myelin and synaptic gene networks in these samples yielded 
a significant association for one myelin network and only in the African-ancestry group.  
Potential population differences should be kept in mind when comparing association or 
other studies conducted in different ancestry groups.     
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In a series of studies exploring the relationships between seven genes and symptoms of 
schizophrenia, we found a significant association of PAH with delusions, GABRB3 with 
hallucinations, and SNAP25 with both of these symptom factors.  AKT1 alleles conferred 
greater levels of Schneiderian symptoms, but dysbindin, MAOB, and SLC6A4 were not 
related to any symptom dimensions.  Understanding the genetic influences on the 
symptoms of schizophrenia could contribute to the generation of more targeted 
treatments for them.  It may also lead to the identification of reliable subtypes and 
eventually aid in uncovering the predisposing biological mechanisms.  Similar studies 
investigating modifier gene effects but encompassing a greater number of genes would be 
useful in these regards.   
 
The question of whether schizophrenia is one disease or several has lingered since its 
identification and remains one of the most pertinent questions in this field.  Distinct 
genetic risk factors giving rise to similar symptom profiles presents challenges to the 
detection of susceptibility genes.  The simulation study addressing detection of a pseudo-
modifier gene in one subgroup with a slightly different set of symptoms explores a 
variety of parameters impacting association results under these conditions.     
 
It is possible that some of the inconsistent associations reported for schizophrenia 
candidate genes are due to epistatic interactions.  If the interaction of two genes confers 
greater disease risk than the genes individually, the genes may not be detected in 
examinations of main effects.  The final study presented here explored approaches for 
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detecting epistatic effects in family data under different models of epistasis.  The 
haplotype relative risk (HRR) approach, involving generation of one pseudocontrol, 
yields greater power for detection under conditions of dominance, but the Cordell 
approach with fifteen pseudocontrols is more powerful under most other models. 
 
As national and international collaborations grow to produce ever larger cohorts of 
subjects, better detection of genetic loci influencing schizophrenia should follow.  But if 
many thousands of loci, most with very small effect sizes, are contributing to the 
schizophrenia phenotype, it may not be possible to identify all of them.  The gene-finding 
strategies implemented for monogenic disorders and complex disorders with limited 
genetic heterogeneity are not well suited for complex diseases with hundreds or 
thousands of susceptibility loci.  Novel approaches must be developed and applied to data 
from many populations if we are to fully understand the genetic underpinnings of 
schizophrenia and other highly complex diseases.   
 
Environmental risk factors between or within populations could also influence the 
diagnosis and manifestation of schizophrenia.  Although with a heritability of ~81% 
(Sullivan et al, 2003) it is appropriate to focus most efforts on the genetic risk factors for 
schizophrenia, environmental influences on the liability to schizophrenia and the ways 
they may interact with susceptibility genes also deserve mention here.  However, ~20% 
of the variance in liability to schizophrenia is environmental in origin, and this certainly 
merits investigation in its own right.  The prenatal viral exposure theory of schizophrenia 
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etiology has been championed through season of birth studies (Davies et al, 2003), 
animal model generation through prenatal maternal immune system activation (Ozawa et 
al, 2006), and recent GWAS studies pointing to immune system genes (Purcell et al, 
2009; Shi et al, 2009; Stefansson et al, 2009).  Other environmental factors have been 
posited such as immigrating to another country (Cantor-Graae and Selten, 2005).  The 
disorienting nature of adapting to another culture may lead to psychosis in some 
individuals, or discrimination could foster persecutory beliefs that spiral into psychotic 
features.  Cannabis use may confer additional risk in people predisposed to developing 
schizophrenia (Moore et al, 2007).  Additional environmental theories abound, and their 
study should not be marginalized since environmental manipulation is more tractable and 
palatable than genetic alterations for prevention and intervention strategies. 
 
Nevertheless, the majority of people who experience these risk factors do not go on to 
develop schizophrenia, underscoring the importance of genetic liability to these 
influences.  Genetic variation remains the primary cause of schizophrenia and the best 
hope for development of more efficacious treatments.  It is obvious that with copious 
genetic heterogeneity and a variety of potential environmental risk factors, many different 
causal mechanisms are likely acting to produce the phenotype termed schizophrenia.   
 
Decades of research have highlighted the complexity of the genetic foundations giving 
rise to schizophrenia, but conclusive findings have remained elusive.  The advent of high-
throughput genotyping and new computational strategies has made more complex 
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analyses feasible.  Nascent methods such as network or pathway analysis may capture 
variants disrupting biological process known to have gone awry or even uncover 
previously unknown mechanisms leading to the disease.  Investigations of epistatic 
interactions could also lead to a better understanding of the constellation of genetic 
alterations resulting in schizophrenia, and explorations of symptoms and their genetic 
bases will also likely shed light on this enigmatic disease. 
 
Such diverse research tactics are appropriate for this symptomatically and genetically 
heterogeneous disease.  The rapid progress from a broad range of research domains 
engenders hope that we will eventually unlock the etiological mechanisms of 
schizophrenia, but it is clear that many more years of research in this field lie ahead.  The 
ultimate goals of preventing schizophrenia when possible and treating it when not will be 
best served by understanding the mechanisms giving rise to this disease.   
 
 116
 
 
 
 
 
 
 
 
 
 
Reference List 
 
 
 
 
 117
 
 
 
 
 
 
 
 
 
 
Reference List 
 
 
 
Illumina, Inc.  2006. 7-16-2008.  
Ref Type: Electronic Citation 
affymetrix . 2006. 7-15-2008.  
Ref Type: Electronic Citation 
Abecasis,G.R., Cookson,W.O., and Cardon,L.R., 2000. Pedigree tests of transmission 
disequilibrium. Eur J Hum Genet. 8, 545-551. 
Aberg,K., Saetre,P., Lindholm,E., Ekholm,B., Pettersson,U., Adolfsson,R., and Jazin,E., 
2006. Human QKI, a new candidate gene for schizophrenia involved in myelination. Am 
J Med Genet B Neuropsychiatr Genet. 141B, 84-90. 
Adebimpe,V.R., Chu,C.C., Klein,H.E., and Lange,M.H., 1982. Racial and geographic 
differences in the psychopathology of schizophrenia. Am J Psychiatry. 139, 888-891. 
Alcaniz,S. and Silva,F.J., 1997. Phenylalanine hydroxylase participation in the synthesis 
of serotonin and pteridines in Drosophila melanogaster - A software package for the 
construction and drawing of evolutionary trees for the Microsoft Windows environment. 
Comparative Biochemistry and Physiology - Part C Pharmacology, Toxicology, and 
Endocrinology. 116, 205-212. 
Allen,N.C., Bagade,S., McQueen,M.B., Ioannidis,J.P., Kavvoura,F.K., Khoury,M.J., 
Tanzi,R.E., and Bertram,L., 2008. Systematic meta-analyses and field synopsis of genetic 
association studies in schizophrenia: the SzGene database. Nat Genet. 40, 827-834. 
 118
Andreasen,N.C., Flashman,L., Flaum,M., Arndt,S., Swayze,V., O'Leary,D.S., 
Ehrhardt,J.C., and Yuh,W.T., 1994. Regional brain abnormalities in schizophrenia 
measured with magnetic resonance imaging. JAMA. 272, 1763-1769. 
Andreasen,N.C., Arndt,S., Alliger,R., Miller,D., and Flaum,M., 1995. Symptoms of 
schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry. 52, 341-351. 
Arnold,L.M., Keck,P.E., Jr., Collins,J., Wilson,R., Fleck,D.E., Corey,K.B., Amicone,J., 
Adebimpe,V.R., and Strakowski,S.M., 2004. Ethnicity and first-rank symptoms in 
patients with psychosis. Schizophr Res. 67, 207-212. 
Bajestan,S.N., Sabouri,A.H., Nakamura,M., Takashima,H., Keikhaee,M.R., Behdani,F., 
Fayyazi,M.R., Sargolzaee,M.R., Bajestan,M.N., Sabouri,Z., Khayami,E., Haghighi,S., 
Hashemi,S.B., Eiraku,N., Tufani,H., Najmabadi,H., Arimura,K., Sano,A., and Osame,M., 
2006. Association of AKT1 haplotype with the risk of schizophrenia in Iranian 
population. Am J Med Genet B Neuropsychiatr Genet. 141B, 383-386. 
Bakker,S.C., Hoogendoorn,M.L., Selten,J.P., Verduijn,W., Pearson,P.L., Sinke,R.J., and 
Kahn,R.S., 2004. Neuregulin 1: genetic support for schizophrenia subtypes. Mol 
Psychiatry. 9, 1061-1063. 
Barrett,J.C., Hansoul,S., Nicolae,D.L., Cho,J.H., Duerr,R.H., Rioux,J.D., Brant,S.R., 
Silverberg,M.S., Taylor,K.D., Barmada,M.M., Bitton,A., Dassopoulos,T., Datta,L.W., 
Green,T., Griffiths,A.M., Kistner,E.O., Murtha,M.T., Regueiro,M.D., Rotter,J.I., 
Schumm,L.P., Steinhart,A.H., Targan,S.R., Xavier,R.J., Libioulle,C., Sandor,C., 
Lathrop,M., Belaiche,J., Dewit,O., Gut,I., Heath,S., Laukens,D., Mni,M., Rutgeerts,P., 
Van Gossum,A., Zelenika,D., Franchimont,D., Hugot,J.P., de Vos,M., Vermeire,S., 
Louis,E., Cardon,L.R., Anderson,C.A., Drummond,H., Nimmo,E., Ahmad,T., 
Prescott,N.J., Onnie,C.M., Fisher,S.A., Marchini,J., Ghori,J., Bumpstead,S., Gwilliam,R., 
Tremelling,M., Deloukas,P., Mansfield,J., Jewell,D., Satsangi,J., Mathew,C.G., 
Parkes,M., Georges,M., and Daly,M.J., 2008. Genome-wide association defines more 
than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 40, 955-962. 
Beaulieu,J.M., Sotnikova,T.D., Yao,W.D., Kockeritz,L., Woodgett,J.R., 
Gainetdinov,R.R., and Caron,M.G., 2004. Lithium antagonizes dopamine-dependent 
behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl 
Acad Sci U S A. 101, 5099-5104. 
 119
Beckmann,J.S., Tomfohrde,J., Barnes,R.I., Williams,M., Broux,O., Richard,I., 
Weissenbach,J., and Bowcock,A.M., 1993. A linkage map of human chromosome 15 
with an average resolution of 2 cM and containing 55 polymorphic microsatellites. Hum 
Mol Genet. 2, 2019-2030. 
Benson,M.A., Newey,S.E., Martin-Rendon,E., Hawkes,R., and Blake,D.J., 2001. 
Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in 
muscle and brain. J Biol Chem. 276, 24232-24241. 
Benzel,I., Bansal,A., Browning,B.L., Galwey,N.W., Maycox,P.R., McGinnis,R., 
Smart,D., St Clair,D., Yates,P., and Purvis,I., 2007. Interactions among genes in the 
ErbB-Neuregulin signalling network are associated with increased susceptibility to 
schizophrenia. Behav Brain Funct. 3, 31. 
Bhugra,D., 2005. The global prevalence of schizophrenia. PLoS Med. 2, e151. 
Bleuler,E., 1950. Dementia praecox, or the group of schizophrenias. International 
Universities Press, New York. 
Braff,D.L., Geyer,M.A., and Swerdlow,N.R., 2001. Human studies of prepulse inhibition 
of startle: normal subjects, patient groups, and pharmacological studies. 
Psychopharmacology (Berl). 156, 234-258. 
Bramon,E., Rabe-Hesketh,S., Sham,P., Murray,R.M., and Frangou,S., 2004. Meta-
analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. 70, 315-329. 
Breier,A., 1995. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res. 
14, 187-202. 
Brown,A.S., 2006. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull. 
32, 200-202. 
Brown,R., Colter,N., Corsellis,J.A., Crow,T.J., Frith,C.D., Jagoe,R., Johnstone,E.C., and 
Marsh,L., 1986. Postmortem evidence of structural brain changes in schizophrenia. 
Differences in brain weight, temporal horn area, and parahippocampal gyrus compared 
with affective disorder. Arch Gen Psychiatry. 43, 36-42. 
 120
Budel,S., Padukkavidana,T., Liu,B.P., Feng,Z., Hu,F., Johnson,S., Lauren,J., Park,J.H., 
McGee,A.W., Liao,J., Stillman,A., Kim,J.E., Yang,B.Z., Sodi,S., Gelernter,J., Zhao,H., 
Hisama,F., Arnsten,A.F., and Strittmatter,S.M., 2008. Genetic variants of Nogo-66 
receptor with possible association to schizophrenia block myelin inhibition of axon 
growth. J Neurosci. 28, 13161-13172. 
Burdick,K.E., Lencz,T., Funke,B., Finn,C.T., Szeszko,P.R., Kane,J.M., Kucherlapati,R., 
and Malhotra,A.K., 2006. Genetic variation in DTNBP1 influences general cognitive 
ability. Hum Mol Genet. 15, 1563-1568. 
Burdick,K.E., Goldberg,T.E., Funke,B., Bates,J.A., Lencz,T., Kucherlapati,R., and 
Malhotra,A.K., 2007. DTNBP1 genotype influences cognitive decline in schizophrenia. 
Schizophr Res. 89, 169-172. 
Burdick,K.E., Kamiya,A., Hodgkinson,C.A., Lencz,T., DeRosse,P., Ishizuka,K., 
Elashvili,S., Arai,H., Goldman,D., Sawa,A., and Malhotra,A.K., 2008. Elucidating the 
relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence 
of epistasis and competitive binding. Hum Mol Genet. 17, 2462-2473. 
Burne,J.F., Staple,J.K., and Raff,M.C., 1996. Glial cells are increased proportionally in 
transgenic optic nerves with increased numbers of axons. J Neurosci. 16, 2064-2073. 
Butt,A.M. and Ransom,B.R., 1989. Visualization of oligodendrocytes and astrocytes in 
the intact rat optic nerve by intracellular injection of lucifer yellow and horseradish 
peroxidase. Glia. 2, 470-475. 
Byerley,W., Bailey,M.E., Hicks,A.A., Riley,B.P., Darlison,M.G., Holik,J., Hoff,M., 
Umar,F., Reimherr,F., and Wender,P., 1995. Schizophrenia and GABAA receptor 
subunit genes. Psychiatr Genet. 5, 23-29. 
Byne,W., Kidkardnee,S., Tatusov,A., Yiannoulos,G., Buchsbaum,M.S., and 
Haroutunian,V., 2006. Schizophrenia-associated reduction of neuronal and 
oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res. 85, 
245-253. 
Byne,W., Fernandes,J., Haroutunian,V., Huacon,D., Kidkardnee,S., Kim,J., Tatusov,A., 
Thakur,U., and Yiannoulos,G., 2007. Reduction of right medial pulvinar volume and 
neuron number in schizophrenia. Schizophr Res. 90, 71-75. 
 121
Cantor-Graae,E. and Selten,J.P., 2005. Schizophrenia and migration: a meta-analysis and 
review. Am J Psychiatry. 162, 12-24. 
Cardno,A.G., Bowen,T., Guy,C.A., Jones,L.A., McCarthy,G., Williams,N.M., 
Murphy,K.C., Spurlock,G., Gray,M., Sanders,R.D., Craddock,N., McGuffin,P., 
Owen,M.J., and O'Donovan,M.C., 1999. CAG repeat length in the hKCa3 gene and 
symptom dimensions in schizophrenia. Biol Psychiatry. 45, 1592-1596. 
Carrera,N., Sanjuan,J., Molto,M.D., Carracedo,A., and Costas,J., 2008. Recent adaptive 
selection at MAOB and ancestral susceptibility to schizophrenia. Am J Med Genet B 
Neuropsychiatr Genet. 
Carroll,L.S., Kendall,K., O'Donovan,M.C., Owen,M.J., and Williams,N.M., 2009. 
Evidence that putative ADHD low risk alleles at SNAP25 may increase the risk of 
schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 
Chakraborty,A. and McKenzie,K., 2002. Does racial discrimination cause mental illness? 
Br J Psychiatry. 180, 475-477. 
Chao,H.M. and Richardson,M.A., 2002. Aromatic amino acid hydroxylase genes and 
schizophrenia. Am J Med Genet. 114, 626-630. 
Chen,Q., Wang,X., O'Neill,F.A., Walsh,D., Fanous,A., Kendler,K.S., and Chen,X., 2007. 
Association study of CSF2RB with schizophrenia in Irish family and case - control 
samples. Mol Psychiatry. 
Chen,X. and Kwok,P.Y., 1997. Template-directed dye-terminator incorporation (TDI) 
assay: a homogeneous DNA diagnostic method based on fluorescence resonance energy 
transfer. Nucleic Acids Res. 25, 347-353. 
Chiba,S., Hashimoto,R., Hattori,S., Yohda,M., Lipska,B., Weinberger,D.R., and 
Kunugi,H., 2006. Effect of antipsychotic drugs on DISC1 and dysbindin expression in 
mouse frontal cortex and hippocampus. J Neural Transm. 113, 1337-1346. 
Compston,A., Zajicek,J., Sussman,J., Webb,A., Hall,G., Muir,D., Shaw,C., Wood,A., and 
Scolding,N., 1997. Glial lineages and myelination in the central nervous system. J Anat. 
190 ( Pt 2), 161-200. 
 122
Cook,E.H., Jr., Courchesne,R.Y., Cox,N.J., Lord,C., Gonen,D., Guter,S.J., Lincoln,A., 
Nix,K., Haas,R., Leventhal,B.L., and Courchesne,E., 1998. Linkage-disequilibrium 
mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet. 62, 1077-1083. 
Cordell,H.J., 2002. Epistasis: what it means, what it doesn't mean, and statistical methods 
to detect it in humans. Hum Mol Genet. 11, 2463-2468. 
Cordell,H.J., Barratt,B.J., and Clayton,D.G., 2004. Case/pseudocontrol analysis in 
genetic association studies: A unified framework for detection of genotype and haplotype 
associations, gene-gene and gene-environment interactions, and parent-of-origin effects. 
Genet Epidemiol. 26, 167-185. 
Corvin,A., McGhee,K.A., Murphy,K., Donohoe,G., Nangle,J.M., Schwaiger,S., 
Kenny,N., Clarke,S., Meagher,D., Quinn,J., Scully,P., Baldwin,P., Browne,D., Walsh,C., 
Waddington,J.L., Morris,D.W., and Gill,M., 2007. Evidence for association and epistasis 
at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample. Am J 
Med Genet B Neuropsychiatr Genet. 144, 949-953. 
Corvin,A., Donohoe,G., Nangle,J.M., Schwaiger,S., Morris,D., and Gill,M., 2008. A 
dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. 
Neurosci Lett. 431, 146-149. 
Cotter,D., Mackay,D., Frangou,S., Hudson,L., and Landau,S., 2004. Cell density and 
cortical thickness in Heschl's gyrus in schizophrenia, major depression and bipolar 
disorder. Br J Psychiatry. 185, 258-259. 
Craddock,N. and Lendon,C., 1999. Chromosome Workshop: chromosomes 11, 14, and 
15. Am J Med Genet. 88, 244-254. 
Craddock,N., O'Donovan,M.C., and Owen,M.J., 2007. Phenotypic and genetic 
complexity of psychosis. Invited commentary on ... Schizophrenia: a common disease 
caused by multiple rare alleles. Br J Psychiatry. 190, 200-203. 
Dann,J., DeLisi,L.E., Devoto,M., Laval,S., Nancarrow,D.J., Shields,G., Smith,A., 
Loftus,J., Peterson,P., Vita,A., Comazzi,M., Invernizzi,G., Levinson,D.F., 
Wildenauer,D., Mowry,B.J., Collier,D., Powell,J., Crowe,R.R., Andreasen,N.C., 
Silverman,J.M., Mohs,R.C., Murray,R.M., Walters,M.K., Lennon,D.P., Crow,T.J., and ., 
 123
1997. A linkage study of schizophrenia to markers within Xp11 near the MAOB gene. 
Psychiatry Res. 70, 131-143. 
Datta,S.R., McQuillin,A., Puri,V., Choudhury,K., Thirumalai,S., Lawrence,J., Pimm,J., 
Bass,N., Lamb,G., Moorey,H., Morgan,J., Punukollu,B., Kandasami,G., Kirwin,S., 
Sule,A., Quested,D., Curtis,D., and Gurling,H.M., 2007. Failure to confirm allelic and 
haplotypic association between markers at the chromosome 6p22.3 dystrobrevin-binding 
protein 1 (DTNBP1) locus and schizophrenia. Behav Brain Funct. 3, 50. 
Davies,G., Welham,J., Chant,D., Torrey,E.F., and McGrath,J., 2003. A systematic review 
and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. 
Schizophr Bull. 29, 587-593. 
de Chaldee,M., Laurent,C., Thibaut,F., Martinez,M., Samolyk,D., Petit,M., Campion,D., 
and Mallet,J., 1999. Linkage disequilibrium on the COMT gene in French schizophrenics 
and controls. Am J Med Genet. 88, 452-457. 
DeLisi,L.E., Goldin,L.R., Maxwell,M.E., Kazuba,D.M., and Gershon,E.S., 1987. Clinical 
features of illness in siblings with schizophrenia or schizoaffective disorder. Arch Gen 
Psychiatry. 44, 891-896. 
Dell'Angelica,E.C., 2004. The building BLOC(k)s of lysosomes and related organelles. 
Curr Opin Cell Biol. 16, 458-464. 
DeRosse,P., Funke,B., Burdick,K.E., Lencz,T., Ekholm,J.M., Kane,J.M., 
Kucherlapati,R., and Malhotra,A.K., 2006. Dysbindin genotype and negative symptoms 
in schizophrenia. Am J Psychiatry. 163, 532-534. 
DeRosse,P., Funke,B., Burdick,K.E., Lencz,T., Goldberg,T.E., Kane,J.M., 
Kucherlapati,R., and Malhotra,A.K., 2006. COMT genotype and manic symptoms in 
schizophrenia. Schizophr Res. 87, 28-31. 
DeRosse,P., Hodgkinson,C.A., Lencz,T., Burdick,K.E., Kane,J.M., Goldman,D., and 
Malhotra,A.K., 2007. Disrupted in schizophrenia 1 genotype and positive symptoms in 
schizophrenia. Biol Psychiatry. 61, 1208-1210. 
 124
Dhossche,D.M., 2004. Autism as early expression of catatonia. Med Sci Monit. 10, 
RA31-RA39. 
Donohoe,G., Morris,D.W., Clarke,S., McGhee,K.A., Schwaiger,S., Nangle,J.M., 
Garavan,H., Robertson,I.H., Gill,M., and Corvin,A., 2007. Variance in neurocognitive 
performance is associated with dysbindin-1 in schizophrenia: a preliminary study. 
Neuropsychologia. 45, 454-458. 
Dracheva,S., Davis,K.L., Chin,B., Woo,D.A., Schmeidler,J., and Haroutunian,V., 2006. 
Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex 
and hippocampus in elderly schizophrenia patients. Neurobiol Dis. 21, 531-540. 
Duan,J., Martinez,M., Sanders,A.R., Hou,C., Burrell,G.J., Krasner,A.J., Schwartz,D.B., 
and Gejman,P.V., 2007. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: 
association evidence in the 3' end of the gene. Hum Hered. 64, 97-106. 
Dudbridge,F., 2003. Pedigree disequilibrium tests for multilocus haplotypes. Genet 
Epidemiol. 25, 115-121. 
Edwards,T.L., Wang,X., Chen,Q., Wormly,B., Riley,B., O'Neill,F.A., Walsh,D., 
Ritchie,M.D., Kendler,K.S., and Chen,X., 2008. Interaction between interleukin 3 and 
dystrobrevin-binding protein 1 in schizophrenia. Schizophr Res. 106, 208-217. 
Emamian,E.S., Hall,D., Birnbaum,M.J., Karayiorgou,M., and Gogos,J.A., 2004. 
Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat 
Genet. 36, 131-137. 
Falk C.T. and Rubenstein P., 1987.  Haplotype relative risks:  an easy reliable way to 
construct a proper control sample for risk calculations.  Ann Hum Genet.  51, 227-233. 
Fallin,M.D., Lasseter,V.K., Avramopoulos,D., Nicodemus,K.K., Wolyniec,P.S., 
McGrath,J.A., Steel,G., Nestadt,G., Liang,K.Y., Huganir,R.L., Valle,D., and Pulver,A.E., 
2005. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen 
of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet. 77, 
918-936. 
 125
Fan,J.B. and Sklar,P., 2005. Meta-analysis reveals association between serotonin 
transporter gene STin2 VNTR polymorphism and schizophrenia. Mol Psychiatry. 10, 
928-38, 891. 
Fanous AH, O'Neill FA, Walsh D, and Kendler KS. Factor analysis of psychotic 
symptoms and concordance between chart review and direct structured interview in their 
assessment. unknown . 12-12-2008.  
Ref Type: In Press 
Fanous,A.H., Neale,M.C., Straub,R.E., Webb,B.T., O'Neill,A.F., Walsh,D., and 
Kendler,K.S., 2004. Clinical features of psychotic disorders and polymorphisms in 
HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study. 
Am J Med Genet B Neuropsychiatr Genet. 125, 69-78. 
Fanous,A.H., van den Oord,E.J., Riley,B.P., Aggen,S.H., Neale,M.C., O'Neill,F.A., 
Walsh,D., and Kendler,K.S., 2005. Relationship between a high-risk haplotype in the 
DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry. 162, 
1824-1832. 
Fanous,A.H. and Kendler,K.S., 2005. Genetic heterogeneity, modifier genes, and 
quantitative phenotypes in psychiatric illness: searching for a framework. Mol Psychiatry. 
10, 6-13. 
Fanous,A.H. and Kendler,K.S., 2008. Genetics of clinical features and subtypes of 
schizophrenia: a review of the recent literature. Curr Psychiatry Rep. 10, 164-170. 
Faraone,S.V., Skol,A.D., Tsuang,D.W., Young,K.A., Haverstock,S.L., Prabhudesai,S., 
Mena,F., Menon,A.S., Leong,L., Sautter,F., Baldwin,C., Bingham,S., Weiss,D., 
Collins,J., Keith,T., Vanden Eng,J.L., Boehnke,M., Tsuang,M.T., and Schellenberg,G.D., 
2005. Genome scan of schizophrenia families in a large Veterans Affairs Cooperative 
Study sample: evidence for linkage to 18p11.32 and for racial heterogeneity on 
chromosomes 6 and 14. Am J Med Genet B Neuropsychiatr Genet. 139B, 91-100. 
Fatemi,S.H., Earle,J.A., Stary,J.M., Lee,S., and Sedgewick,J., 2001. Altered levels of the 
synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood 
disorders and schizophrenia. Neuroreport. 12, 3257-3262. 
 126
Fearon,P. and Morgan,C., 2006. Environmental factors in schizophrenia: the role of 
migrant studies. Schizophr Bull. 32, 405-408. 
Fearon,P., Kirkbride,J.B., Morgan,C., Dazzan,P., Morgan,K., Lloyd,T., Hutchinson,G., 
Tarrant,J., Fung,W.L., Holloway,J., Mallett,R., Harrison,G., Leff,J., Jones,P.B., and 
Murray,R.M., 2006. Incidence of schizophrenia and other psychoses in ethnic minority 
groups: results from the MRC AESOP Study. Psychol Med. 36, 1541-1550. 
Ford,J.M., Mathalon,D.H., Whitfield,S., Faustman,W.O., and Roth,W.T., 2002. Reduced 
communication between frontal and temporal lobes during talking in schizophrenia. Biol 
Psychiatry. 51, 485-492. 
Funke,B., Finn,C.T., Plocik,A.M., Lake,S., DeRosse,P., Kane,J.M., Kucherlapati,R., and 
Malhotra,A.K., 2004. Association of the DTNBP1 locus with schizophrenia in a U.S. 
population. Am J Hum Genet. 75, 891-898. 
Gabriel,S.M., Haroutunian,V., Powchik,P., Honer,W.G., Davidson,M., Davies,P., and 
Davis,K.L., 1997. Increased concentrations of presynaptic proteins in the cingulate cortex 
of subjects with schizophrenia. Arch Gen Psychiatry. 54, 559-566. 
Georgieva,L., Moskvina,V., Peirce,T., Norton,N., Bray,N.J., Jones,L., Holmans,P., 
Macgregor,S., Zammit,S., Wilkinson,J., Williams,H., Nikolov,I., Williams,N., Ivanov,D., 
Davis,K.L., Haroutunian,V., Buxbaum,J.D., Craddock,N., Kirov,G., Owen,M.J., and 
O'Donovan,M.C., 2006. Convergent evidence that oligodendrocyte lineage transcription 
factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc 
Natl Acad Sci U S A. 103, 12469-12474. 
Glantz,L.A., Gilmore,J.H., Lieberman,J.A., and Jarskog,L.F., 2006. Apoptotic 
mechanisms and the synaptic pathology of schizophrenia. Schizophr Res. 81, 47-63. 
Golimbet,V.E., Alfimova,M.V., Shcherbatikh,T., Kaleda,V.G., Abramova,L.I., and 
Rogaev,E.I., 2003. Serotonin transporter gene polymorphism and schizoid personality 
traits in the patients with psychosis and psychiatrically well subjects. World J Biol 
Psychiatry. 4, 25-29. 
Golimbet,V.E., Alfimova,M.V., Shchebatykh,T.V., Abramova,L.I., Kaleda,V.G., and 
Rogaev,E.I., 2004. Serotonin transporter polymorphism and depressive-related symptoms 
in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 126, 1-7. 
 127
Goltsov,A.A., Eisensmith,R.C., Naughton,E.R., Jin,L., Chakraborty,R., and Woo,S.L., 
1993. A single polymorphic STR system in the human phenylalanine hydroxylase gene 
permits rapid prenatal diagnosis and carrier screening for phenylketonuria. Hum Mol 
Genet. 2, 577-581. 
Grimes,C.A. and Jope,R.S., 2001. The multifaceted roles of glycogen synthase kinase 
3beta in cellular signaling. Prog Neurobiol. 65, 391-426. 
Grimsby,J., Chen,K., Devor,E.J., Cloninger,C.R., and Shih,J.C., 1992. Dinucleotide 
repeat (TG)23 polymorphism in the MAOB gene. Nucleic Acids Res. 20, 924. 
Hakak,Y., Walker,J.R., Li,C., Wong,W.H., Davis,K.L., Buxbaum,J.D., Haroutunian,V., 
and Fienberg,A.A., 2001. Genome-wide expression analysis reveals dysregulation of 
myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 98, 4746-
4751. 
Halim,N.D., Weickert,C.S., McClintock,B.W., Hyde,T.M., Weinberger,D.R., 
Kleinman,J.E., and Lipska,B.K., 2003. Presynaptic proteins in the prefrontal cortex of 
patients with schizophrenia and rats with abnormal prefrontal development. Mol 
Psychiatry. 8, 797-810. 
Hall,D., Gogos,J.A., and Karayiorgou,M., 2004. The contribution of three strong 
candidate schizophrenia susceptibility genes in demographically distinct populations. 
Genes Brain Behav. 3, 240-248. 
Hanninen,K., Katila,H., Saarela,M., Rontu,R., Mattila,K.M., Fan,M., Hurme,M., and 
Lehtimaki,T., 2007. Interleukin-1 beta gene polymorphism and its interactions with 
neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatry 
Clin Neurosci. 
Haroutunian,V., Katsel,P., Dracheva,S., Stewart,D.G., and Davis,K.L., 2007. Variations 
in oligodendrocyte-related gene expression across multiple cortical regions: implications 
for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol. 10, 565-573. 
Harrison,P.J. and Owen,M.J., 2003. Genes for schizophrenia? Recent findings and their 
pathophysiological implications. Lancet. 361, 417-419. 
 128
Hayes,S., Turecki,G., Brisebois,K., Lopes-Cendes,I., Gaspar,C., Riess,O., Ranum,L.P., 
Pulst,S.M., and Rouleau,G.A., 2000. CAG repeat length in RAI1 is associated with age at 
onset variability in spinocerebellar ataxia type 2 (SCA2). Hum Mol Genet. 9, 1753-1758. 
Held,P.K., 2006. Disorders of tyrosine catabolism. Mol Genet Metab. 88, 103-106. 
Hof,P.R., Haroutunian,V., Friedrich,V.L., Jr., Byne,W., Buitron,C., Perl,D.P., and 
Davis,K.L., 2003. Loss and altered spatial distribution of oligodendrocytes in the superior 
frontal gyrus in schizophrenia. Biol Psychiatry. 53, 1075-1085. 
Holliday,E.G., Handoko,H.Y., James,M.R., McGrath,J.J., Nertney,D.A., Tirupati,S., 
Thara,R., Levinson,D.F., Hayward,N.K., Mowry,B.J., and Nyholt,D.R., 2006. 
Association study of the dystrobrevin-binding gene with schizophrenia in Australian and 
Indian samples. Twin Res Hum Genet. 9, 531-539. 
Holliday,E.G., Mowry,B.J., and Nyholt,D.R., 2008. A reanalysis of 409 European-
Ancestry and African American schizophrenia pedigrees reveals significant linkage to 
8p23.3 with evidence of locus heterogeneity. Am J Med Genet B Neuropsychiatr Genet. 
147B, 1080-1088. 
Howson,J.M., Barratt,B.J., Todd,J.A., and Cordell,H.J., 2005. Comparison of population- 
and family-based methods for genetic association analysis in the presence of interacting 
loci. Genet Epidemiol. 29, 51-67. 
Huang,K., Tang,W., Tang,R., Xu,Z., He,Z., Li,Z., Xu,Y., Li,X., He,G., Feng,G., He,L., 
and Shi,Y., 2008. Positive association between OLIG2 and schizophrenia in the Chinese 
Han population. Hum Genet. 122, 659-660. 
Hutchinson,G., Takei,N., Sham,P., Harvey,I., and Murray,R.M., 1999. Factor analysis of 
symptoms in schizophrenia: differences between White and Caribbean patients in 
Camberwell. Psychol Med. 29, 607-612. 
Ide,M., Ohnishi,T., Murayama,M., Matsumoto,I., Yamada,K., Iwayama,Y., Dedova,I., 
Toyota,T., Asada,T., Takashima,A., and Yoshikawa,T., 2006. Failure to support a genetic 
contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. J 
Neurochem. 99, 277-287. 
 129
Ikeda,M., Iwata,N., Suzuki,T., Kitajima,T., Yamanouchi,Y., Kinoshita,Y., Inada,T., and 
Ozaki,N., 2004. Association of AKT1 with schizophrenia confirmed in a Japanese 
population. Biol Psychiatry. 56, 698-700. 
Ikeda,M., Takahashi,N., Saito,S., Aleksic,B., Watanabe,Y., Nunokawa,A., 
Yamanouchi,Y., Kitajima,T., Kinoshita,Y., Kishi,T., Kawashima,K., Hashimoto,R., 
Ujike,H., Inada,T., Someya,T., Takeda,M., Ozaki,N., and Iwata,N., 2008. Failure to 
replicate the association between NRG1 and schizophrenia using Japanese large sample. 
Schizophr Res. 101, 1-8. 
International Schizophrenia Consortium, 2008. Rare chromosomal deletions and 
duplications increase risk of schizophrenia. Nature. 455, 237-241. 
Ioannidis,J.P., Ntzani,E.E., and Trikalinos,T.A., 2004. 'Racial' differences in genetic 
effects for complex diseases. Nat Genet. 36, 1312-1318. 
Jakobsdottir,J., Conley,Y.P., Weeks,D.E., Mah,T.S., Ferrell,R.E., and Gorin,M.B., 2005. 
Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum 
Genet. 77, 389-407. 
Jeans,A.F., Oliver,P.L., Johnson,R., Capogna,M., Vikman,J., Molnar,Z., Babbs,A., 
Partridge,C.J., Salehi,A., Bengtsson,M., Eliasson,L., Rorsman,P., and Davies,K.E., 2007. 
A dominant mutation in Snap25 causes impaired vesicle trafficking, sensorimotor gating, 
and ataxia in the blind-drunk mouse. Proc Natl Acad Sci U S A. 104, 2431-2436. 
Joo,E.J., Lee,K.Y., Jeong,S.H., Ahn,Y.M., Koo,Y.J., and Kim,Y.S., 2006. The dysbindin 
gene (DTNBP1) and schizophrenia: no support for an association in the Korean 
population. Neurosci Lett. 407, 101-106. 
Jungerius,B.J., Hoogendoorn,M.L., Bakker,S.C., Van't Slot,R., Bardoel,A.F., 
Ophoff,R.A., Wijmenga,C., Kahn,R.S., and Sinke,R.J., 2008. An association screen of 
myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. 
Mol Psychiatry. 13, 1060-1068. 
Kaiser,R., Konneker,M., Henneken,M., Dettling,M., Muller-Oerlinghausen,B., Roots,I., 
and Brockmoller,J., 2000. Dopamine D4 receptor 48-bp repeat polymorphism: no 
association with response to antipsychotic treatment, but association with catatonic 
schizophrenia. Mol Psychiatry. 5, 418-424. 
 130
Kanazawa,T., Glatt,S.J., Tsutsumi,A., Kikuyama,H., Koh,J., Yoneda,H., and 
Tsuang,M.T., 2007. Schizophrenia is not associated with the functional candidate gene 
ERBB3: results from a case-control study. Am J Med Genet B Neuropsychiatr Genet. 
144, 113-116. 
Karson,C.N., Mrak,R.E., Schluterman,K.O., Sturner,W.Q., Sheng,J.G., and Griffin,W.S., 
1999. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in 
schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mol Psychiatry. 4, 39-
45. 
Kaufmann,C.A., Suarez,B., Malaspina,D., Pepple,J., Svrakic,D., Markel,P.D., Meyer,J., 
Zambuto,C.T., Schmitt,K., Matise,T.C., Harkavy Friedman,J.M., Hampe,C., Lee,H., 
Shore,D., Wynne,D., Faraone,S.V., Tsuang,M.T., and Cloninger,C.R., 1998. NIMH 
Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-
American pedigrees. Am J Med Genet. 81, 282-289. 
Kawashima,K., Kishi,T., Ikeda,M., Kitajima,T., Yamanouchi,Y., Kinoshita,Y., 
Takahashi,N., Saito,S., Ohi,K., Yasuda,Y., Hashimoto,R., Takeda,M., Inada,T., Ozaki,N., 
and Iwata,N., 2008. No association between tagging SNPs of SNARE complex genes 
(STX1A, VAMP2 and SNAP25) and schizophrenia in a Japanese population. Am J Med 
Genet B Neuropsychiatr Genet. 147B, 1327-1331. 
Kendler,K.S., Gruenberg,A.M., and Tsuang,M.T., 1988. A family study of the subtypes 
of schizophrenia. Am J Psychiatry. 145, 57-62. 
Keverne,E.B., 1999. GABA-ergic neurons and the neurobiology of schizophrenia and 
other psychoses. Brain Res Bull. 48, 467-473. 
Kim,J.W., Lee,Y.S., Cho,E.Y., Jang,Y.L., Park,D.Y., Choi,K.S., Jeun,H.O., Cho,S.H., 
Jang,S.Y., and Hong,K.S., 2006. Linkage and association of schizophrenia with genetic 
variations in the locus of neuregulin 1 in Korean population. Am J Med Genet B 
Neuropsychiatr Genet. 141, 281-286. 
Kirov,G., Ivanov,D., Williams,N.M., Preece,A., Nikolov,I., Milev,R., Koleva,S., 
Dimitrova,A., Toncheva,D., O'Donovan,M.C., and Owen,M.J., 2004. Strong evidence for 
association between the dystrobrevin binding protein 1 gene (DTNBP1) and 
schizophrenia in 488 parent-offspring trios from Bulgaria. Biol Psychiatry. 55, 971-975. 
 131
Kirov,G., Gumus,D., Chen,W., Norton,N., Georgieva,L., Sari,M., O'Donovan,M.C., 
Erdogan,F., Owen,M.J., Ropers,H.H., and Ullmann,R., 2008. Comparative genome 
hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet. 
17, 458-465. 
Krabbendam,L. and van Os,J., 2005. Schizophrenia and urbanicity: a major 
environmental influence--conditional on genetic risk. Schizophr Bull. 31, 795-799. 
Kraepelin,E., 1921. Manic-depressive illness and paranoia. E & S Livingstone, 
Edinburgh, Scotland. 
Kramer,E.M., Schardt,A., and Nave,K.A., 2001. Membrane traffic in myelinating 
oligodendrocytes. Microsc Res Tech. 52, 656-671. 
Krieckhaus,E.E., Donahoe,J.W., and Morgan,M.A., 1992. Paranoid schizophrenia may be 
caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry. 31, 560-570. 
Kubicki,M., McCarley,R., Westin,C.F., Park,H.J., Maier,S., Kikinis,R., Jolesz,F.A., and 
Shenton,M.E., 2007. A review of diffusion tensor imaging studies in schizophrenia. J 
Psychiatr Res. 41, 15-30. 
Kung,L., Conley,R., Chute,D.J., Smialek,J., and Roberts,R.C., 1998. Synaptic changes in 
the striatum of schizophrenic cases: a controlled postmortem ultrastructural study. 
Synapse. 28, 125-139. 
Lachman,H.M., Pedrosa,E., Nolan,K.A., Glass,M., Ye,K., and Saito,T., 2006. Analysis of 
polymorphisms in AT-rich domains of neuregulin 1 gene in schizophrenia. Am J Med 
Genet B Neuropsychiatr Genet. 141, 102-109. 
Lawrie,S.M., Buechel,C., Whalley,H.C., Frith,C.D., Friston,K.J., and Johnstone,E.C., 
2002. Reduced frontotemporal functional connectivity in schizophrenia associated with 
auditory hallucinations. Biol Psychiatry. 51, 1008-1011. 
Levinson,D.F., Mowry,B.J., Escamilla,M.A., and Faraone,S.V., 2002. The Lifetime 
Dimensions of Psychosis Scale (LDPS): description and interrater reliability. Schizophr 
Bull. 28, 683-695. 
 132
Lewis,D.A., Cruz,D.A., Melchitzky,D.S., and Pierri,J.N., 2001. Lamina-specific deficits 
in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with 
schizophrenia: evidence for fewer projections from the thalamus. Am J Psychiatry. 158, 
1411-1422. 
Li,T., Stefansson,H., Gudfinnsson,E., Cai,G., Liu,X., Murray,R.M., Steinthorsdottir,V., 
Januel,D., Gudnadottir,V.G., Petursson,H., Ingason,A., Gulcher,J.R., Stefansson,K., and 
Collier,D.A., 2004. Identification of a novel neuregulin 1 at-risk haplotype in Han 
schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk 
haplotype. Mol Psychiatry. 9, 698-704. 
Li,T., Zhang,F., Liu,X., Sun,X., Sham,P.C., Crombie,C., Ma,X., Wang,Q., Meng,H., 
Deng,W., Yates,P., Hu,X., Walker,N., Murray,R.M., St Clair,D., and Collier,D.A., 2005. 
Identifying potential risk haplotypes for schizophrenia at the DTNBP1 locus in Han 
Chinese and Scottish populations. Mol Psychiatry. 10, 1037-1044. 
Lim,K.O., Tew,W., Kushner,M., Chow,K., Matsumoto,B., and DeLisi,L.E., 1996. 
Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am J 
Psychiatry. 153, 1548-1553. 
Lin,S., Jiang,S., Wu,X., Qian,Y., Wang,D., Tang,G., and Gu,N., 2000. Association 
analysis between mood disorder and monoamine oxidase gene. Am J Med Genet. 96, 12-
14. 
Liu,C.M., Liu,Y.L., Fann,C.S., Yang,W.C., Wu,J.Y., Hung,S.I., Chen,W.J., Chueh,C.M., 
Liu,W.M., Liu,C.C., Hsieh,M.H., Hwang,T.J., Faraone,S.V., Tsuang,M.T., and 
Hwu,H.G., 2007. No association evidence between schizophrenia and dystrobrevin-
binding protein 1 (DTNBP1) in Taiwanese families. Schizophr Res. 93, 391-398. 
Liu,X., Qin,W., He,G., Yang,Y., Chen,Q., Zhou,J., Li,D., Gu,N., Xu,Y., Feng,G., 
Sang,H., Hao,X., Zhang,K., Wang,S., and He,L., 2005. A family-based association study 
of the MOG gene with schizophrenia in the Chinese population. Schizophr Res. 73, 275-
280. 
Liu,Y.C., Huang,C.L., Wu,P.L., Chang,Y.C., Huang,C.H., and Lane,H.Y., 2008. Lack of 
association between AKT1 variances versus clinical manifestations and social function in 
patients with schizophrenia. J Psychopharmacol. 
 133
Liu,Y.L., Fann,C.S., Liu,C.M., Wu,J.Y., Hung,S.I., Chan,H.Y., Chen,J.J., Pan,C.C., 
Liu,S.K., Hsieh,M.H., Hwang,T.J., Ouyang,W.C., Chen,C.Y., Lin,J.J., Chou,F.H., 
Chueh,C.M., Liu,W.M., Tsuang,M.M., Faraone,S.V., Tsuang,M.T., Chen,W.J., and 
Hwu,H.G., 2006. Absence of significant associations between four AKT1 SNP markers 
and schizophrenia in the Taiwanese population. Psychiatr Genet. 16, 39-41. 
Loftus,J., DeLisi,L.E., and Crow,T.J., 2000. Factor structure and familiality of first-rank 
symptoms in sibling pairs with schizophrenia and schizoaffective disorder. Br J 
Psychiatry. 177, 15-19. 
Macgregor,S., Craddock,N., and Holmans,P.A., 2006. Use of phenotypic covariates in 
association analysis by sequential addition of cases. Eur J Hum Genet. 14, 529-534. 
Madison,D.L., Krueger,W.H., Cheng,D., Trapp,B.D., and Pfeiffer,S.E., 1999. SNARE 
complex proteins, including the cognate pair VAMP-2 and syntaxin-4, are expressed in 
cultured oligodendrocytes. J Neurochem. 72, 988-998. 
Maeno,N., Takahashi,N., Saito,S., Ji,X., Ishihara,R., Aoyama,N., Branko,A., Miura,H., 
Ikeda,M., Suzuki,T., Kitajima,T., Yamanouchi,Y., Kinoshita,Y., Iwata,N., Inada,T., and 
Ozaki,N., 2007. Association of SOX10 with schizophrenia in the Japanese population. 
Psychiatr Genet. 17, 227-231. 
Maher BS, Reimers MA, Riley BP, and Kendler KS. Allelic heterogeneity in genetic 
association meta-analysis:  An application to DTNBP1 and schizophrenia. unknown . 12-
9-2008.  
Ref Type: In Press 
Malhotra,A.K., Goldman,D., Mazzanti,C., Clifton,A., Breier,A., and Pickar,D., 1998. A 
functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in 
neuroleptic-free schizophrenics. Mol Psychiatry. 3, 328-332. 
Manolio,T.A., Rodriguez,L.L., Brooks,L., Abecasis,G., Ballinger,D., Daly,M., 
Donnelly,P., Faraone,S.V., Frazer,K., Gabriel,S., Gejman,P., Guttmacher,A., Harris,E.L., 
Insel,T., Kelsoe,J.R., Lander,E., McCowin,N., Mailman,M.D., Nabel,E., Ostell,J., 
Pugh,E., Sherry,S., Sullivan,P.F., Thompson,J.F., Warram,J., Wholley,D., Milos,P.M., 
and Collins,F.S., 2007. New models of collaboration in genome-wide association studies: 
the Genetic Association Information Network. Nat Genet. 39, 1045-1051. 
 134
Martin,E.R., Ritchie,M.D., Hahn,L., Kang,S., and Moore,J.H., 2006. A novel method to 
identify gene-gene effects in nuclear families: the MDR-PDT. Genet Epidemiol. 30, 111-
123. 
Maycox,P.R., Kelly,F., Taylor,A., Bates,S., Reid,J., Logendra,R., Barnes,M.R., 
Larminie,C., Jones,N., Lennon,M., Davies,C., Hagan,J.J., Scorer,C.A., Angelinetta,C., 
Akbar,T., Hirsch,S., Mortimer,A.M., Barnes,T.R., and de Belleroche,J., 2009. Analysis 
of gene expression in two large schizophrenia cohorts identifies multiple changes 
associated with nerve terminal function. Mol Psychiatry. 
McClay,J.L., Fanous,A., van den Oord,E.J., Webb,B.T., Walsh,D., O'Neill,F.A., 
Kendler,K.S., and Chen,X., 2006. Catechol-O-methyltransferase and the clinical features 
of psychosis. Am J Med Genet B Neuropsychiatr Genet. 141, 935-938. 
McClellan,J.M., Susser,E., and King,M.C., 2007. Schizophrenia: a common disease 
caused by multiple rare alleles. Br J Psychiatry. 190, 194-199. 
McGlashan,T.H. and Fenton,W.S., 1991. Classical subtypes for schizophrenia: literature 
review for DSM-IV. Schizophr Bull. 17, 609-632. 
McGrath,J.A., Avramopoulos,D., Lasseter,V.K., Wolyniec,P.S., Fallin,M.D., Liang,K.Y., 
Nestadt,G., Thornquist,M.H., Luke,J.R., Chen,P.L., Valle,D., and Pulver,A.E., 2009. 
Familiality of novel factorial dimensions of schizophrenia. Arch Gen Psychiatry. 66, 591-
600. 
McGuffin,P., Farmer,A., and Harvey,I., 1991. A polydiagnostic application of 
operational criteria in studies of psychotic illness. Development and reliability of the 
OPCRIT system. Arch Gen Psychiatry. 48, 764-770. 
Minsky,S., Vega,W., Miskimen,T., Gara,M., and Escobar,J., 2003. Diagnostic patterns in 
Latino, African American, and European American psychiatric patients. Arch Gen 
Psychiatry. 60, 637-644. 
Mitkus,S.N., Hyde,T.M., Vakkalanka,R., Kolachana,B., Weinberger,D.R., Kleinman,J.E., 
and Lipska,B.K., 2008. Expression of oligodendrocyte-associated genes in dorsolateral 
prefrontal cortex of patients with schizophrenia. Schizophr Res. 98, 129-138. 
 135
Mittal,V.A., Ellman,L.M., and Cannon,T.D., 2008. Gene-environment interaction and 
covariation in schizophrenia: the role of obstetric complications. Schizophr Bull. 34, 
1083-1094. 
Moore,J.H. and Williams,S.M., 2005. Traversing the conceptual divide between 
biological and statistical epistasis: systems biology and a more modern synthesis. 
Bioessays. 27, 637-646. 
Moore,T.H., Zammit,S., Lingford-Hughes,A., Barnes,T.R., Jones,P.B., Burke,M., and 
Lewis,G., 2007. Cannabis use and risk of psychotic or affective mental health outcomes: 
a systematic review. Lancet. 370, 319-328. 
Morris,D.W., McGhee,K.A., Schwaiger,S., Scully,P., Quinn,J., Meagher,D., 
Waddington,J.L., Gill,M., and Corvin,A.P., 2003. No evidence for association of the 
dysbindin gene [DTNBP1] with schizophrenia in an Irish population-based study. 
Schizophr Res. 60, 167-172. 
Morris,D.W., Murphy,K., Kenny,N., Purcell,S.M., McGhee,K.A., Schwaiger,S., 
Nangle,J.M., Donohoe,G., Clarke,S., Scully,P., Quinn,J., Meagher,D., Baldwin,P., 
Crumlish,N., O'Callaghan,E., Waddington,J.L., Gill,M., and Corvin,A.P., 2008. 
Dysbindin (DTNBP1) and the biogenesis of lysosome-related organelles complex 1 
(BLOC-1): main and epistatic gene effects are potential contributors to schizophrenia 
susceptibility. Biol Psychiatry. 63, 24-31. 
Mukherjee,S., Shukla,S., Woodle,J., Rosen,A.M., and Olarte,S., 1983. Misdiagnosis of 
schizophrenia in bipolar patients: a multiethnic comparison. Am J Psychiatry. 140, 1571-
1574. 
Musil,R., Spellmann,I., Riedel,M., Dehning,S., Douhet,A., Maino,K., Zill,P., Muller,N., 
Moller,H.J., and Bondy,B., 2008. SNAP-25 gene polymorphisms and weight gain in 
schizophrenic patients. J Psychiatr Res. 42, 963-970. 
Muthen LK and Muthen BO, 2001. Mplus: Statistical Analysis with Latent Variables: 
User's Guide. Muthen and Muthen, Los Angeles. 
Mutsuddi,M., Morris,D.W., Waggoner,S.G., Daly,M.J., Scolnick,E.M., and Sklar,P., 
2006. Analysis of high-resolution HapMap of DTNBP1 (Dysbindin) suggests no 
 136
consistency between reported common variant associations and schizophrenia. Am J 
Hum Genet. 79, 903-909. 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National 
Diabetes Information Clearinghouse (NDIC). NIH . 2008. 7-12-2008.  
Ref Type: Electronic Citation 
Nicodemus,K.K., Luna,A., Vakkalanka,R., Goldberg,T., Egan,M., Straub,R.E., and 
Weinberger,D.R., 2006. Further evidence for association between ErbB4 and 
schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. 
Mol Psychiatry. 11, 1062-1065. 
Nicodemus,K.K., Kolachana,B.S., Vakkalanka,R., Straub,R.E., Giegling,I., Egan,M.F., 
Rujescu,D., and Weinberger,D.R., 2007. Evidence for statistical epistasis between 
catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), 
GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet. 120, 889-906. 
Norman,R.M., Malla,A.K., Morrison-Stewart,S.L., Helmes,E., Williamson,P.C., 
Thomas,J., and Cortese,L., 1997. Neuropsychological correlates of syndromes in 
schizophrenia. Br J Psychiatry. 170, 134-139. 
Norton,N., Moskvina,V., Morris,D.W., Bray,N.J., Zammit,S., Williams,N.M., 
Williams,H.J., Preece,A.C., Dwyer,S., Wilkinson,J.C., Spurlock,G., Kirov,G., 
Buckland,P., Waddington,J.L., Gill,M., Corvin,A.P., Owen,M.J., and O'Donovan,M.C., 
2006. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases 
susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 141B, 96-101. 
Norton,N., Williams,H.J., Dwyer,S., Carroll,L., Peirce,T., Moskvina,V., Segurado,R., 
Nikolov,I., Williams,N.M., Ikeda,M., Iwata,N., Owen,M.J., and O'Donovan,M.C., 2007. 
Association analysis of AKT1 and schizophrenia in a UK case control sample. Schizophr 
Res. 93, 58-65. 
Novak,G., Kim,D., Seeman,P., and Tallerico,T., 2002. Schizophrenia and Nogo: elevated 
mRNA in cortex, and high prevalence of a homozygous CAA insert. Brain Res Mol 
Brain Res. 107, 183-189. 
Numakawa,T., Yagasaki,Y., Ishimoto,T., Okada,T., Suzuki,T., Iwata,N., Ozaki,N., 
Taguchi,T., Tatsumi,M., Kamijima,K., Straub,R.E., Weinberger,D.R., Kunugi,H., and 
 137
Hashimoto,R., 2004. Evidence of novel neuronal functions of dysbindin, a susceptibility 
gene for schizophrenia. Hum Mol Genet. 13, 2699-2708. 
Ogilvie,A.D., Battersby,S., Bubb,V.J., Fink,G., Harmar,A.J., Goodwim,G.M., and 
Smith,C.A., 1996. Polymorphism in serotonin transporter gene associated with 
susceptibility to major depression. Lancet. 347, 731-733. 
Ohtsuki,T., Inada,T., and Arinami,T., 2004. Failure to confirm association between 
AKT1 haplotype and schizophrenia in a Japanese case-control population. Mol 
Psychiatry. 9, 981-983. 
Onstad,S., Skre,I., Torgersen,S., and Kringlen,E., 1991. Subtypes of schizophrenia--
evidence from a twin-family study. Acta Psychiatr Scand. 84, 203-206. 
Ott,U., Reuter,M., Hennig,J., and Vaitl,D., 2005. Evidence for a common biological basis 
of the Absorption trait, hallucinogen effects, and positive symptoms: epistasis between 5-
HT2a and COMT polymorphisms. Am J Med Genet B Neuropsychiatr Genet. 137B, 29-
32. 
Ozawa,K., Hashimoto,K., Kishimoto,T., Shimizu,E., Ishikura,H., and Iyo,M., 2006. 
Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and 
cognitive impairment in the offspring: a neurodevelopmental animal model of 
schizophrenia. Biol Psychiatry. 59, 546-554. 
Pakkenberg,B., 1987. Post-mortem study of chronic schizophrenic brains. Br J 
Psychiatry. 151, 744-752. 
Pakkenberg,B., 1992. Stereological quantitation of human brains from normal and 
schizophrenic individuals. Acta Neurol Scand Suppl. 137, 20-33. 
Pakkenberg,B., 1993. Total nerve cell number in neocortex in chronic schizophrenics and 
controls estimated using optical disectors. Biol Psychiatry. 34, 768-772. 
Parra,E.J., Marcini,A., Akey,J., Martinson,J., Batzer,M.A., Cooper,R., Forrester,T., 
Allison,D.B., Deka,R., Ferrell,R.E., and Shriver,M.D., 1998. Estimating African 
American admixture proportions by use of population-specific alleles. Am J Hum Genet. 
63, 1839-1851. 
 138
Pedersen,C.B. and Mortensen,P.B., 2001. Evidence of a dose-response relationship 
between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry. 58, 
1039-1046. 
Pedrosa,E., Ye,K., Nolan,K.A., Morrell,L., Okun,J.M., Persky,A.D., Saito,T., and 
Lachman,H.M., 2007. Positive association of schizophrenia to JARID2 gene. Am J Med 
Genet B Neuropsychiatr Genet. 144B, 45-51. 
Peirce,T.R., Bray,N.J., Williams,N.M., Norton,N., Moskvina,V., Preece,A., 
Haroutunian,V., Buxbaum,J.D., Owen,M.J., and O'Donovan,M.C., 2006. Convergent 
evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene 
for schizophrenia. Arch Gen Psychiatry. 63, 18-24. 
Peralta,V. and Cuesta,M.J., 2001. How many and which are the psychopathological 
dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res. 49, 
269-285. 
Perdry,H., Maher,B.S., Babron,M.C., McHenry,T., Clerget-Darpoux,F., and 
Marazita,M.L., 2007. An ordered subset approach to including covariates in the 
transmission disequilibrium test. BMC Proc. 1 Suppl 1, S77. 
Petryshen,T.L., Middleton,F.A., Kirby,A., Aldinger,K.A., Purcell,S., Tahl,A.R., 
Morley,C.P., McGann,L., Gentile,K.L., Rockwell,G.N., Medeiros,H.M., Carvalho,C., 
Macedo,A., Dourado,A., Valente,J., Ferreira,C.P., Patterson,N.J., Azevedo,M.H., 
Daly,M.J., Pato,C.N., Pato,M.T., and Sklar,P., 2005. Support for involvement of 
neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry. 10, 366-74, 328. 
Pierri,J.N., Chaudry,A.S., Woo,T.U., and Lewis,D.A., 1999. Alterations in chandelier 
neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J 
Psychiatry. 156, 1709-1719. 
Prata,D.P., Mechelli,A., Fu,C.H., Picchioni,M., Toulopoulou,T., Bramon,E., Walshe,M., 
Murray,R.M., Collier,D.A., and McGuire,P., 2009. Epistasis between the DAT 3' UTR 
VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and 
patients with schizophrenia. Proc Natl Acad Sci U S A. 106, 13600-13605. 
 139
Pulst,S.M., Santos,N., Wang,D., Yang,H., Huynh,D., Velazquez,L., and Figueroa,K.P., 
2005. Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium 
channel modifies age of onset. Brain. 128, 2297-2303. 
Purcell,S., Neale,B., Todd-Brown,K., Thomas,L., Ferreira,M.A., Bender,D., Maller,J., 
Sklar,P., de Bakker,P.I., Daly,M.J., and Sham,P.C., 2007. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum Genet. 81, 559-
575. 
Purcell,S.M., Wray,N.R., Stone,J.L., Visscher,P.M., O'Donovan,M.C., Sullivan,P.F., and 
Sklar,P., 2009. Common polygenic variation contributes to risk of schizophrenia and 
bipolar disorder. Nature. 460, 748-752. 
Qin,W., Gao,J., Xing,Q., Yang,J., Qian,X., Li,X., Guo,Z., Chen,H., Wang,L., Huang,X., 
Gu,N., Feng,G., and He,L., 2005. A family-based association study of PLP1 and 
schizophrenia. Neurosci Lett. 375, 207-210. 
Qu,M., Yue,W., Tang,F., Wang,L., Han,Y., and Zhang,D., 2008. Polymorphisms of 
Transferrin gene are associated with schizophrenia in Chinese Han population. J 
Psychiatr Res. 42, 877-883. 
Reynolds,G.P., Yao,Z., Zhang,X., Sun,J., and Zhang,Z., 2005. Pharmacogenetics of 
treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms 
separately associate with positive and negative symptom response. Eur 
Neuropsychopharmacol. 15, 143-151. 
Richardson,M.A., Read,L.L., Clelland,J.D., Chao,H.M., Reilly,M.A., Romstad,A., and 
Suckow,R.F., 2003. Phenylalanine hydroxylase gene in psychiatric patients: screening 
and functional assay of mutations. Biol Psychiatry. 53, 543-553. 
Rietkerk,T., Boks,M.P., Sommer,I.E., de Jong,S., Kahn,R.S., and Ophoff,R.A., 2009. 
Network analysis of positional candidate genes of schizophrenia highlights myelin-
related pathways. Mol Psychiatry. 14, 353-355. 
Riley BP, Kuo PH, Maher BS, Fanous AH, Sun J, Wormley, B., O'Neill FA, Walsh D, 
Zhao Z, and Kendler KS. The dystrobrevin binding protein 1 (DTNBP1) gene is 
associated with schizophrenia in the Irish Case Control Study of Schizophrenia (ICCSS) 
sample. Biol.Psychiatry . 1-22-2009. Ref Type: In Press 
 140
Salvatore,F., Scudiero,O., and Castaldo,G., 2002. Genotype-phenotype correlation in 
cystic fibrosis: the role of modifier genes. Am J Med Genet. 111, 88-95. 
Sanders,A.R., Duan,J., Levinson,D.F., Shi,J., He,D., Hou,C., Burrell,G.J., Rice,J.P., 
Nertney,D.A., Olincy,A., Rozic,P., Vinogradov,S., Buccola,N.G., Mowry,B.J., 
Freedman,R., Amin,F., Black,D.W., Silverman,J.M., Byerley,W.F., Crowe,R.R., 
Cloninger,C.R., Martinez,M., and Gejman,P.V., 2008. No significant association of 14 
candidate genes with schizophrenia in a large European ancestry sample: implications for 
psychiatric genetics. Am J Psychiatry. 165, 497-506. 
SAS Institute Inc. SAS software version 9.1.3.  2005. Cary, NC.  
Ref Type: Computer Program 
Schwab,S.G., Knapp,M., Mondabon,S., Hallmayer,J., Borrmann-Hassenbach,M., 
Albus,M., Lerer,B., Rietschel,M., Trixler,M., Maier,W., and Wildenauer,D.B., 2003. 
Support for association of schizophrenia with genetic variation in the 6p22.3 gene, 
dysbindin, in sib-pair families with linkage and in an additional sample of triad families. 
Am J Hum Genet. 72, 185-190. 
Schwab,S.G., Hoefgen,B., Hanses,C., Hassenbach,M.B., Albus,M., Lerer,B., Trixler,M., 
Maier,W., and Wildenauer,D.B., 2005. Further evidence for association of variants in the 
AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol 
Psychiatry. 58, 446-450. 
Selemon,L.D., Rajkowska,G., and Goldman-Rakic,P.S., 1995. Abnormally high neuronal 
density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and 
occipital area 17. Arch Gen Psychiatry. 52, 805-818. 
Selemon,L.D., Rajkowska,G., and Goldman-Rakic,P.S., 1998. Elevated neuronal density 
in prefrontal area 46 in brains from schizophrenic patients: application of a three-
dimensional, stereologic counting method. J Comp Neurol. 392, 402-412. 
Selemon,L.D. and Goldman-Rakic,P.S., 1999. The reduced neuropil hypothesis: a circuit 
based model of schizophrenia. Biol Psychiatry. 45, 17-25. 
Serretti,A., Lilli,R., Lorenzi,C., Lattuada,E., and Smeraldi,E., 2001. DRD4 exon 3 
variants associated with delusional symptomatology in major psychoses: a study on 2,011 
affected subjects. Am J Med Genet. 105, 283-290. 
 141
Shi,J., Levinson,D.F., Duan,J., Sanders,A.R., Zheng,Y., Pe'er,I., Dudbridge,F., 
Holmans,P.A., Whittemore,A.S., Mowry,B.J., Olincy,A., Amin,F., Cloninger,C.R., 
Silverman,J.M., Buccola,N.G., Byerley,W.F., Black,D.W., Crowe,R.R., Oksenberg,J.R., 
Mirel,D.B., Kendler,K.S., Freedman,R., and Gejman,P.V., 2009. Common variants on 
chromosome 6p22.1 are associated with schizophrenia. Nature. 460, 753-757. 
Silberberg,G., Darvasi,A., Pinkas-Kramarski,R., and Navon,R., 2006. The involvement 
of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B 
Neuropsychiatr Genet. 141B, 142-148. 
So,H.C., Fong,P.Y., Chen,R.Y., Hui,T.C., Ng,M.Y., Cherny,S.S., Mak,W.W., 
Cheung,E.F., Chan,R.C., Chen,E.Y., Li,T., and Sham,P.C., 2009. Identification of 
neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia 
in a Southern Chinese population. Am J Med Genet B Neuropsychiatr Genet. 
Sobell,J.L., Heston,L.L., and Sommer,S.S., 1993. Novel association approach for 
determining the genetic predisposition to schizophrenia: case-control resource and testing 
of a candidate gene. Am J Med Genet. 48, 28-35. 
Sowell,E.R., Peterson,B.S., Thompson,P.M., Welcome,S.E., Henkenius,A.L., and 
Toga,A.W., 2003. Mapping cortical change across the human life span. Nat Neurosci. 6, 
309-315. 
Spitzer R.L., Williams J.B., and Gibbon J., 1979. Structured Clinical Interview for DSM-
III-R Patient Edition. American Psychiatric Press, Washington DC. 
Spitzer RL and Williams JBW, 1985. Structured Clinical Interview for DSM-III-R 
(SCID). Biometrics Research Department, New York State Psychiatric Institute, New 
York. 
Stahl,S.M. and Buckley,P.F., 2007. Negative symptoms of schizophrenia: a problem that 
will not go away. Acta Psychiatr Scand. 115, 4-11. 
Stark,A.K., Uylings,H.B., Sanz-Arigita,E., and Pakkenberg,B., 2004. Glial cell loss in the 
anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with 
schizophrenia. Am J Psychiatry. 161, 882-888. 
 142
Stefansson,H., Sigurdsson,E., Steinthorsdottir,V., Bjornsdottir,S., Sigmundsson,T., 
Ghosh,S., Brynjolfsson,J., Gunnarsdottir,S., Ivarsson,O., Chou,T.T., Hjaltason,O., 
Birgisdottir,B., Jonsson,H., Gudnadottir,V.G., Gudmundsdottir,E., Bjornsson,A., 
Ingvarsson,B., Ingason,A., Sigfusson,S., Hardardottir,H., Harvey,R.P., Lai,D., Zhou,M., 
Brunner,D., Mutel,V., Gonzalo,A., Lemke,G., Sainz,J., Johannesson,G., Andresson,T., 
Gudbjartsson,D., Manolescu,A., Frigge,M.L., Gurney,M.E., Kong,A., Gulcher,J.R., 
Petursson,H., and Stefansson,K., 2002. Neuregulin 1 and susceptibility to schizophrenia. 
Am J Hum Genet. 71, 877-892. 
Stefansson,H., Rujescu,D., Cichon,S., Pietilainen,O.P., Ingason,A., Steinberg,S., 
Fossdal,R., Sigurdsson,E., Sigmundsson,T., Buizer-Voskamp,J.E., Hansen,T., 
Jakobsen,K.D., Muglia,P., Francks,C., Matthews,P.M., Gylfason,A., Halldorsson,B.V., 
Gudbjartsson,D., Thorgeirsson,T.E., Sigurdsson,A., Jonasdottir,A., Jonasdottir,A., 
Bjornsson,A., Mattiasdottir,S., Blondal,T., Haraldsson,M., Magnusdottir,B.B., 
Giegling,I., Moller,H.J., Hartmann,A., Shianna,K.V., Ge,D., Need,A.C., Crombie,C., 
Fraser,G., Walker,N., Lonnqvist,J., Suvisaari,J., Tuulio-Henriksson,A., Paunio,T., 
Toulopoulou,T., Bramon,E., Di Forti,M., Murray,R., Ruggeri,M., Vassos,E., Tosato,S., 
Walshe,M., Li,T., Vasilescu,C., Muhleisen,T.W., Wang,A.G., Ullum,H., Djurovic,S., 
Melle,I., Olesen,J., Kiemeney,L.A., Franke,B., Sabatti,C., Freimer,N.B., Gulcher,J.R., 
Thorsteinsdottir,U., Kong,A., Andreassen,O.A., Ophoff,R.A., Georgi,A., Rietschel,M., 
Werge,T., Petursson,H., Goldstein,D.B., Nothen,M.M., Peltonen,L., Collier,D.A., St 
Clair,D., and Stefansson,K., 2008. Large recurrent microdeletions associated with 
schizophrenia. Nature. 455, 232-236. 
Steinberg,M.H., 2005. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 
129, 465-481. 
Strakowski,S.M., Flaum,M., Amador,X., Bracha,H.S., Pandurangi,A.K., Robinson,D., 
and Tohen,M., 1996. Racial differences in the diagnosis of psychosis. Schizophr Res. 21, 
117-124. 
Straub,R.E., Speer,M.C., Luo,Y., Rojas,K., Overhauser,J., Ott,J., and Gilliam,T.C., 1993. 
A microsatellite genetic linkage map of human chromosome 18. Genomics. 15, 48-56. 
Straub,R.E., Sullivan,P.F., Ma,Y., Myakishev,M.V., Harris-Kerr,C., Wormley,B., 
Kadambi,B., Sadek,H., Silverman,M.A., Webb,B.T., Neale,M.C., Bulik,C.M., 
Joyce,P.R., and Kendler,K.S., 1999. Susceptibility genes for nicotine dependence: a 
genome scan and followup in an independent sample suggest that regions on 
chromosomes 2, 4, 10, 16, 17 and 18 merit further study. Mol Psychiatry. 4, 129-144. 
 143
Straub,R.E., Jiang,Y., MacLean,C.J., Ma,Y., Webb,B.T., Myakishev,M.V., Harris-
Kerr,C., Wormley,B., Sadek,H., Kadambi,B., Cesare,A.J., Gibberman,A., Wang,X., 
O'Neill,F.A., Walsh,D., and Kendler,K.S., 2002. Genetic variation in the 6p22.3 gene 
DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with 
schizophrenia. Am J Hum Genet. 71, 337-348. 
Suarez,B.K., Duan,J., Sanders,A.R., Hinrichs,A.L., Jin,C.H., Hou,C., Buccola,N.G., 
Hale,N., Weilbaecher,A.N., Nertney,D.A., Olincy,A., Green,S., Schaffer,A.W., 
Smith,C.J., Hannah,D.E., Rice,J.P., Cox,N.J., Martinez,M., Mowry,B.J., Amin,F., 
Silverman,J.M., Black,D.W., Byerley,W.F., Crowe,R.R., Freedman,R., Cloninger,C.R., 
Levinson,D.F., and Gejman,P.V., 2006. Genomewide linkage scan of 409 European-
ancestry and African American families with schizophrenia: suggestive evidence of 
linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample. Am J Hum Genet. 
78, 315-333. 
Sullivan,E.V., Shear,P.K., Lim,K.O., Zipursky,R.B., and Pfefferbaum,A., 1996. 
Cognitive and motor impairments are related to gray matter volume deficits in 
schizophrenia. Biol Psychiatry. 39, 234-240. 
Sullivan,P.F., Kendler,K.S., and Neale,M.C., 2003. Schizophrenia as a complex trait: 
evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 60, 1187-1192. 
Sun,J., Kuo,P.H., Riley,B.P., Kendler,K.S., and Zhao,Z., 2008. Candidate genes for 
schizophrenia: a survey of association studies and gene ranking. Am J Med Genet B 
Neuropsychiatr Genet. 147B, 1173-1181. 
Sweet,R.A., Bergen,S.E., Sun,Z., Marcsisin,M.J., Sampson,A.R., and Lewis,D.A., 2007. 
Anatomical evidence of impaired feedforward auditory processing in schizophrenia. Biol 
Psychiatry. 61, 854-864. 
Tachikawa,H., Harada,S., Kawanishi,Y., Okubo,T., and Suzuki,T., 2001. Polymorphism 
of the 5'-upstream region of the human SNAP-25 gene: an association analysis with 
schizophrenia. Neuropsychobiology. 43, 131-133. 
Takahashi,S., Cui,Y.H., Kojima,T., Han,Y.H., Zhou,R.L., Kamioka,M., Yu,S.Y., 
Matsuura,M., Matsushima,E., Wilcox,M., Arinami,T., Shen,Y.C., Faraone,S.V., and 
Tsuang,M.T., 2003. Family-based association study of markers on chromosome 22 in 
schizophrenia using African-American, European-American, and Chinese families. Am J 
Med Genet B Neuropsychiatr Genet. 120B, 11-17. 
 144
Talbot,K., Eidem,W.L., Tinsley,C.L., Benson,M.A., Thompson,E.W., Smith,R.J., 
Hahn,C.G., Siegel,S.J., Trojanowski,J.Q., Gur,R.E., Blake,D.J., and Arnold,S.E., 2004. 
Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal 
formation in schizophrenia. J Clin Invest. 113, 1353-1363. 
Tan,E.C., Chong,S.A., Wang,H., Chew-Ping,L.E., and Teo,Y.Y., 2005. Gender-specific 
association of insertion/deletion polymorphisms in the nogo gene and chronic 
schizophrenia. Brain Res Mol Brain Res. 139, 212-216. 
Tang,J.X., Chen,W.Y., He,G., Zhou,J., Gu,N.F., Feng,G.Y., and He,L., 2004. 
Polymorphisms within 5' end of the Neuregulin 1 gene are genetically associated with 
schizophrenia in the Chinese population. Mol Psychiatry. 9, 11-12. 
The Wellcome Trust Case Control Consortium, 2007. Genome-wide association study of 
14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447, 661-678. 
Thiselton,D.L., Vladimirov,V.I., Kuo,P.H., McClay,J., Wormley,B., Fanous,A., 
O'Neill,F.A., Walsh,D., van den Oord,E.J., Kendler,K.S., and Riley,B.P., 2008. AKT1 is 
associated with schizophrenia across multiple symptom dimensions in the Irish study of 
high density schizophrenia families. Biol Psychiatry. 63, 449-457. 
Thompson,P.M., Sower,A.C., and Perrone-Bizzozero,N.I., 1998. Altered levels of the 
synaptosomal associated protein SNAP-25 in schizophrenia. Biol Psychiatry. 43, 239-
243. 
Thompson,P.M., Rosenberger,C., Holt,S., and Perrone-Bizzozero,N.I., 1998. Measuring 
synaptosomal associated protein-25 kDa in human cerebral spinal fluid. J Psychiatr Res. 
32, 297-300. 
Thompson,P.M., Rosenberger,C., and Qualls,C., 1999. CSF SNAP-25 in schizophrenia 
and bipolar illness. A pilot study. Neuropsychopharmacology. 21, 717-722. 
Thompson,P.M., Kelley,M., Yao,J., Tsai,G., and van Kammen,D.P., 2003. Elevated 
cerebrospinal fluid SNAP-25 in schizophrenia. Biol Psychiatry. 53, 1132-1137. 
 145
Thompson,P.M., Egbufoama,S., and Vawter,M.P., 2003. SNAP-25 reduction in the 
hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol 
Psychiatry. 27, 411-417. 
Thomson,P.A., Wray,N.R., Millar,J.K., Evans,K.L., Hellard,S.L., Condie,A., Muir,W.J., 
Blackwood,D.H., and Porteous,D.J., 2005. Association between the TRAX/DISC locus 
and both bipolar disorder and schizophrenia in the Scottish population. Mol Psychiatry. 
10, 657-68, 616. 
Tkachev,D., Mimmack,M.L., Ryan,M.M., Wayland,M., Freeman,T., Jones,P.B., 
Starkey,M., Webster,M.J., Yolken,R.H., and Bahn,S., 2003. Oligodendrocyte dysfunction 
in schizophrenia and bipolar disorder. Lancet. 362, 798-805. 
Tochigi,M., Zhang,X., Ohashi,J., Hibino,H., Otowa,T., Rogers,M., Kato,T., Okazaki,Y., 
Kato,N., Tokunaga,K., and Sasaki,T., 2006. Association study of the dysbindin 
(DTNBP1) gene in schizophrenia from the Japanese population. Neurosci Res. 56, 154-
158. 
Toda,M. and Abi-Dargham,A., 2007. Dopamine hypothesis of schizophrenia: making 
sense of it all. Curr Psychiatry Rep. 9, 329-336. 
Tosato,S., Ruggeri,M., Bonetto,C., Bertani,M., Marrella,G., Lasalvia,A., Cristofalo,D., 
Aprili,G., Tansella,M., Dazzan,P., Diforti,M., Murray,R.M., and Collier,D.A., 2007. 
Association study of dysbindin gene with clinical and outcome measures in a 
representative cohort of Italian schizophrenic patients. Am J Med Genet B 
Neuropsychiatr Genet. 144, 647-659. 
Tsuang,M.T., Stone,W.S., and Faraone,S.V., 1999. Schizophrenia: a review of genetic 
studies. Harv Rev Psychiatry. 7, 185-207. 
Turunen,J.A., Peltonen,J.O., Pietilainen,O.P., Hennah,W., Loukola,A., Paunio,T., 
Silander,K., Ekelund,J., Varilo,T., Partonen,T., Lonnqvist,J., and Peltonen,L., 2007. The 
role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland. 
Schizophr Res. 91, 27-36. 
Uebelhack,R., Franke,L., Kutter,D., Thoma,J., and Seidel,K., 1987. Reduced platelet 
phenylalanine hydroxylating activity in a subgroup of untreated schizophrenics. Biochem 
Med Metab Biol. 37, 357-359. 
 146
Uranova,N.A., Vostrikov,V.M., Orlovskaya,D.D., and Rachmanova,V.I., 2004. 
Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a 
study from the Stanley Neuropathology Consortium. Schizophr Res. 67, 269-275. 
Uranova,N.A., Vostrikov,V.M., Vikhreva,O.V., Zimina,I.S., Kolomeets,N.S., and 
Orlovskaya,D.D., 2007. The role of oligodendrocyte pathology in schizophrenia. Int J 
Neuropsychopharmacol. 10, 537-545. 
van den Oord,E.J., Sullivan,P.F., Jiang,Y., Walsh,D., O'Neill,F.A., Kendler,K.S., and 
Riley,B.P., 2003. Identification of a high-risk haplotype for the dystrobrevin binding 
protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol 
Psychiatry. 8, 499-510. 
van den Oord,E.J., Jiang,Y., Riley,B.P., Kendler,K.S., and Chen,X., 2003. FP-TDI SNP 
scoring by manual and statistical procedures: a study of error rates and types. 
Biotechniques. 34, 610-20, 622. 
Vilella,E., Costas,J., Sanjuan,J., Guitart,M., De Diego,Y., Carracedo,A., Martorell,L., 
Valero,J., Labad,A., De Frutos,R., Najera,C., Molto,M.D., Toirac,I., Guillamat,R., 
Brunet,A., Valles,V., Perez,L., Leon,M., de Fonseca,F.R., Phillips,C., and Torres,M., 
2007. Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and 
RGS4 nor their genetic interaction. J Psychiatr Res. 
Vogel,F., 1985. Phenotypic deviations in heterozygotes of phenylketonuria (PKU). Prog 
Clin Biol Res. 177, 337-349. 
Voineskos,A.N., de,L., V, Bulgin,N.L., van Adrichem,Q., Shaikh,S., Lang,D.J., 
Honer,W.G., and Kennedy,J.L., 2008. A family-based association study of the myelin-
associated glycoprotein and 2',3'-cyclic nucleotide 3'-phosphodiesterase genes with 
schizophrenia. Psychiatr Genet. 18, 143-146. 
Vostrikov,V.M., Uranova,N.A., Rakhmanova,V.I., and Orlovskaia,D.D., 2004. [Lowered 
oligodendroglial cell density in the prefrontal cortex in schizophrenia]. Zh Nevrol 
Psikhiatr Im S S Korsakova. 104, 47-51. 
Vostrikov,V.M., Uranova,N.A., and Orlovskaya,D.D., 2007. Deficit of perineuronal 
oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr 
Res. 94, 273-280. 
 147
Wan,C., Yang,Y., Feng,G., Gu,N., Liu,H., Zhu,S., He,L., and Wang,L., 2005. 
Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia 
in the Chinese Han population. Neurosci Lett. 388, 126-131. 
Ward,K.E., Friedman,L., Wise,A., and Schulz,S.C., 1996. Meta-analysis of brain and 
cranial size in schizophrenia. Schizophr Res. 22, 197-213. 
Washington University. PRESYNAPTIC PROTEINS, SYNAPTIC VESICLE 
DOCKING & MEMBRANE FUSION. internet . 2005.  
Ref Type: Electronic Citation 
Wassef,A., Baker,J., and Kochan,L.D., 2003. GABA and schizophrenia: a review of basic 
science and clinical studies. J Clin Psychopharmacol. 23, 601-640. 
Wei,J. and Hemmings,G.P., 1999. A study of linkage disequilibrium between 
polymorphic loci for monamine oxidases A and B in schizophrenia. Psychiatr Genet. 9, 
177-181. 
Weickert,C.S., Straub,R.E., McClintock,B.W., Matsumoto,M., Hashimoto,R., 
Hyde,T.M., Herman,M.M., Weinberger,D.R., and Kleinman,J.E., 2004. Human 
dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal 
cortex and midbrain. Arch Gen Psychiatry. 61, 544-555. 
Weickert,C.S., Rothmond,D.A., Hyde,T.M., Kleinman,J.E., and Straub,R.E., 2008. 
Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia 
patients. Schizophr Res. 98, 105-110. 
Wickham,H., Walsh,C., Asherson,P., Taylor,C., Sigmundson,T., Gill,M., Owen,M.J., 
McGuffin,P., Murray,R., and Sham,P., 2001. Familiality of symptom dimensions in 
schizophrenia. Schizophr Res. 47, 223-232. 
Wilcox,M.A., Faraone,S.V., Su,J., Van Eerdewegh,P., and Tsuang,M.T., 2002. Genome 
scan of three quantitative traits in schizophrenia pedigrees. Biol Psychiatry. 52, 847-854. 
Wilkins,A., Majed,H., Layfield,R., Compston,A., and Chandran,S., 2003. 
Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular 
 148
mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic 
factor. J Neurosci. 23, 4967-4974. 
Williams,N.M., Preece,A., Morris,D.W., Spurlock,G., Bray,N.J., Stephens,M., Norton,N., 
Williams,H., Clement,M., Dwyer,S., Curran,C., Wilkinson,J., Moskvina,V., 
Waddington,J.L., Gill,M., Corvin,A.P., Zammit,S., Kirov,G., Owen,M.J., and 
O'Donovan,M.C., 2004. Identification in 2 independent samples of a novel schizophrenia 
risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch Gen Psychiatry. 
61, 336-344. 
Wong,A.H., Macciardi,F., Klempan,T., Kawczynski,W., Barr,C.L., Lakatoo,S., 
Wong,M., Buckle,C., Trakalo,J., Boffa,E., Oak,J., Azevedo,M.H., Dourado,A., Coelho,I., 
Macedo,A., Vicente,A., Valente,J., Ferreira,C.P., Pato,M.T., Pato,C.N., Kennedy,J.L., 
and Van Tol,H.H., 2003. Identification of candidate genes for psychosis in rat models, 
and possible association between schizophrenia and the 14-3-3eta gene. Mol Psychiatry. 
8, 156-166. 
Wong,A.H., Trakalo,J., Likhodi,O., Yusuf,M., Macedo,A., Azevedo,M.H., Klempan,T., 
Pato,M.T., Honer,W.G., Pato,C.N., Van Tol,H.H., and Kennedy,J.L., 2004. Association 
between schizophrenia and the syntaxin 1A gene. Biol Psychiatry. 56, 24-29. 
Wonodi,I., Hong,L.E., Avila,M.T., Buchanan,R.W., Carpenter,W.T., Jr., Stine,O.C., 
Mitchell,B.D., and Thaker,G.K., 2005. Association between polymorphism of the 
SNAP29 gene promoter region and schizophrenia. Schizophr Res. 78, 339-341. 
Woo,T.U. and Crowell,A.L., 2005. Targeting synapses and myelin in the prevention of 
schizophrenia. Schizophr Res. 73, 193-207. 
Wood,L.S., Pickering,E.H., and Dechairo,B.M., 2007. Significant support for DAO as a 
schizophrenia susceptibility locus: examination of five genes putatively associated with 
schizophrenia. Biol Psychiatry. 61, 1195-1199. 
Xu,B., Roos,J.L., Levy,S., van Rensburg,E.J., Gogos,J.A., and Karayiorgou,M., 2008. 
Strong association of de novo copy number mutations with sporadic schizophrenia. Nat 
Genet. 40, 880-885. 
Xu,M.Q., Xing,Q.H., Zheng,Y.L., Li,S., Gao,J.J., He,G., Guo,T.W., Feng,G.Y., Xu,F., 
and He,L., 2007. Association of AKT1 gene polymorphisms with risk of schizophrenia 
 149
and with response to antipsychotics in the Chinese population. J Clin Psychiatry. 68, 
1358-1367. 
Yang,Y.F., Qin,W., Shugart,Y.Y., He,G., Liu,X.M., Zhou,J., Zhao,X.Z., Chen,Q., 
La,Y.J., Xu,Y.F., Li,X.W., Gu,N.F., Feng,G.Y., Song,H., Wang,P., and He,L., 2005. 
Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of 
family trios. Schizophr Res. 75, 11-19. 
Young,C.E., Arima,K., Xie,J., Hu,L., Beach,T.G., Falkai,P., and Honer,W.G., 1998. 
SNAP-25 deficit and hippocampal connectivity in schizophrenia. Cereb Cortex. 8, 261-
268. 
Zammit,S., Jones,G., Jones,S.J., Norton,N., Sanders,R.D., Milham,C., McCarthy,G.M., 
Jones,L.A., Cardno,A.G., Gray,M., Murphy,K.C., O'Donovan,M.C., and Owen,M.J., 
2004. Polymorphisms in the MAOA, MAOB, and COMT genes and aggressive behavior 
in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 128, 19-20. 
Zeggini,E., Scott,L.J., Saxena,R., Voight,B.F., Marchini,J.L., Hu,T., de Bakker,P.I., 
Abecasis,G.R., Almgren,P., Andersen,G., Ardlie,K., Bostrom,K.B., Bergman,R.N., 
Bonnycastle,L.L., Borch-Johnsen,K., Burtt,N.P., Chen,H., Chines,P.S., Daly,M.J., 
Deodhar,P., Ding,C.J., Doney,A.S., Duren,W.L., Elliott,K.S., Erdos,M.R., Frayling,T.M., 
Freathy,R.M., Gianniny,L., Grallert,H., Grarup,N., Groves,C.J., Guiducci,C., Hansen,T., 
Herder,C., Hitman,G.A., Hughes,T.E., Isomaa,B., Jackson,A.U., Jorgensen,T., Kong,A., 
Kubalanza,K., Kuruvilla,F.G., Kuusisto,J., Langenberg,C., Lango,H., Lauritzen,T., Li,Y., 
Lindgren,C.M., Lyssenko,V., Marvelle,A.F., Meisinger,C., Midthjell,K., Mohlke,K.L., 
Morken,M.A., Morris,A.D., Narisu,N., Nilsson,P., Owen,K.R., Palmer,C.N., Payne,F., 
Perry,J.R., Pettersen,E., Platou,C., Prokopenko,I., Qi,L., Qin,L., Rayner,N.W., Rees,M., 
Roix,J.J., Sandbaek,A., Shields,B., Sjogren,M., Steinthorsdottir,V., Stringham,H.M., 
Swift,A.J., Thorleifsson,G., Thorsteinsdottir,U., Timpson,N.J., Tuomi,T., Tuomilehto,J., 
Walker,M., Watanabe,R.M., Weedon,M.N., Willer,C.J., Illig,T., Hveem,K., Hu,F.B., 
Laakso,M., Stefansson,K., Pedersen,O., Wareham,N.J., Barroso,I., Hattersley,A.T., 
Collins,F.S., Groop,L., McCarthy,M.I., Boehnke,M., and Altshuler,D., 2008. Meta-
analysis of genome-wide association data and large-scale replication identifies additional 
susceptibility loci for type 2 diabetes. Nat Genet. 40, 638-645. 
Zhang,X.Y., Zhou,D.F., Zhang,P.Y., and Wei,J., 2000. The CCK-A receptor gene 
possibly associated with positive symptoms of schizophrenia. Mol Psychiatry. 5, 239-
240. 
 150
Zinkstok,J.R., de Wilde,O., van Amelsvoort,T.A., Tanck,M.W., Baas,F., and 
Linszen,D.H., 2007. Association between the DTNBP1 gene and intelligence: a case-
control study in young patients with schizophrenia and related disorders and unaffected 
siblings. Behav Brain Funct. 3, 19. 
Zipursky,R.B., Lim,K.O., Sullivan,E.V., Brown,B.W., and Pfefferbaum,A., 1992. 
Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry. 
49, 195-205. 
Zucchero,T.M., Cooper,M.E., Maher,B.S., Daack-Hirsch,S., Nepomuceno,B., Ribeiro,L., 
Caprau,D., Christensen,K., Suzuki,Y., Machida,J., Natsume,N., Yoshiura,K., Vieira,A.R., 
Orioli,I.M., Castilla,E.E., Moreno,L., Arcos-Burgos,M., Lidral,A.C., Field,L.L., Liu,Y.E., 
Ray,A., Goldstein,T.H., Schultz,R.E., Shi,M., Johnson,M.K., Kondo,S., Schutte,B.C., 
Marazita,M.L., and Murray,J.C., 2004. Interferon regulatory factor 6 (IRF6) gene 
variants and the risk of isolated cleft lip or palate. N Engl J Med. 351, 769-780. 
 
 151
Appendix A:  Exploratory Factor Analysis factor loadings for the combined GAIN 
sample and individual groups.   
 
             Combined Sample 
 
  1 2 3
delusions  0.836 0.233 0.288
paranoia  0.773 0.188 0.243
hallucinations  0.779 ‐0.108 0.088
control delusions  0.546 0.148 0.156
conversing/commenting/cont hall  0.746 ‐0.066 0.012
abnormal perception of thought  0.504 0.118 0.100
blunted affect  0.145 ‐0.157 0.668
poverty of speech  0.076 ‐0.162 0.707
formal thought disorder  0.175 0.084 0.597
bizarre behavior  0.188 0.114 0.565
depression  0.185 0.450 ‐0.283
mania    ‐0.033 0.897 0.063
depression with psychotic features  0.263 0.465 ‐0.172
mania with psychotic features  0.015 0.934 0.140
 
 
     African Ancestry  European Ancestry 
 
  1 2  3   1 2  3
delusions  0.897 0.175  0.100   0.677 0.579  0.242
paranoia  0.813 0.109  0.079   0.634 0.503  0.205
hallucinations  0.781 ‐0.165  0.075   0.810 0.107  ‐0.071
control delusions  0.558 0.125  0.134   0.535 0.176  0.183
conversing/commenting/cont hall  0.715 ‐0.164  ‐0.008   0.786 0.018  ‐0.008
abnormal perception of thought  0.523 0.115  0.069   0.502 0.105  0.118
blunted affect  0.188 ‐0.193  0.678   0.175 0.575  ‐0.194
poverty of speech  0.136 ‐0.261  0.729   0.099 0.596  ‐0.149
formal thought disorder  0.278 0.206  0.580   0.058 0.617  0.071
bizarre behavior  0.271 0.236  0.515   0.113 0.585  0.093
depression  0.221 0.070  ‐0.476   0.255 ‐0.270  0.486
mania    0.043 0.908  ‐0.125   ‐0.015 0.063  0.867
depression with psychotic features  0.351 0.037  ‐0.369   0.324 ‐0.200  0.490
mania with psychotic features  0.077 0.971  ‐0.050   0.023 0.171  0.922
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Appendix B:  Myelin and synaptic gene networks  
 
myelin-
core (16) 
myelin-extended 
(54) 
 synaptic-
core (48) 
synaptic-extended 
(69) 
QKI APP  SNAP23 AMPH 
OLIG1 CANX  SNAP25 CAMK2B 
OLIG2 CAV1  SNAP29 CFTR 
SOX10 CD44  VAMP1 GAP43 
TF CD82  VAMP2 GOSR1 
CNP CDKN1B  VAMP3 GOSR2 
MOG CLDN11  VAMP4 HNF4A 
PLP1 CNP  VAMP5 NAPA 
MOBP CSDA  VAMP7 NRXN1 
CLDN11 DAB1  VAMP8 NSF 
MAL EGFR  STX1A NSFL1C 
NGFR ERBB2  STX2 PLCG1 
RTN4R ERBB3  STX3 PRKCA 
MAG FN1  STX4 PRKCB1 
ERBB3 FYN  STX5 PRKCD 
NRG1 HBEGF  STX6 PRKCE 
 HLA-A  STX7 PRKCG 
 HNF4A  STX8 PSEN1 
 IL2  STX11 RAB3A 
 IL4  STX16 Rab5 
 IL6  STX17 RABEP1 
 INS  STX18 SNAP23 
 ITGB1  SYN1 SNAP25 
 LCK  SYN2 SNAP29 
 MAG  SYN3 SPTAN1 
 MAL  SYT1 SRC 
 MAP1B  SYT2 STX11 
 MBP  SYT3 STX16 
 MOBP  SYT4 STX17 
 MOG  SYT5 STX18 
 NEUROG3  SYT6 STX1A 
 NGFR  SYT7 STX1B 
 NOTCH1  SYT8 STX2 
 NRG1  SYT11 STX3 
 OLIG1  SYT13 STX4 
 OLIG2  SYT14 STX5 
 PIK3R1  SYT15 STX6 
 PLG  SYT16 STX7 
 PLP1  SV2A STX8 
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 PRKCE  SV2B STXBP1 
 PRNP  SV2C SV2A 
 PTK2  NSF SV2B 
 PTPN11  STXBP1 SV2C 
 QKI  AMPH SYN1 
 RANBP9  GAP43 SYN2 
 RHOA  RAB3GAP2 SYN3 
 SHC1  RAB3A SYNCRIP 
 SOX10  RAB5A SYT1 
 SRC   SYT11 
 SYK   SYT13 
 TF   SYT14 
 TNF   SYT16 
 TSPAN3   SYT2 
 TSPAN4   SYT3 
    SYT4 
    SYT5 
    SYT6 
    SYT7 
    SYT8 
    USO1 
    VAMP1 
    VAMP2 
    VAMP3 
    VAMP4 
    VAMP5 
    VAMP7 
    VAMP8 
    VCL 
    ZDHHC7 
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Core Synaptic Network with superimposed empirical p-values 
 
 
.72 .13
 
 
Extended Synaptic Network with superimposed empirical p-values 
 
.88 .27
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Core Myelin Network results with superimposed empirical p-values 
 
.02 .88
 
 
 
 
 
 
Extended Myelin Network results with superimposed empirical p-values 
 
 
.18 .56
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Appendix C:  Penetrance matrices used in epistasis simulations  
Numbers in parentheses denote the models adapted from Howson et al (2008).  
 
 
  0 1 2    0 1 2
epistatic (4) 0 1 1 20  additive (7) 0 1 10 100
 1 1 1 40   1 2 11 101
 2 1 1 80   2 4 13 103
           
           
  0 1 2    0 1 2
epistatic (5) 0 1 1 1  additive  0 1 2 4
 1 1 1 1   1 2 4 6
 2 1 1 50   2 4 6 8
           
           
  0 1 2    0 1 2
heterogeneity (11) 0 1 1 20  crossover (14) 0 3 3 15
 1 1 1 20   1 2 2 30
 2 4 4 20   2 1 1 60
           
           
  0 1 2    0 1 2
heterogeneity (12) 0 1 1 2  crossover (15) 0 1 1 150
 1 1 1 2   1 2 2 100
 2 2 2 2   2 4 4 50
           
           
           
  0 1 2       
dominance  0 1 1 1       
 1 1 x x       
 2 1 x x       
           
 x = 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4, 6, 8      
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